CINXE.COM

<!DOCTYPE html><html><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><title>NIDDK Central Repository</title><meta name="next-head-count" content="3"/><link data-next-font="size-adjust" rel="preconnect" href="/" crossorigin="anonymous"/><link rel="preload" href="/_next/static/css/93e60cbdc9b67ef2.css" as="style"/><link rel="stylesheet" href="/_next/static/css/93e60cbdc9b67ef2.css" data-n-g=""/><link rel="preload" href="/_next/static/css/d3df112486f97f47.css" as="style"/><link rel="stylesheet" href="/_next/static/css/d3df112486f97f47.css" data-n-p=""/><link rel="preload" href="/_next/static/css/87bb5f7dea526b9e.css" as="style"/><link rel="stylesheet" href="/_next/static/css/87bb5f7dea526b9e.css" data-n-p=""/><link rel="preload" href="/_next/static/css/b6e30ba3265008c4.css" as="style"/><link rel="stylesheet" href="/_next/static/css/b6e30ba3265008c4.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-42372ed130431b0a.js"></script><script src="/_next/static/chunks/webpack-dcf4136cb4ed4a3e.js" defer=""></script><script src="/_next/static/chunks/framework-e952fed463eb8e34.js" defer=""></script><script src="/_next/static/chunks/main-97bba83dfe7e8d62.js" defer=""></script><script src="/_next/static/chunks/pages/_app-daedab1e29253550.js" defer=""></script><script src="/_next/static/chunks/29107295-a3480e51fe70b9c7.js" defer=""></script><script src="/_next/static/chunks/223-300e47a3735c5f9b.js" defer=""></script><script src="/_next/static/chunks/977-2288711ec40003fc.js" defer=""></script><script src="/_next/static/chunks/877-4fe059427ee3fbd6.js" defer=""></script><script src="/_next/static/chunks/141-acc0ae3ff4936193.js" defer=""></script><script src="/_next/static/chunks/790-7ea9ede518fd904a.js" defer=""></script><script src="/_next/static/chunks/982-52532064f5e139bb.js" defer=""></script><script src="/_next/static/chunks/pages/search/study-35f2e500baa1f136.js" defer=""></script><script src="/_next/static/4IwPCL7p9Vb_-_lB6rNWm/_buildManifest.js" defer=""></script><script src="/_next/static/4IwPCL7p9Vb_-_lB6rNWm/_ssgManifest.js" defer=""></script></head><body><div id="__next"><div class="CoreLayout_coreLayout__AbvUo "><div class="CoreLayout_container__C25fM"><div class="GovBanner_govBanner__l6GMd"><div class="GovBanner_bannerHeader__OJ1DM"><img src="/images/us_flag_small.png"/><p>An official website of the United States government</p><p><button><a>Here's how you would know <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="10" height="10" fill="currentColor" class="bi bi-chevron-down"><path fill-rule="evenodd" d="M1.646 4.646a.5.5 0 0 1 .708 0L8 10.293l5.646-5.647a.5.5 0 0 1 .708.708l-6 6a.5.5 0 0 1-.708 0l-6-6a.5.5 0 0 1 0-.708"></path></svg></a></button></p></div></div><div class="PageHeader_logoContainer__lq_Xl row"><div class="PageHeader_content__Yo7eT col"><a href="https://www.niddk.nih.gov"><div><svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" width="300px" height="100px" viewBox="-528 662 578 130" enable-background="new -528 662 578 130" xml:space="preserve"><title>NIH: National Institute of Diabetes and Digestive and Kidney Diseases</title><g><g><path fill="#646569" d="M-383.6,698.1v58h-10.1l0,0v-26.3h-26.6v26.3h-10.1v-58h10.1v23.2h26.6v-23.2l0,0H-383.6z M-440.6,756.4 L-440.6,756.4h-10.1v-58h10.1V756.4z M-460.7,756.4L-460.7,756.4h-10.8l-26.6-42.8h-0.3v42.8h-9.8l0,0v-58l0,0h10.8l0,0l26.6,42.8 h0.3v-42.8h9.8V756.4z M-347.7,727l-35.9-65h-132.6c-6.7,0-11.9,5.4-11.9,11.9v106c0,6.7,5.4,11.9,11.9,11.9h132.3L-347.7,727z"></path><path fill="#71963E" d="M-374.5,792l36.1-65l-35.9-65h9c4.9,0,10.8,3.6,13.2,7.7l31.5,57.3l-31.7,57.3c-2.3,4.4-8.3,7.7-13.4,7.7 H-374.5z"></path></g><g><path fill="#616365" d="M-305,674.6h4.4l10.8,17.5l0,0v-17.5h3.9v24h-4.4l-10.8-17.5l0,0v17.5h-3.9 C-305,698.6-305,674.6-305,674.6z"></path><path fill="#616365" d="M-266.6,694.8c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5c-1,0.3-2.1,0.5-3.1,0.5c-0.8,0-1.5,0-2.3-0.3 c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6c0.3-0.5,1-1.3,1.5-1.5 c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3c0.3,0,0.8-0.3,1-0.5 c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8s-1.3,1.3-1.3,2.1h-3.9 c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3c0.8,0,1.8,0,2.6,0.3l2.3,0.8 c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V694.8L-266.6,694.8L-266.6,694.8z M-270.5,689.9c-0.8,0.3-1.3,0.5-2.1,0.8 c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3s-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3c0,0.3,0,0.8,0.3,1l0.8,0.8 c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1c0.3-0.5,0.5-1,0.5-1.5v-2.6L-270.5,689.9 L-270.5,689.9z"></path><path fill="#616365" d="M-264.3,681.3h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0.3,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-264.3,681.3L-264.3,681.3z"></path><path fill="#616365" d="M-251.4,674.6h3.9v3.6h-3.9V674.6z M-251.4,681.3h3.9v17.3h-3.9V681.3z"></path><path fill="#616365" d="M-235.4,699.1c-1.3,0-2.6-0.3-3.6-0.8c-2.1-0.8-3.9-2.6-4.6-4.6c-0.5-1-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-2.1,1.8-2.8c0.8-0.8,1.8-1.5,2.8-1.8c2.3-1,4.9-1,7.2,0c2.1,0.8,3.9,2.6,4.6,4.6c0.5,1,0.5,2.3,0.5,3.6s-0.3,2.3-0.5,3.6 c-0.5,1-1,2.1-1.8,2.8c-0.8,0.8-1.8,1.5-2.8,1.8C-232.8,698.9-234.1,699.1-235.4,699.1z M-235.4,696c0.8,0,1.5-0.3,2.3-0.5 c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0.3-1.5,0.3-3.1,0-4.6c-0.3-0.8-0.5-1.3-0.8-2.1c-0.5-0.5-1-1-1.5-1.3 c-0.8-0.3-1.5-0.5-2.3-0.5c-0.8,0-1.5,0.3-2.3,0.5c-0.5,0.3-1,0.8-1.5,1.3s-0.8,1.3-0.8,2.1c-0.3,1.5-0.3,3.1,0,4.6 c0.3,0.8,0.5,1.3,0.8,2.1c0.5,0.5,1,1,1.5,1.3C-236.9,696-236.2,696-235.4,696z"></path><path fill="#616365" d="M-223.3,681.3h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3s-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.6V681.3z"></path><path fill="#616365" d="M-189.5,694.8c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5s-2.1,0.5-3.1,0.5c-0.8,0-1.5,0-2.3-0.3 c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6c0.3-0.5,1-1.3,1.5-1.5 c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3c0.3,0,0.8-0.3,1-0.5 c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1h-3.9c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V694.8L-189.5,694.8L-189.5,694.8z M-193.1,689.9 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3c-0.5,0-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-193.1,689.9L-193.1,689.9z"></path><path fill="#616365" d="M-185.1,674.6h3.9v24h-3.9V674.6z"></path><path fill="#616365" d="M-167.3,674.6h4.1v24h-4.1V674.6z"></path><path fill="#616365" d="M-158.5,681.3h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3c-0.5,0.3-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-158.5,681.3L-158.5,681.3z"></path><path fill="#616365" d="M-136.3,693c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3s0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8c-0.5-0.3-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c1.5,0.8,2.3,2.6,2.3,4.1h-3.9 c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5c-0.3,0.3-0.3,0.8-0.3,1 c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6c-0.5,0.8-1,1.3-1.8,1.8 c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3c-1,0-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1c-0.8-0.5-1.3-1-1.5-1.8 c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-136.3,693L-136.3,693z"></path><path fill="#616365" d="M-123.7,681.3h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-123.7,681.3L-123.7,681.3z"></path><path fill="#616365" d="M-110.5,674.6h3.9v3.6h-3.9V674.6z M-110.5,681.3h3.9v17.3h-3.9V681.3z"></path><path fill="#616365" d="M-104.4,681.3h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-104.4,681.3L-104.4,681.3z"></path><path fill="#616365" d="M-76,698.6h-3.9v-2.3l0,0c-0.5,0.8-1.3,1.5-2.1,2.1c-0.8,0.5-1.8,0.8-2.8,0.8c-1.8,0.3-3.6-0.5-4.9-1.8 c-1.3-1.5-1.8-3.4-1.5-5.2v-11.1h3.9v10.6c-0.3,1,0.3,2.3,0.8,3.1c0.5,0.5,1.5,1,2.3,1c0.8,0,1.3,0,2.1-0.3c0.5-0.3,1-0.5,1.3-1 l0.8-1.5c0.3-0.5,0.3-1.3,0.3-1.8v-10.1h3.9V698.6L-76,698.6L-76,698.6z"></path><path fill="#616365" d="M-73.7,681.3h2.8v-5.2h3.9v5.2h3.4v2.8H-67v10.3c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-73.7,681.3L-73.7,681.3z"></path><path fill="#616365" d="M-57.9,690.9c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8 c1,0.5,2.1,1.3,2.6,2.3c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-57.9,690.9L-57.9,690.9z M-48.9,688.3 c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5 c-0.3,0.5-0.3,1.3-0.5,1.8H-48.9z"></path><path fill="#616365" d="M-24.9,699.1c-1.3,0-2.6-0.3-3.6-0.8c-2.1-0.8-3.9-2.6-4.6-4.6c-0.5-1-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-2.1,1.8-2.8c0.8-0.8,1.8-1.5,2.8-1.8c2.3-1,4.9-1,7.2,0c2.1,0.8,3.9,2.6,4.6,4.6c0.5,1,0.5,2.3,0.5,3.6s-0.3,2.3-0.5,3.6 c-0.5,1-1,2.1-1.8,2.8c-0.8,0.8-1.8,1.5-2.8,1.8C-22.3,699.1-23.6,699.4-24.9,699.1z M-24.9,696c0.8,0,1.5-0.3,2.3-0.5 c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0.3-1.5,0.3-3.1,0-4.6c-0.3-0.8-0.5-1.3-0.8-2.1c-0.5-0.5-1-1-1.5-1.3 c-0.8-0.3-1.5-0.5-2.3-0.5s-1.5,0.3-2.3,0.5c-0.5,0.3-1,0.8-1.5,1.3c-0.5,0.5-0.8,1.3-0.8,2.1c-0.3,1.5-0.3,3.1,0,4.6 c0.3,0.8,0.5,1.3,0.8,2.1c0.5,0.5,1,1,1.5,1.3C-26.5,696-25.7,696-24.9,696z"></path><path fill="#616365" d="M-14.6,681.3h2.8v-1.5c0-0.8,0.3-1.8,0.5-2.6c0-0.5,0.5-1.3,1-1.5l1.5-0.8c0.5,0,1.3-0.3,1.8-0.3 c0.8,0,1.8,0,2.6,0.3v3.1c-0.3,0-0.5,0-0.8-0.3h-1c-0.5,0-1,0-1.3,0.3c-0.3,0.5-0.5,1-0.5,1.5v1.8h3.4v2.8h-3.4v14.4h-3.9v-14.4 h-2.8L-14.6,681.3L-14.6,681.3L-14.6,681.3z"></path><path fill="#616365" d="M-304.8,715.1h9.8c1.5,0,3.4,0.3,4.6,1c1.3,0.8,2.3,1.5,3.4,2.6s1.5,2.6,1.8,3.9c0.5,1.5,0.5,3.1,0.5,4.6 s-0.3,3.1-0.5,4.6c-0.3,1.3-1,2.8-1.8,3.9c-0.8,1-2.1,2.1-3.4,2.6c-1.5,0.5-3.1,1-4.6,1h-9.8V715.1L-304.8,715.1z M-300.6,735.8 h4.1c1.3,0,2.8-0.3,4.1-0.8c1-0.3,1.8-1,2.3-1.8c0.5-0.8,1-1.8,1.3-2.8c0.3-2.3,0.3-4.4,0-6.7c-0.3-1-0.5-2.1-1.3-2.8 c-0.8-0.8-1.5-1.3-2.3-1.8c-1.3-0.5-2.8-0.8-4.1-0.8h-4.1V735.8L-300.6,735.8z"></path><path fill="#616365" d="M-281,715.1h3.9v3.6h-3.9V715.1z M-281,721.8h3.9v17.3h-3.9V721.8z"></path><path fill="#616365" d="M-258.6,735.3c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3 c-0.3,0.3-0.5,0-0.8,0.3h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5c-1,0.3-2.1,0.5-3.1,0.5 c-0.8,0-1.5,0-2.3-0.3s-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6 c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3 c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1h-3.9c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V735.3L-258.6,735.3L-258.6,735.3z M-262.5,730.4 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3s-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-262.5,730.4L-262.5,730.4z"></path><path fill="#616365" d="M-254.5,715.1h3.9v8.8l0,0c0.3-0.5,0.5-0.8,1-1c0.5-0.3,0.8-0.5,1.3-0.8s1-0.5,1.5-0.5 c0.5,0,1-0.3,1.5-0.3c1.3,0,2.6,0.3,3.6,0.8c1,0.5,1.8,1.3,2.6,2.1c0.8,0.8,1.3,1.8,1.5,2.8c0.3,1.3,0.5,2.3,0.5,3.6 c0,1-0.3,2.3-0.5,3.4c-0.3,1-0.8,2.1-1.3,2.8c-0.5,0.8-1.3,1.5-2.3,2.1c-1,0.5-2.3,0.8-3.4,0.8h-1.8c-0.5,0-1.3-0.3-1.8-0.5 c-0.5-0.3-1-0.5-1.5-0.8s-0.8-0.8-1-1.3l0,0v2.3h-3.9V715.1z M-241.1,730.4c0-0.8,0-1.5-0.3-2.3c-0.3-0.8-0.5-1.5-1-2.1 c-0.5-0.5-1-1-1.5-1.3c-0.5-0.3-1.3-0.5-2.1-0.5c-1.3,0-2.8,0.5-3.6,1.5c-0.8,1.3-1.3,2.8-1.3,4.4c0,0.8,0,1.5,0.3,2.3 c0.3,0.8,0.5,1.3,1,1.8s1,1,1.5,1.3s1.3,0.5,2.1,0.5c0.8,0,1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1 C-241.3,731.4-241.1,731.1-241.1,730.4z"></path><path fill="#616365" d="M-231,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9H-231V731.4L-231,731.4z M-221.7,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.3,1.8H-221.7z"></path><path fill="#616365" d="M-216.8,721.8h2.8v-5.2h3.9v5.2h3.4v2.8h-3.4V735c0,0.3,0,0.5,0.3,0.8c0,0.3,0.3,0.5,0.5,0.5 c0.3,0.3,0.8,0.3,1,0.3h1.5v2.8c-0.5,0-0.8,0-1.3,0.3h-1.3c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3 c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4L-216.8,721.8L-216.8,721.8z"></path><path fill="#616365" d="M-200.8,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9h-12.6V731.4L-200.8,731.4z M-192.1,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.3,1.8H-192.1z"></path><path fill="#616365" d="M-182.2,733.4c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3 c0.5-0.3,0.8-0.5,1-0.8c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8c-0.5-0.3-1.3-0.3-1.8-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3 c0-0.8,0.3-1.8,0.8-2.3c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1 c1.5,0.8,2.3,2.6,2.3,4.1h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6h3.6V733.4L-182.2,733.4z"></path><path fill="#616365" d="M-144.1,735.3c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3 c-0.3,0.3-0.5,0-0.8,0.3h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5c-1,0.3-2.1,0.5-3.1,0.5 c-0.8,0-1.5,0-2.3-0.3c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.5-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6 c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.3c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3 c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1h-3.6c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3v8.8L-144.1,735.3L-144.1,735.3z M-147.9,730.4 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3c-0.5,0-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-147.9,730.4L-147.9,730.4z"></path><path fill="#616365" d="M-139.9,721.8h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3s-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-139.9,721.8L-139.9,721.8z"></path><path fill="#616365" d="M-104.4,739.1h-3.6v-2.3l0,0c-0.5,1-1.3,1.8-2.3,2.1c-1,0.5-2.1,0.8-3.1,0.8c-1.3,0-2.6-0.3-3.6-0.8 c-1-0.5-1.8-1.3-2.6-2.1c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6c0-1.3,0.3-2.8,0.5-4.1c0.5-1,1-2.1,1.8-2.8 c0.5-0.8,1.5-1.3,2.3-1.5c1-0.3,1.8-0.5,2.8-0.5c0.5,0,1,0,1.5,0.3c0.5,0,1,0.3,1.5,0.5l1.5,0.8c0.5,0.3,0.8,0.8,1,1.3l0,0v-8.8 h3.9v23.7H-104.4z M-117.8,730.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1.3,0.8,1.8c0.5,0.5,1,1,1.5,1.3s1.3,0.5,2.1,0.5 c0.8,0,1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0.3-0.8,0.3-1.5,0.3-2.3c0-1.5-0.5-3.1-1.3-4.4 c-0.8-1-2.3-1.5-3.6-1.5c-0.8,0-1.5,0.3-2.3,0.5c-0.8,0.3-1.3,0.8-1.5,1.5c-0.5,0.5-0.8,1.3-0.8,2.1 C-117.5,729.1-117.5,729.8-117.8,730.6z"></path><path fill="#616365" d="M-90.2,715.1h9.8c1.5,0,3.4,0.3,4.6,1c1.3,0.5,2.3,1.5,3.4,2.6s1.5,2.3,1.8,3.9c0.5,1.5,0.5,3.1,0.5,4.6 s-0.3,3.1-0.5,4.6c-0.3,1.3-1,2.8-1.8,3.9c-0.8,1-2.1,2.1-3.4,2.6c-1.5,0.5-3.1,1-4.6,1h-9.8V715.1L-90.2,715.1z M-86,735.8h4.1 c1.3,0,2.8-0.3,4.1-0.8c1-0.3,1.8-1,2.3-1.8c0.5-0.8,1-1.8,1.3-2.8c0.3-2.3,0.3-4.4,0-6.7c-0.3-1-0.5-2.1-1.3-2.8 c-0.5-0.8-1.3-1.5-2.3-1.8c-1.3-0.5-2.8-0.8-4.1-0.8H-86L-86,735.8L-86,735.8z"></path><path fill="#616365" d="M-66.2,715.1h3.9v3.6h-3.9V715.1z M-66.2,721.8h3.9v17.3h-3.9V721.8z"></path><path fill="#616365" d="M-42.2,738.1c0.3,2.3-0.8,4.4-2.3,5.9c-1.8,1.3-4.1,2.1-6.4,1.8c-0.8,0-1.8,0-2.6-0.3 c-0.8-0.3-1.5-0.5-2.3-1c-0.8-0.5-1.3-1-1.8-1.8c-0.5-0.8-0.8-1.5-0.8-2.6h3.9c0,0.5,0.3,1,0.5,1.3c0.3,0.3,0.5,0.5,1,0.8 c0.5,0.3,0.8,0.3,1.3,0.3h1.3c2.1,0.5,4.1-1,4.4-2.8c0-0.5,0-1,0-1.5v-2.6l0,0c-0.5,1-1.3,1.8-2.3,2.3c-1,0.5-2.1,0.8-3.1,0.8 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.5-1.8-1-2.3-2.1c-0.5-0.8-1-1.8-1.3-2.8c-0.3-1.3-0.5-2.3-0.5-3.6c0-1,0.3-2.3,0.5-3.4 c0.3-1,0.8-2.1,1.5-2.8c0.8-0.8,1.5-1.5,2.6-1.8c1-0.5,2.3-0.8,3.4-0.8s2.1,0.3,3.1,0.8c0.8,0.5,1.5,1.3,2.1,2.1l0,0v-2.3h3.9 L-42.2,738.1L-42.2,738.1z M-50.7,736c0.8,0,1.5-0.3,2.1-0.5c0.5-0.3,1-0.8,1.5-1.3c0.3-0.8,0.5-1.3,0.8-2.1 c0.3-0.8,0.3-1.5,0.3-2.3c0-0.8,0-1.3-0.3-2.1c-0.3-0.5-0.5-1.3-0.8-1.8c-0.3-0.5-0.8-1-1.5-1.3c-1.3-0.8-2.8-0.8-4.1,0 c-0.5,0.3-1,0.8-1.3,1.3c-0.3,0.8-0.5,1.3-0.8,2.1c-0.3,1.3-0.3,2.8,0,4.1c0.3,0.5,0.5,1.3,0.8,1.8c0.3,0.5,0.8,1,1.3,1.3 C-52.2,735.8-51.5,736-50.7,736L-50.7,736z"></path><path fill="#616365" d="M-35.5,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8s2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4s0.5,2.6,0.3,3.9h-12.6V731.4L-35.5,731.4z M-26.5,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H-26.5z"></path><path fill="#616365" d="M-16.9,733.4c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3 c0.5-0.3,0.8-0.5,1-0.8c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8c-0.5-0.3-1.3-0.3-1.8-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3 c0-0.8,0.3-1.8,0.8-2.3c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1 c1.5,0.8,2.3,2.6,2.3,4.1h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0.3-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1s-1.3-1-1.5-1.8 c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-16.9,733.4L-16.9,733.4z"></path><path fill="#616365" d="M-4,721.8h2.8v-5.2h3.9v5.2H6v2.8H2.7V735c0,0.3,0,0.5,0.3,0.8l0.5,0.5c0.3,0,0.8,0.3,1,0.3H6v2.8 c-0.5,0-0.8,0-1.3,0.3H3.5c-0.8,0-1.5,0-2.3-0.3l-1.5-0.8c-0.3-0.5-0.5-0.8-0.8-1.3c0-0.5-0.3-1.3-0.3-1.8v-10.3h-2.8v-3.4H-4 L-4,721.8z"></path><path fill="#616365" d="M8.9,715.1h3.9v3.6H8.9V715.1z M8.9,721.8h3.9v17.3H8.9V721.8z"></path><path fill="#616365" d="M15.1,721.8h4.1l4.4,13.4l0,0l4.1-13.4h3.9l-6.2,17.3H21L15.1,721.8z"></path><path fill="#616365" d="M37.3,731.4c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.5,0.5,1,0.8,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-1.5,0.8-3.1,1.3-4.9,1.5 c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.3,0.5-3.6 c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9H37.3V731.4L37.3,731.4z M46.3,728.8c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H46.3z"></path><path fill="#616365" d="M-290.8,775.5c0,0.3,0,0.8,0.3,1c0,0.3,0.3,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 h-1.3c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5s-2.1,0.5-3.1,0.5c-0.8,0-1.5,0-2.3-0.3s-1.3-0.5-1.8-1 s-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8 c0.8-0.3,1.5-0.3,2.3-0.5c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1,0,1.5-0.3c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3 c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8c-0.8,0.5-1.3,1.3-1.3,2.1h-3.9 c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3c0.8,0,1.8,0,2.6,0.3l2.3,0.8 c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V775.5L-290.8,775.5L-290.8,775.5z M-294.7,770.6c-0.8,0.3-1.3,0.5-2.1,0.8 c-0.8,0-1.8,0.3-2.6,0.3s-0.8,0.3-1.3,0.3c-0.5,0-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3c0,0.3,0,0.8,0.3,1l0.8,0.8 c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1c0.3-0.5,0.5-1,0.5-1.5v-2.6L-294.7,770.6 L-294.7,770.6z"></path><path fill="#616365" d="M-286.7,762.1h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3s-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-286.7,762.1L-286.7,762.1z"></path><path fill="#616365" d="M-251.1,779.4h-3.6V777l0,0c-0.5,1-1.3,1.8-2.3,2.1c-1,0.5-2.1,0.8-3.1,0.8c-1.3,0-2.6-0.3-3.6-0.8 c-1-0.5-1.8-1.3-2.6-2.1c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.8,0.5-4.1c0.5-1,1-2.1,1.8-2.8 c0.5-0.8,1.5-1.3,2.3-1.5c1-0.3,1.8-0.5,2.8-0.5c0.5,0,1,0,1.5,0.3c0.5,0,1,0.3,1.5,0.5l1.5,0.8c0.5,0.3,0.8,0.8,1,1.3l0,0v-8.8 h3.9v23.7H-251.1L-251.1,779.4z M-264.5,770.8c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1.3,0.8,1.8c0.5,0.5,1,1,1.5,1.3s1.3,0.5,2.1,0.5 s1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0-0.8,0.3-1.5,0.3-2.3c0-1.5-0.5-3.1-1.3-4.4 c-0.8-1-2.3-1.5-3.6-1.5c-0.8,0-1.5,0.3-2.3,0.5c-0.5,0.3-1.3,1-1.5,1.5c-0.5,0.5-0.8,1.3-0.8,2.1V770.8L-264.5,770.8z"></path><path fill="#616365" d="M-237.2,755.4h4.1v10.8l10.6-10.8h5.2l-9.5,9.5l10.3,14.4h-5.2l-7.7-11.3l-3.4,3.4v8h-4.1v-24 L-237.2,755.4L-237.2,755.4z"></path><path fill="#616365" d="M-214.2,755.4h3.9v3.6h-3.9V755.4z M-214.2,762.1h3.9v17.3h-3.9V762.1z"></path><path fill="#616365" d="M-190,779.4h-3.6V777l0,0c-0.5,1-1.3,1.8-2.3,2.1c-1,0.5-2.1,0.8-3.1,0.8c-1.3,0-2.6-0.3-3.6-0.8 c-1-0.5-1.8-1.3-2.6-2.1c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6s0.3-2.8,0.5-4.1c0.5-1,1-2.1,1.8-2.8 c0.5-0.8,1.5-1.3,2.3-1.5c1-0.3,1.8-0.5,2.8-0.5c0.5,0,1,0,1.5,0.3c0.5,0,1,0.3,1.5,0.5l1.5,0.8c0.5,0.3,0.8,0.8,1,1.3l0,0v-8.8 h3.9v23.7H-190L-190,779.4z M-203.4,770.8c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1.3,0.8,1.8c0.5,0.5,1,1,1.5,1.3 c0.5,0.3,1.3,0.5,2.1,0.5c0.8,0,1.5-0.3,2.3-0.5c0.5-0.3,1-0.8,1.5-1.3c0.5-0.5,0.8-1.3,0.8-2.1c0-0.8,0.3-1.5,0.3-2.3 c0-1.5-0.5-3.1-1.3-4.4c-0.8-1-2.3-1.5-3.6-1.5c-0.8,0-1.5,0.3-2.3,0.5c-0.5,0.3-1.3,1-1.5,1.5c-0.5,0.5-0.8,1.3-0.8,2.1V770.8z"></path><path fill="#616365" d="M-185.9,762.1h3.6v2.6l0,0c0.5-1,1.3-1.8,2.3-2.3c1-0.5,2.1-0.8,3.1-0.8c2.8-0.3,5.7,1.8,5.9,4.9 c0,0.3,0,0.8,0,1v11.9h-3.9v-10.8c0-1-0.3-2.1-0.8-3.1c-0.5-0.8-1.5-1.3-2.6-1c-0.5,0-1.3,0-1.8,0.3c-0.5,0.3-1,0.5-1.3,1 c-0.3,0.5-0.5,1-0.8,1.5c-0.3,0.5-0.3,1.3-0.3,1.8v10.3h-3.9v-17.3L-185.9,762.1L-185.9,762.1z"></path><path fill="#616365" d="M-163.7,771.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.3,0.5,1,1,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8c1.3,0,2.6,0.3,3.6,0.8 c1,0.5,2.1,1.3,2.6,2.3c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-163.7,771.6L-163.7,771.6z M-154.7,769 c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5 c-0.3,0.5-0.3,1.3-0.3,1.8H-154.7z"></path><path fill="#616365" d="M-150,762.1h4.1l4.6,12.9l0,0l4.4-12.9h3.9l-6.7,18.3c-0.3,0.8-0.5,1.5-1,2.3c-0.3,0.5-0.5,1.3-1,1.8 c-0.5,0.5-1,1-1.5,1.3c-0.8,0.3-1.8,0.5-2.6,0.5c-0.8,0-1.8,0-2.6-0.3V783c0.3,0,0.8,0,1,0.3s0.8,0.3,1,0c0.3,0,0.8,0,1-0.3 c0.3,0,0.5-0.3,0.8-0.5c0.3-0.3,0.3-0.5,0.5-0.8s0.3-0.8,0.3-1l0.5-1.3L-150,762.1z"></path><path fill="#616365" d="M-120.6,755.4h9.8c1.5,0,3.4,0.3,4.6,1c1.3,0.5,2.3,1.5,3.4,2.6c1,1,1.5,2.3,1.8,3.9 c0.5,1.5,0.5,3.1,0.5,4.6s-0.3,3.1-0.5,4.6c-0.5,1.3-1,2.6-1.8,3.9c-0.8,1-2.1,2.1-3.4,2.6c-1.5,0.5-3.1,1-4.6,1h-9.8V755.4 L-120.6,755.4z M-116.5,776h4.1c1.3,0,2.8-0.3,4.1-0.8c1-0.3,1.8-1,2.3-1.8s1-1.8,1.3-2.8c0.3-2.3,0.3-4.4,0-6.7 c-0.3-1-0.5-2.1-1.3-2.8c-0.5-0.8-1.3-1.5-2.3-1.8c-1.3-0.5-2.8-0.8-4.1-0.8h-4.1V776L-116.5,776z"></path><path fill="#616365" d="M-96.9,755.4h3.9v3.6h-3.9V755.4z M-96.9,762.1h3.9v17.3h-3.9V762.1z"></path><path fill="#616365" d="M-86,773.7c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3c0.5,0,0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8s-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c0.5,0.3,1.3,1,1.5,1.5 c0.5,0.8,0.8,1.5,0.8,2.6h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8s1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3c-1,0-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-86,773.7L-86,773.7z"></path><path fill="#616365" d="M-68.2,771.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.3,0.5,1,1,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8s2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-68.2,771.6L-68.2,771.6z M-59.5,769c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H-59.5z"></path><path fill="#616365" d="M-38.1,775.5c0,0.3,0,0.8,0.3,1c0.3,0.3,0.5,0.3,0.8,0.3h1v2.6c-0.3,0-0.5,0-0.5,0.3c-0.3,0-0.5,0-0.8,0.3 c-0.3,0-0.5,0-0.8,0h-0.5c-0.8,0-1.5-0.3-2.1-0.5c-0.5-0.3-1-1-1-1.5c-0.8,0.8-1.8,1.3-2.8,1.5s-2.1,0.5-3.1,0.5 c-0.8,0-1.5,0-2.3-0.3c-0.8-0.3-1.3-0.5-1.8-1s-1-1-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.5-2.6 c0.3-0.5,1-1.3,1.5-1.5c0.5-0.5,1.3-0.8,2.1-0.8c0.8-0.3,1.5-0.3,2.3-0.5c0.8-0.3,1.3-0.3,2.1-0.3c0.5,0,1.3-0.3,1.5-0.3 c0.3,0,0.8-0.3,1-0.5c0.3-0.3,0.5-0.8,0.5-1.3c0-0.5,0-0.8-0.3-1.3l-0.8-0.8c-0.3-0.3-0.8-0.3-1-0.3h-1.3c-1,0-1.8,0.3-2.6,0.8 c-0.8,0.5-1.3,1.3-1.3,2.1H-53c0-1,0.3-2.1,0.8-2.8c0.5-0.8,1-1.3,1.8-1.8c0.8-0.5,1.5-0.8,2.6-1c1-0.3,1.8-0.3,2.8-0.3 c0.8,0,1.8,0,2.6,0.3l2.3,0.8c0.5,0.3,1.3,1,1.5,1.5c0.5,0.8,0.8,1.5,0.5,2.3V775.5L-38.1,775.5z M-41.9,770.6 c-0.8,0.3-1.3,0.5-2.1,0.8c-0.8,0-1.8,0.3-2.6,0.3c-0.8,0-0.8,0.3-1.3,0.3s-0.8,0.3-1,0.5l-0.8,0.8c-0.3,0.5-0.3,0.8-0.3,1.3 c0,0.3,0,0.8,0.3,1l0.8,0.8c0.3,0.3,0.8,0.3,1,0.3h1c0.5,0,0.8,0,1.3-0.3c0.5,0,1-0.3,1.3-0.5c0.5-0.3,0.8-0.5,1-1 c0.3-0.5,0.5-1,0.5-1.5v-2.6L-41.9,770.6L-41.9,770.6z"></path><path fill="#616365" d="M-31.1,773.7c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3s0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8s-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c0.5,0.3,1.3,1,1.5,1.5 c0.5,0.8,0.8,1.5,0.8,2.6h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8c0.5,0.3,1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6h3.6L-31.1,773.7L-31.1,773.7z"></path><path fill="#616365" d="M-13.6,771.6c0,0.8,0,1.3,0.3,2.1c0.3,0.5,0.5,1,0.8,1.5c0.3,0.5,1,1,1.5,1c0.5,0.3,1.3,0.5,2.1,0.5 c1,0,1.8-0.3,2.6-0.8c0.8-0.5,1.3-1.3,1.5-2.1h3.6c-0.3,1-0.5,1.8-1,2.6c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.3,1 c-0.8,0.3-1.8,0.3-2.6,0.3c-1.3,0-2.6-0.3-3.6-0.8c-1-0.3-1.8-1-2.6-1.8c-0.8-0.8-1.3-1.8-1.5-2.8c-0.3-1.3-0.5-2.3-0.5-3.6 s0.3-2.3,0.5-3.6c0.5-1,1-1.8,1.5-2.8c0.8-0.8,1.5-1.5,2.6-2.1c1-0.5,2.3-0.8,3.6-0.8s2.6,0.3,3.6,0.8c1,0.5,2.1,1.3,2.6,2.3 c0.8,1,1.3,2.1,1.5,3.4c0.3,1.3,0.5,2.6,0.3,3.9L-13.6,771.6L-13.6,771.6z M-4.8,769c0-0.5-0.3-1.3-0.3-1.8l-0.8-1.5 c-0.3-0.5-0.8-0.8-1.3-1c-1.3-0.3-2.3-0.3-3.6,0c-0.5,0.3-1,0.5-1.3,1c-0.5,0.5-0.8,1-1,1.5c-0.3,0.5-0.3,1.3-0.5,1.8H-4.8z"></path><path fill="#616365" d="M5,773.7c0,1,0.5,1.8,1.3,2.3c0.8,0.5,1.5,0.8,2.6,0.8h1.3c0.5,0,0.8-0.3,1.3-0.3c0.5,0,0.8-0.3,1-0.8 c0.3-0.5,0.3-0.8,0.3-1.3c0-0.5-0.3-1-0.5-1.3c-0.5-0.3-0.8-0.5-1.3-0.8s-1.3-0.3-1.8-0.5c-0.8-0.3-1.3-0.3-2.1-0.5 c-0.8-0.3-1.3-0.3-2.1-0.5c-0.8-0.3-1.3-0.5-1.8-1c-0.5-0.3-1-0.8-1.3-1.5c-0.3-0.8-0.5-1.5-0.5-2.3c0-0.8,0.3-1.8,0.8-2.3 c0.5-0.5,1-1,1.8-1.5c0.8-0.5,1.5-0.8,2.3-0.8c1.8-0.3,3.4-0.3,5.2,0c0.8,0.3,1.5,0.5,2.3,1c0.5,0.3,1.3,1,1.5,1.5 c0.5,0.8,0.8,1.5,0.8,2.6h-3.9c0-0.8-0.5-1.5-1.3-1.8c-0.8-0.3-1.5-0.5-2.3-0.5h-1c-0.3,0-0.8,0-1,0.3c-0.3,0-0.5,0.3-0.8,0.5 c-0.3,0.3-0.3,0.8-0.3,1c0,0.5,0.3,0.8,0.5,1c0.5,0.3,0.8,0.5,1.3,0.8s1.3,0.3,1.8,0.5c0.8,0.3,1.3,0.3,2.1,0.5 c0.8,0.3,1.3,0.3,2.1,0.5c0.8,0.3,1.3,0.5,1.8,1c0.5,0.3,1,0.8,1.3,1.5c0.3,0.5,0.5,1.3,0.5,2.1c0,1-0.3,1.8-0.8,2.6 c-0.5,0.8-1,1.3-1.8,1.8c-0.8,0.5-1.5,0.8-2.6,1c-1,0.3-1.8,0.3-2.8,0.3s-2.1,0-3.1-0.3c-0.8-0.3-1.5-0.5-2.3-1 c-0.8-0.5-1.3-1-1.5-1.8c-0.5-0.8-0.5-1.8-0.5-2.6H5L5,773.7L5,773.7z"></path></g></g></svg></div></a></div><div class="PageHeader_searchContent__5k0zQ col"><input name="query" type="text" placeholder="Search the Website..." value=""/><button aria-label="" class="Button_button__OFOdO Button_auto__peQWd Button_primary__WTwSy a a-primary"><svg xmlns="http://www.w3.org/2000/svg" width="23" height="23" fill="currentColor" class="bi bi-search" viewBox="0 0 16 16"><path d="M11.742 10.344a6.5 6.5 0 1 0-1.397 1.398h-.001c.03.04.062.078.098.115l3.85 3.85a1 1 0 0 0 1.415-1.414l-3.85-3.85a1.007 1.007 0 0 0-.115-.1zM12 6.5a5.5 5.5 0 1 1-11 0 5.5 5.5 0 0 1 11 0z"></path></svg></button></div></div><div class="NavBar_stickyContainer___XV6p"><div class="NavBar_headerContainer__KSr1m row"><div class="NavBar_content__GxtKX col"><a href="/home">NIDDK Central Repository</a></div><div class="NavBar_content__GxtKX col"><a href="/user/login"><button aria-label="Sign In / Register" class="Button_button__OFOdO Button_auto__peQWd Button_login__gkznn a a-primary">Sign In / Register</button></a></div></div><nav class="NavBar_NavigationBar__3wGqF navbar navbar-expand navbar-light"><button aria-controls="navbar-collapse" type="button" aria-label="Toggle navigation" class="NavBar_toggle__rY7gT navbar-toggler collapsed"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="30" height="30" fill="white" class="bi bi-list"><path fill-rule="evenodd" d="M2.5 12a.5.5 0 0 1 .5-.5h10a.5.5 0 0 1 0 1H3a.5.5 0 0 1-.5-.5m0-4a.5.5 0 0 1 .5-.5h10a.5.5 0 0 1 0 1H3a.5.5 0 0 1-.5-.5m0-4a.5.5 0 0 1 .5-.5h10a.5.5 0 0 1 0 1H3a.5.5 0 0 1-.5-.5"></path></svg></button><div class="NavBar_collapse__Ki_F1 navbar-collapse collapse" id="navbar-collapse"><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:R9ssm:" aria-expanded="false" role="button" class="NavBar_selected__gZSY5 NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>Repository Resources<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:Rassm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>Helpful Information<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:Rbssm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>Requests<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div><div class="NavBar_navItem__ePCO5 dropdown nav-item"><a id="react-aria-:Rcssm:" aria-expanded="false" role="button" class="NavBar_dropdownToggle__8BR17 dropdown-toggle nav-link" tabindex="0" href="#"><div>About NIDDK-CR<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-caret-down-fill"><path d="M7.247 11.14 2.451 5.658C1.885 5.013 2.345 4 3.204 4h9.592a1 1 0 0 1 .753 1.659l-4.796 5.48a1 1 0 0 1-1.506 0z"></path></svg></div></a></div></div></nav></div><div style="position:relative;overflow:hidden;width:100%" class="Banner_parallax__Gp6_i"></div><div><div class="container-fluid"><div class="StudyExplorer_Row__Uiaxu row"><div class="StudyExplorer_sidebarContainer__sJpC8 CollapsibleSideBar_container__RAhB5 col-lg-2"><div class="CollapsibleSideBar_toggleContainer__AepNw"><div class="CollapsibleSideBar_title__rebmz ">Search</div><button class="CollapsibleSideBar_toggleButton__V4sJZ" aria-label="Hide Search"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" width="1em" height="1em" fill="currentColor" class="bi bi-chevron-double-left"><path fill-rule="evenodd" d="M8.354 1.646a.5.5 0 0 1 0 .708L2.707 8l5.647 5.646a.5.5 0 0 1-.708.708l-6-6a.5.5 0 0 1 0-.708l6-6a.5.5 0 0 1 .708 0"></path><path fill-rule="evenodd" d="M12.354 1.646a.5.5 0 0 1 0 .708L6.707 8l5.647 5.646a.5.5 0 0 1-.708.708l-6-6a.5.5 0 0 1 0-.708l6-6a.5.5 0 0 1 .708 0"></path></svg></button></div><div class=" CollapsibleSideBar_sidebar__xRPmm"><div class="SearchBarContainer_searchRow__3_XzW"><div class="row"><div class="SearchBarContainer_rowAlign__7ubZQ"><div class="SearchBar_searchBar__UbU3M"><div class="Input_autocompleteContainer___sfYc"><input type="text" class="Input_searchInput__o6cFR" aria-label="Search bar autocomplete" placeholder="Search for Studies using Study Metadata..." value=""/></div><button type="submit" aria-label="Search Button" class="Button_button__OFOdO Button_auto__peQWd SearchBar_searchButton__nhLkE Button_primary__WTwSy a a-primary"><span class="Button_iconLeft__dfwTS"><svg xmlns="http://www.w3.org/2000/svg" width="23" height="23" fill="currentColor" class="bi bi-search" viewBox="0 0 16 16"><path d="M11.742 10.344a6.5 6.5 0 1 0-1.397 1.398h-.001c.03.04.062.078.098.115l3.85 3.85a1 1 0 0 0 1.415-1.414l-3.85-3.85a1.007 1.007 0 0 0-.115-.1zM12 6.5a5.5 5.5 0 1 1-11 0 5.5 5.5 0 0 1 11 0z"></path></svg></span>Search</button></div></div></div></div><div class="StudyExplorer_filtersTitle__9C1ef">Filters</div><div class="BadgeSection_badgeContainer__NXRQb"><div class="BadgeSection_badgeSection__0_kEc"></div></div><div tabindex="0" id="-1" aria-label="Research Area collapsable section" class=" Accordion_filterAccordion__FRmA3 accordion"><div class="undefined Accordion_filterItem__KJDOV accordion-item"><h2 class="undefined Accordion_filterHeader__RktDS accordion-header"><button type="button" aria-expanded="false" class="accordion-button collapsed">Research Area</button></h2><div class="accordion-collapse collapse"><div class="undefined Accordion_filterBody__n0i21 accordion-body"><div role="region" aria-live="polite"><div class="mb-3 row"><form class="FacetAggregate_clearIconContainer__ustR7"><input aria-label="Research Area filter search bar" type="text" placeholder="Search for filter..." value=""/><span><svg xmlns="http://www.w3.org/2000/svg" width="21" height="21" viewBox="0 0 21 21" fill="none"><circle cx="10.4286" cy="10.4286" r="9.92857" fill="white" stroke="#868686"></circle><path d="M15.2969 15.2958L5.56354 5.5625" stroke="#6C757D" stroke-width="2" stroke-miterlimit="10"></path><path d="M5.56354 15.2958L15.2969 5.5625" stroke="#6C757D" stroke-width="2" stroke-miterlimit="10"></path></svg></span></form></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Diabetes" class="form-check-input"/><label title="" for="Diabetes" class="form-check-label">Diabetes (67)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Digestive Diseases" class="form-check-input"/><label title="" for="Digestive Diseases" class="form-check-label">Digestive Diseases (24)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Endocrine Diseases and Metabolic Diseases" class="form-check-input"/><label title="" for="Endocrine Diseases and Metabolic Diseases" class="form-check-label">Endocrine Diseases and Metabolic Diseases (6)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hematologic Diseases" class="form-check-input"/><label title="" for="Hematologic Diseases" class="form-check-label">Hematologic Diseases (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Kidney Disease" class="form-check-input"/><label title="" for="Kidney Disease" class="form-check-label">Kidney Disease (44)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Liver Disease" class="form-check-input"/><label title="" for="Liver Disease" class="form-check-label">Liver Disease (47)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Multidisciplinary Research" class="form-check-input"/><label title="" for="Multidisciplinary Research" class="form-check-label">Multidisciplinary Research (49)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Nutrition" class="form-check-input"/><label title="" for="Nutrition" class="form-check-label">Nutrition (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Obesity" class="form-check-input"/><label title="" for="Obesity" class="form-check-label">Obesity (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Pancreatic Disease" class="form-check-input"/><label title="" for="Pancreatic Disease" class="form-check-label">Pancreatic Disease (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urologic Diseases" class="form-check-input"/><label title="" for="Urologic Diseases" class="form-check-label">Urologic Diseases (27)</label></div></div></div></div></div></div><div tabindex="0" id="-1" aria-label="Network collapsable section" class=" Accordion_filterAccordion__FRmA3 accordion"><div class="undefined Accordion_filterItem__KJDOV accordion-item"><h2 class="undefined Accordion_filterHeader__RktDS accordion-header"><button type="button" aria-expanded="false" class="accordion-button collapsed">Network</button></h2><div class="accordion-collapse collapse"><div class="undefined Accordion_filterBody__n0i21 accordion-body"><div role="region" aria-live="polite"><div class="mb-3 row"><form class="FacetAggregate_clearIconContainer__ustR7"><input aria-label="Network filter search bar" type="text" placeholder="Search for filter..." value=""/><span><svg xmlns="http://www.w3.org/2000/svg" width="21" height="21" viewBox="0 0 21 21" fill="none"><circle cx="10.4286" cy="10.4286" r="9.92857" fill="white" stroke="#868686"></circle><path d="M15.2969 15.2958L5.56354 5.5625" stroke="#6C757D" stroke-width="2" stroke-miterlimit="10"></path><path d="M5.56354 15.2958L15.2969 5.5625" stroke="#6C757D" stroke-width="2" stroke-miterlimit="10"></path></svg></span></form></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Acute Kidney Injury Network (AKI)" class="form-check-input"/><label title="" for="Acute Kidney Injury Network (AKI)" class="form-check-label">Acute Kidney Injury Network (AKI) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Acute Liver Failure Study Group (ALFSG)" class="form-check-input"/><label title="" for="Acute Liver Failure Study Group (ALFSG)" class="form-check-label">Acute Liver Failure Study Group (ALFSG) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Adult Living Donor Liver Transplantation Studies (A2ALL Network)" class="form-check-input"/><label title="" for="Adult Living Donor Liver Transplantation Studies (A2ALL Network)" class="form-check-label">Adult Living Donor Liver Transplantation Studies (A2ALL Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="African American Study of Kidney Disease Study Group (AASK)" class="form-check-input"/><label title="" for="African American Study of Kidney Disease Study Group (AASK)" class="form-check-label">African American Study of Kidney Disease Study Group (AASK) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="ChiLDReN Network (ChiLDReN)" class="form-check-input"/><label title="" for="ChiLDReN Network (ChiLDReN)" class="form-check-label">ChiLDReN Network (ChiLDReN) (17)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Chronic Kidney Disease Consortium (CKD)" class="form-check-input"/><label title="" for="Chronic Kidney Disease Consortium (CKD)" class="form-check-label">Chronic Kidney Disease Consortium (CKD) (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Chronic Prostatitis Collaborative Research Network (CPCRN)" class="form-check-input"/><label title="" for="Chronic Prostatitis Collaborative Research Network (CPCRN)" class="form-check-label">Chronic Prostatitis Collaborative Research Network (CPCRN) (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Clinical Islet Transplantation Consortium (CITC)" class="form-check-input"/><label title="" for="Clinical Islet Transplantation Consortium (CITC)" class="form-check-label">Clinical Islet Transplantation Consortium (CITC) (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP Network)" class="form-check-input"/><label title="" for="Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP Network)" class="form-check-label">Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cure Glomerulonephropathy (CureGN Network)" class="form-check-input"/><label title="" for="Cure Glomerulonephropathy (CureGN Network)" class="form-check-label">Cure Glomerulonephropathy (CureGN Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Dialysis Access Consortium (DAC)" class="form-check-input"/><label title="" for="Dialysis Access Consortium (DAC)" class="form-check-label">Dialysis Access Consortium (DAC) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Drug-Induced Liver Injury Network (DILIN)" class="form-check-input"/><label title="" for="Drug-Induced Liver Injury Network (DILIN)" class="form-check-label">Drug-Induced Liver Injury Network (DILIN) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="FSGS Study Group (FSGS)" class="form-check-input"/><label title="" for="FSGS Study Group (FSGS)" class="form-check-label">FSGS Study Group (FSGS) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Familial Barrett's Esophagus Consortium (FBEC)" class="form-check-input"/><label title="" for="Familial Barrett's Esophagus Consortium (FBEC)" class="form-check-label">Familial Barrett's Esophagus Consortium (FBEC) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Frequent Hemodialysis Network (FHN)" class="form-check-input"/><label title="" for="Frequent Hemodialysis Network (FHN)" class="form-check-label">Frequent Hemodialysis Network (FHN) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Gastroparesis Clinical Research Consortium (GpCRC)" class="form-check-input"/><label title="" for="Gastroparesis Clinical Research Consortium (GpCRC)" class="form-check-label">Gastroparesis Clinical Research Consortium (GpCRC) (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatitis B Research Network (HBRN)" class="form-check-input"/><label title="" for="Hepatitis B Research Network (HBRN)" class="form-check-label">Hepatitis B Research Network (HBRN) (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Interstitial Cystitis Clinical Research Network (ICCRN)" class="form-check-input"/><label title="" for="Interstitial Cystitis Clinical Research Network (ICCRN)" class="form-check-label">Interstitial Cystitis Clinical Research Network (ICCRN) (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Liver Transplantation Database (LTD)" class="form-check-input"/><label title="" for="Liver Transplantation Database (LTD)" class="form-check-label">Liver Transplantation Database (LTD) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Lower Urinary Tract Dysfunction Research Network (LURN Network)" class="form-check-input"/><label title="" for="Lower Urinary Tract Dysfunction Research Network (LURN Network)" class="form-check-label">Lower Urinary Tract Dysfunction Research Network (LURN Network) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia (MIST Network)" class="form-check-input"/><label title="" for="Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia (MIST Network)" class="form-check-label">Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia (MIST Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP Network)" class="form-check-input"/><label title="" for="Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP Network)" class="form-check-label">Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP Network) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Nonalcoholic Steatohepatitis Clinical Research Network (NASH)" class="form-check-input"/><label title="" for="Nonalcoholic Steatohepatitis Clinical Research Network (NASH)" class="form-check-label">Nonalcoholic Steatohepatitis Clinical Research Network (NASH) (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="PALF Network (PALF Network)" class="form-check-input"/><label title="" for="PALF Network (PALF Network)" class="form-check-label">PALF Network (PALF Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Prevention of Lower Urinary Tract Symptoms Consortium (PLUS)" class="form-check-input"/><label title="" for="Prevention of Lower Urinary Tract Symptoms Consortium (PLUS)" class="form-check-label">Prevention of Lower Urinary Tract Symptoms Consortium (PLUS) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="RIVUR Network (RIVUR Network)" class="form-check-input"/><label title="" for="RIVUR Network (RIVUR Network)" class="form-check-label">RIVUR Network (RIVUR Network) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Silymarin Trials for Hepatitis C and NASH (SyNCH Network)" class="form-check-input"/><label title="" for="Silymarin Trials for Hepatitis C and NASH (SyNCH Network)" class="form-check-label">Silymarin Trials for Hepatitis C and NASH (SyNCH Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="The Environmental Determinants of Diabetes in the Young (TEDDY) Network (TEDDY Network)" class="form-check-input"/><label title="" for="The Environmental Determinants of Diabetes in the Young (TEDDY) Network (TEDDY Network)" class="form-check-label">The Environmental Determinants of Diabetes in the Young (TEDDY) Network (TEDDY Network) (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="The HALT Progression of Polycystic Kidney Disease (HALT PKD Network)" class="form-check-input"/><label title="" for="The HALT Progression of Polycystic Kidney Disease (HALT PKD Network)" class="form-check-label">The HALT Progression of Polycystic Kidney Disease (HALT PKD Network) (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="The RISE Consortium (RISE)" class="form-check-input"/><label title="" for="The RISE Consortium (RISE)" class="form-check-label">The RISE Consortium (RISE) (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="The Treatment Options for Type 2 Diabetes in Adolescents and Youth Network (TODAY Network)" class="form-check-input"/><label title="" for="The Treatment Options for Type 2 Diabetes in Adolescents and Youth Network (TODAY Network)" class="form-check-label">The Treatment Options for Type 2 Diabetes in Adolescents and Youth Network (TODAY Network) (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Type 1 Diabetes Genetics Consortium (T1DGC Network)" class="form-check-input"/><label title="" for="Type 1 Diabetes Genetics Consortium (T1DGC Network)" class="form-check-label">Type 1 Diabetes Genetics Consortium (T1DGC Network) (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Type 1 Diabetes TrialNet (TrialNet)" class="form-check-input"/><label title="" for="Type 1 Diabetes TrialNet (TrialNet)" class="form-check-label">Type 1 Diabetes TrialNet (TrialNet) (19)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urinary Incontinence Research Network (UITN)" class="form-check-input"/><label title="" for="Urinary Incontinence Research Network (UITN)" class="form-check-label">Urinary Incontinence Research Network (UITN) (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urinary Stone Disease Research Network (USDRN)" class="form-check-input"/><label title="" for="Urinary Stone Disease Research Network (USDRN)" class="form-check-label">Urinary Stone Disease Research Network (USDRN) (2)</label></div></div></div></div></div></div><div tabindex="0" id="-1" aria-label="Target Population collapsable section" class=" Accordion_filterAccordion__FRmA3 accordion"><div class="undefined Accordion_filterItem__KJDOV accordion-item"><h2 class="undefined Accordion_filterHeader__RktDS accordion-header"><button type="button" aria-expanded="false" class="accordion-button collapsed">Target Population</button></h2><div class="accordion-collapse collapse"><div class="undefined Accordion_filterBody__n0i21 accordion-body"><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Adults" class="form-check-input"/><label title="" for="Adults" class="form-check-label">Adults (149)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Children" class="form-check-input"/><label title="" for="Children" class="form-check-label">Children (87)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Dialysis Patients" class="form-check-input"/><label title="" for="Dialysis Patients" class="form-check-label">Dialysis Patients (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Pregnant (or Nursing) Women" class="form-check-input"/><label title="" for="Pregnant (or Nursing) Women" class="form-check-label">Pregnant (or Nursing) Women (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Transplant Patients" class="form-check-input"/><label title="" for="Transplant Patients" class="form-check-label">Transplant Patients (21)</label></div></div></div></div></div></div><div tabindex="0" id="-1" aria-label="Data Availability collapsable section" class=" Accordion_filterAccordion__FRmA3 accordion"><div class="undefined Accordion_filterItem__KJDOV accordion-item"><h2 class="undefined Accordion_filterHeader__RktDS accordion-header"><button type="button" aria-expanded="false" class="accordion-button collapsed">Data Availability</button></h2><div class="accordion-collapse collapse"><div class="undefined Accordion_filterBody__n0i21 accordion-body"><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Data Available for Request" class="form-check-input"/><label title="" for="Data Available for Request" class="form-check-label">Data Available for Request (157)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Data Expected" class="form-check-input"/><label title="" for="Data Expected" class="form-check-label">Data Expected (20)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Data Not Available" class="form-check-input"/><label title="" for="Data Not Available" class="form-check-label">Data Not Available (10)</label></div></div></div></div></div></div><div tabindex="0" id="-1" aria-label="Specimen Availability collapsable section" class=" Accordion_filterAccordion__FRmA3 accordion"><div class="undefined Accordion_filterItem__KJDOV accordion-item"><h2 class="undefined Accordion_filterHeader__RktDS accordion-header"><button type="button" aria-expanded="false" class="accordion-button collapsed">Specimen Availability</button></h2><div class="accordion-collapse collapse"><div class="undefined Accordion_filterBody__n0i21 accordion-body"><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Requires Collaboration with Parent Study" class="form-check-input"/><label title="" for="Requires Collaboration with Parent Study" class="form-check-label">Requires Collaboration with Parent Study (42)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Specimens Available for Request" class="form-check-input"/><label title="" for="Specimens Available for Request" class="form-check-label">Specimens Available for Request (102)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Specimens Expected" class="form-check-input"/><label title="" for="Specimens Expected" class="form-check-label">Specimens Expected (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Specimens Not Available" class="form-check-input"/><label title="" for="Specimens Not Available" class="form-check-label">Specimens Not Available (40)</label></div></div></div></div></div></div><div tabindex="0" id="-1" aria-label="Condition collapsable section" class=" Accordion_filterAccordion__FRmA3 accordion"><div class="undefined Accordion_filterItem__KJDOV accordion-item"><h2 class="undefined Accordion_filterHeader__RktDS accordion-header"><button type="button" aria-expanded="false" class="accordion-button collapsed">Condition</button></h2><div class="accordion-collapse collapse"><div class="undefined Accordion_filterBody__n0i21 accordion-body"><div role="region" aria-live="polite"><div class="mb-3 row"><form class="FacetAggregate_clearIconContainer__ustR7"><input aria-label="Condition filter search bar" type="text" placeholder="Search for filter..." value=""/><span><svg xmlns="http://www.w3.org/2000/svg" width="21" height="21" viewBox="0 0 21 21" fill="none"><circle cx="10.4286" cy="10.4286" r="9.92857" fill="white" stroke="#868686"></circle><path d="M15.2969 15.2958L5.56354 5.5625" stroke="#6C757D" stroke-width="2" stroke-miterlimit="10"></path><path d="M5.56354 15.2958L15.2969 5.5625" stroke="#6C757D" stroke-width="2" stroke-miterlimit="10"></path></svg></span></form></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="AV Fistula Thrombosis" class="form-check-input"/><label title="" for="AV Fistula Thrombosis" class="form-check-label">AV Fistula Thrombosis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Acute Kidney Injury" class="form-check-input"/><label title="" for="Acute Kidney Injury" class="form-check-label">Acute Kidney Injury (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Acute Liver Failure" class="form-check-input"/><label title="" for="Acute Liver Failure" class="form-check-label">Acute Liver Failure (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Alagille Syndrome" class="form-check-input"/><label title="" for="Alagille Syndrome" class="form-check-label">Alagille Syndrome (6)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Alpha 1-Antitrypsin Deficiency" class="form-check-input"/><label title="" for="Alpha 1-Antitrypsin Deficiency" class="form-check-label">Alpha 1-Antitrypsin Deficiency (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Arteriosclerosis Disorder" class="form-check-input"/><label title="" for="Arteriosclerosis Disorder" class="form-check-label">Arteriosclerosis Disorder (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Asthma" class="form-check-input"/><label title="" for="Asthma" class="form-check-label">Asthma (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Autoimmune Hepatitis" class="form-check-input"/><label title="" for="Autoimmune Hepatitis" class="form-check-label">Autoimmune Hepatitis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Barrett Esophagus" class="form-check-input"/><label title="" for="Barrett Esophagus" class="form-check-label">Barrett Esophagus (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Benign Prostatic Hyperplasia" class="form-check-input"/><label title="" for="Benign Prostatic Hyperplasia" class="form-check-label">Benign Prostatic Hyperplasia (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Bile Duct Disorder" class="form-check-input"/><label title="" for="Bile Duct Disorder" class="form-check-label">Bile Duct Disorder (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Biliary Atresia" class="form-check-input"/><label title="" for="Biliary Atresia" class="form-check-label">Biliary Atresia (11)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Biliary Dyskinesia" class="form-check-input"/><label title="" for="Biliary Dyskinesia" class="form-check-label">Biliary Dyskinesia (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Budd-Chiari Syndrome" class="form-check-input"/><label title="" for="Budd-Chiari Syndrome" class="form-check-label">Budd-Chiari Syndrome (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cancer" class="form-check-input"/><label title="" for="Cancer" class="form-check-label">Cancer (9)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cardiovascular Disorder" class="form-check-input"/><label title="" for="Cardiovascular Disorder" class="form-check-label">Cardiovascular Disorder (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Celiac Disease" class="form-check-input"/><label title="" for="Celiac Disease" class="form-check-label">Celiac Disease (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cholelithiasis" class="form-check-input"/><label title="" for="Cholelithiasis" class="form-check-label">Cholelithiasis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cholestasis" class="form-check-input"/><label title="" for="Cholestasis" class="form-check-label">Cholestasis (9)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Chronic Kidney Disease" class="form-check-input"/><label title="" for="Chronic Kidney Disease" class="form-check-label">Chronic Kidney Disease (20)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cirrhosis of Liver" class="form-check-input"/><label title="" for="Cirrhosis of Liver" class="form-check-label">Cirrhosis of Liver (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Colitis" class="form-check-input"/><label title="" for="Colitis" class="form-check-label">Colitis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Congenital Bile Acid Synthesis Defect" class="form-check-input"/><label title="" for="Congenital Bile Acid Synthesis Defect" class="form-check-label">Congenital Bile Acid Synthesis Defect (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Congestive Heart Failure" class="form-check-input"/><label title="" for="Congestive Heart Failure" class="form-check-label">Congestive Heart Failure (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Crigler-Najjar Syndrome" class="form-check-input"/><label title="" for="Crigler-Najjar Syndrome" class="form-check-label">Crigler-Najjar Syndrome (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Crohn Disease" class="form-check-input"/><label title="" for="Crohn Disease" class="form-check-label">Crohn Disease (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cystic Fibrosis" class="form-check-input"/><label title="" for="Cystic Fibrosis" class="form-check-label">Cystic Fibrosis (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Cystic Kidney Disease" class="form-check-input"/><label title="" for="Cystic Kidney Disease" class="form-check-label">Cystic Kidney Disease (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Deep Vein Thrombosis" class="form-check-input"/><label title="" for="Deep Vein Thrombosis" class="form-check-label">Deep Vein Thrombosis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Diabetic Kidney Disease" class="form-check-input"/><label title="" for="Diabetic Kidney Disease" class="form-check-label">Diabetic Kidney Disease (6)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Diabetic Neuropathy" class="form-check-input"/><label title="" for="Diabetic Neuropathy" class="form-check-label">Diabetic Neuropathy (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Diabetic Retinopathy" class="form-check-input"/><label title="" for="Diabetic Retinopathy" class="form-check-label">Diabetic Retinopathy (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Drug-Induced Liver Injury" class="form-check-input"/><label title="" for="Drug-Induced Liver Injury" class="form-check-label">Drug-Induced Liver Injury (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Dyspepsia" class="form-check-input"/><label title="" for="Dyspepsia" class="form-check-label">Dyspepsia (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="End Stage Renal Failure" class="form-check-input"/><label title="" for="End Stage Renal Failure" class="form-check-label">End Stage Renal Failure (16)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Erectile Dysfunction" class="form-check-input"/><label title="" for="Erectile Dysfunction" class="form-check-label">Erectile Dysfunction (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Esophageal Adenocarcinoma" class="form-check-input"/><label title="" for="Esophageal Adenocarcinoma" class="form-check-label">Esophageal Adenocarcinoma (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Fatty Liver Disease" class="form-check-input"/><label title="" for="Fatty Liver Disease" class="form-check-label">Fatty Liver Disease (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Fibromyalgia" class="form-check-input"/><label title="" for="Fibromyalgia" class="form-check-label">Fibromyalgia (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Fibrotic Liver Disease" class="form-check-input"/><label title="" for="Fibrotic Liver Disease" class="form-check-label">Fibrotic Liver Disease (11)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Focal Segmental Glomerulosclerosis" class="form-check-input"/><label title="" for="Focal Segmental Glomerulosclerosis" class="form-check-label">Focal Segmental Glomerulosclerosis (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Fulminant Viral Hepatitis" class="form-check-input"/><label title="" for="Fulminant Viral Hepatitis" class="form-check-label">Fulminant Viral Hepatitis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Gastroparesis" class="form-check-input"/><label title="" for="Gastroparesis" class="form-check-label">Gastroparesis (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Gestational Diabetes" class="form-check-input"/><label title="" for="Gestational Diabetes" class="form-check-label">Gestational Diabetes (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Glomerular Disorder" class="form-check-input"/><label title="" for="Glomerular Disorder" class="form-check-label">Glomerular Disorder (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Glomerulonephritis" class="form-check-input"/><label title="" for="Glomerulonephritis" class="form-check-label">Glomerulonephritis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Glucose Metabolism Disease" class="form-check-input"/><label title="" for="Glucose Metabolism Disease" class="form-check-label">Glucose Metabolism Disease (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Glycogen Storage Disease" class="form-check-input"/><label title="" for="Glycogen Storage Disease" class="form-check-label">Glycogen Storage Disease (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="HIV Infectious Disease" class="form-check-input"/><label title="" for="HIV Infectious Disease" class="form-check-label">HIV Infectious Disease (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hemangioendothelioma" class="form-check-input"/><label title="" for="Hemangioendothelioma" class="form-check-label">Hemangioendothelioma (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatic Encephalopathy" class="form-check-input"/><label title="" for="Hepatic Encephalopathy" class="form-check-label">Hepatic Encephalopathy (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatitis A Virus Infection" class="form-check-input"/><label title="" for="Hepatitis A Virus Infection" class="form-check-label">Hepatitis A Virus Infection (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatitis B Virus Infection" class="form-check-input"/><label title="" for="Hepatitis B Virus Infection" class="form-check-label">Hepatitis B Virus Infection (9)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatitis C Virus Infection" class="form-check-input"/><label title="" for="Hepatitis C Virus Infection" class="form-check-label">Hepatitis C Virus Infection (5)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatoblastoma" class="form-check-input"/><label title="" for="Hepatoblastoma" class="form-check-label">Hepatoblastoma (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hepatocellular Carcinoma" class="form-check-input"/><label title="" for="Hepatocellular Carcinoma" class="form-check-label">Hepatocellular Carcinoma (6)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hypertensive Disorder" class="form-check-input"/><label title="" for="Hypertensive Disorder" class="form-check-label">Hypertensive Disorder (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Hypogonadism" class="form-check-input"/><label title="" for="Hypogonadism" class="form-check-label">Hypogonadism (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="IgA Glomerulonephritis" class="form-check-input"/><label title="" for="IgA Glomerulonephritis" class="form-check-label">IgA Glomerulonephritis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Inborn Disorder of Bile Acid Synthesis" class="form-check-input"/><label title="" for="Inborn Disorder of Bile Acid Synthesis" class="form-check-label">Inborn Disorder of Bile Acid Synthesis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Indeterminate Colitis" class="form-check-input"/><label title="" for="Indeterminate Colitis" class="form-check-label">Indeterminate Colitis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Inflammatory Bowel Disease" class="form-check-input"/><label title="" for="Inflammatory Bowel Disease" class="form-check-label">Inflammatory Bowel Disease (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Interstitial Cystitis" class="form-check-input"/><label title="" for="Interstitial Cystitis" class="form-check-label">Interstitial Cystitis (9)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Irritable Bowel Syndrome" class="form-check-input"/><label title="" for="Irritable Bowel Syndrome" class="form-check-label">Irritable Bowel Syndrome (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Isolated Congenital Hepatic Fibrosis" class="form-check-input"/><label title="" for="Isolated Congenital Hepatic Fibrosis" class="form-check-label">Isolated Congenital Hepatic Fibrosis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Lipoid Nephrosis" class="form-check-input"/><label title="" for="Lipoid Nephrosis" class="form-check-label">Lipoid Nephrosis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Membranous Glomerulonephritis" class="form-check-input"/><label title="" for="Membranous Glomerulonephritis" class="form-check-label">Membranous Glomerulonephritis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Metabolic Dysfunction-Associated Steatohepatitis" class="form-check-input"/><label title="" for="Metabolic Dysfunction-Associated Steatohepatitis" class="form-check-label">Metabolic Dysfunction-Associated Steatohepatitis (11)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Metabolic Dysfunction-Associated Steatotic Liver Disease" class="form-check-input"/><label title="" for="Metabolic Dysfunction-Associated Steatotic Liver Disease" class="form-check-label">Metabolic Dysfunction-Associated Steatotic Liver Disease (14)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Mitochondrial Disease" class="form-check-input"/><label title="" for="Mitochondrial Disease" class="form-check-label">Mitochondrial Disease (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Morbid Obesity" class="form-check-input"/><label title="" for="Morbid Obesity" class="form-check-label">Morbid Obesity (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome" class="form-check-input"/><label title="" for="Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome" class="form-check-label">Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Myocardial Infarction" class="form-check-input"/><label title="" for="Myocardial Infarction" class="form-check-label">Myocardial Infarction (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Myocardial Ischemia" class="form-check-input"/><label title="" for="Myocardial Ischemia" class="form-check-label">Myocardial Ischemia (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Neonatal Hemochromatosis" class="form-check-input"/><label title="" for="Neonatal Hemochromatosis" class="form-check-label">Neonatal Hemochromatosis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Nephritis" class="form-check-input"/><label title="" for="Nephritis" class="form-check-label">Nephritis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Nephrolithiasis" class="form-check-input"/><label title="" for="Nephrolithiasis" class="form-check-label">Nephrolithiasis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Nephrotic Syndrome" class="form-check-input"/><label title="" for="Nephrotic Syndrome" class="form-check-label">Nephrotic Syndrome (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Obesity Disorder" class="form-check-input"/><label title="" for="Obesity Disorder" class="form-check-label">Obesity Disorder (10)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Pancreatic Insufficiency" class="form-check-input"/><label title="" for="Pancreatic Insufficiency" class="form-check-label">Pancreatic Insufficiency (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Pancreatitis" class="form-check-input"/><label title="" for="Pancreatitis" class="form-check-label">Pancreatitis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Parenteral Nutrition-Associated Cholestasis" class="form-check-input"/><label title="" for="Parenteral Nutrition-Associated Cholestasis" class="form-check-label">Parenteral Nutrition-Associated Cholestasis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Peripheral Vascular Disease" class="form-check-input"/><label title="" for="Peripheral Vascular Disease" class="form-check-label">Peripheral Vascular Disease (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Polycystic Kidney Disease" class="form-check-input"/><label title="" for="Polycystic Kidney Disease" class="form-check-label">Polycystic Kidney Disease (4)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Prediabetes Syndrome" class="form-check-input"/><label title="" for="Prediabetes Syndrome" class="form-check-label">Prediabetes Syndrome (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Preeclampsia" class="form-check-input"/><label title="" for="Preeclampsia" class="form-check-label">Preeclampsia (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Primary Hyperoxaluria" class="form-check-input"/><label title="" for="Primary Hyperoxaluria" class="form-check-label">Primary Hyperoxaluria (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Primary Sclerosing Cholangitis" class="form-check-input"/><label title="" for="Primary Sclerosing Cholangitis" class="form-check-label">Primary Sclerosing Cholangitis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Progressive Familial Intrahepatic Cholestasis" class="form-check-input"/><label title="" for="Progressive Familial Intrahepatic Cholestasis" class="form-check-label">Progressive Familial Intrahepatic Cholestasis (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Prostatitis" class="form-check-input"/><label title="" for="Prostatitis" class="form-check-label">Prostatitis (7)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Pulmonary Embolism" class="form-check-input"/><label title="" for="Pulmonary Embolism" class="form-check-label">Pulmonary Embolism (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Pulmonary Hypertension" class="form-check-input"/><label title="" for="Pulmonary Hypertension" class="form-check-label">Pulmonary Hypertension (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Sleep Apnea Syndrome" class="form-check-input"/><label title="" for="Sleep Apnea Syndrome" class="form-check-label">Sleep Apnea Syndrome (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Stroke" class="form-check-input"/><label title="" for="Stroke" class="form-check-label">Stroke (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Type 1 Diabetes Mellitus" class="form-check-input"/><label title="" for="Type 1 Diabetes Mellitus" class="form-check-label">Type 1 Diabetes Mellitus (46)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Type 2 Diabetes Mellitus" class="form-check-input"/><label title="" for="Type 2 Diabetes Mellitus" class="form-check-label">Type 2 Diabetes Mellitus (22)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Tyrosinemia" class="form-check-input"/><label title="" for="Tyrosinemia" class="form-check-label">Tyrosinemia (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Ulcerative Colitis" class="form-check-input"/><label title="" for="Ulcerative Colitis" class="form-check-label">Ulcerative Colitis (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urea Cycle Disorder" class="form-check-input"/><label title="" for="Urea Cycle Disorder" class="form-check-label">Urea Cycle Disorder (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Ureterolithiasis" class="form-check-input"/><label title="" for="Ureterolithiasis" class="form-check-label">Ureterolithiasis (1)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urinary Bladder Disorder" class="form-check-input"/><label title="" for="Urinary Bladder Disorder" class="form-check-label">Urinary Bladder Disorder (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urinary Incontinence" class="form-check-input"/><label title="" for="Urinary Incontinence" class="form-check-label">Urinary Incontinence (8)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Urinary Tract Infection" class="form-check-input"/><label title="" for="Urinary Tract Infection" class="form-check-label">Urinary Tract Infection (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Vascular Disorder" class="form-check-input"/><label title="" for="Vascular Disorder" class="form-check-label">Vascular Disorder (3)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Vesicoureteral Reflux" class="form-check-input"/><label title="" for="Vesicoureteral Reflux" class="form-check-label">Vesicoureteral Reflux (2)</label></div></div><div class="undefined undefined Toggle_toggleContainer__t3y6e"><div class="undefined form-check"><input type="checkbox" id="Wilson Disease" class="form-check-input"/><label title="" for="Wilson Disease" class="form-check-label">Wilson Disease (1)</label></div></div></div></div></div></div></div></div><div class="StudyExplorer_resultSection__yFl5L col-lg-9"><div class="mb-3 narrowTextBackground ResultActions_tableFunctionsContainer__uJZSc ResultActions_sidebarOpen__MogfV row"><div class="ResultActions_rowAlign__E7AmY"><div class="ResultActions_results__KOZPu undefined"><span class="ResultNumbers_bolded__LGjJl">1 - 50</span><span class="ResultNumbers_text__OI24U"> of 187 Results</span><div class="Pagination_row__Gm3hz"><ul class="Pagination_pagination__BG_HW pagination"><li class="page-item disabled"><span class="page-link"><span aria-hidden="true">‹</span><span class="visually-hidden">Previous</span></span></li><li class="page-item active"><span class="page-link">1<span class="visually-hidden">(current)</span></span></li><li class="page-item"><a class="page-link" role="button" tabindex="0" href="#">2</a></li><li class="page-item disabled"><span class="page-link"><span aria-hidden="true">…</span><span class="visually-hidden">More</span></span></li><li class="page-item"><a class="page-link" role="button" tabindex="0" href="#">4</a></li><li class="page-item"><a class="page-link" role="button" tabindex="0" href="#"><span aria-hidden="true">›</span><span class="visually-hidden">Next</span></a></li></ul><span class="Pagination_text__gNN4K">Page</span></div></div><div class="ResultActions_buttonAndToggle__mdDrB undefined"><div role="group" class="btn-group"><input class="btn-check" name="options" type="radio" autoComplete="off" id="tbg-radio-2" value="list"/><label tabindex="0" for="tbg-radio-2" class="SearchResultViewToggle_toggle__lBreB btn btn-primary"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="23" viewBox="0 0 24 23" fill="none"><g id="Group 181"><rect id="Rectangle 151" x="0.5" y="0.5" width="23" height="22" fill="#FFFFFF" stroke="#000000"></rect><path id="Vector 41" d="M4 7H20M4 11.5H20M4 16H20" stroke="#000000" stroke-width="1.5"></path></g></svg> <span class="SearchResultViewToggle_inactive__yb38M">List</span></label><input class="btn-check" name="options" type="radio" autoComplete="off" id="tbg-radio-1" checked="" value="table"/><label tabindex="0" for="tbg-radio-1" class="SearchResultViewToggle_toggle__lBreB btn btn-primary"><svg xmlns="http://www.w3.org/2000/svg" width="21" height="22" viewBox="0 0 21 22" fill="none"><g id="Group 180"><rect id="Rectangle 147" x="0.5" y="0.5" width="8.60819" height="8.60819" fill="#e99f20" stroke="#e99f20"></rect><rect id="Rectangle 149" x="0.5" y="12.7026" width="8.60819" height="8.60819" fill="#e99f20" stroke="#e99f20"></rect><rect id="Rectangle 148" x="11.8891" y="0.5" width="8.60819" height="8.60819" fill="#e99f20" stroke="#e99f20"></rect><rect id="Rectangle 150" x="11.8891" y="12.7026" width="8.60819" height="8.60819" fill="#e99f20" stroke="#e99f20"></rect></g></svg> <span class="SearchResultViewToggle_bold__UdTmX">Table</span></label></div></div></div><div class="ResultActions_rowAlign__E7AmY"><div class="ResultActions_rowAlign__E7AmY"><span class="PerPage_text__Nf6hl">Show: </span><div class="Select_selectContainer__2RxxI PerPage_selectContainer___iIxF"><select class=" PerPage_selectClass__i07bl form-select"><option value="10">10</option><option value="25">25</option><option value="50" selected="">50</option><option value="100">100</option></select></div></div><div class="ResultActions_tableFunctionButtonContainer__thd3s ResultActions_rowAlign__E7AmY"><a href="https://repository.niddk.nih.gov/api/search/v1/studies/csv?size=999&page=1" download=""><button aria-label="Download Results into an Excel Spreadsheet" class="Button_button__OFOdO Button_auto__peQWd Button_liteRounded__NxMDh ResultActions_tableFunctionButton__4EIGk ResultActions_download__K3ppk Button_primary__WTwSy a a-primary"><span class="Button_iconLeft__dfwTS"><svg width="15" height="13" viewBox="0 0 15 13" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M13.8374 8.86925C13.6792 8.71158 13.4877 8.63281 13.262 8.63281H9.33759L8.18749 9.77963C7.85996 10.0939 7.47675 10.2514 7.03685 10.2514C6.59695 10.2514 6.21363 10.0944 5.88658 9.77963L4.74503 8.63281H0.812074C0.586529 8.63281 0.394885 8.71158 0.236696 8.86925C0.0790339 9.02639 0 9.21727 0 9.44219V12.14C0 12.3648 0.0790339 12.5558 0.236696 12.7129C0.394885 12.8701 0.586529 12.9488 0.812074 12.9488H13.262C13.4877 12.9488 13.6792 12.8701 13.8374 12.7129C13.995 12.5558 14.0741 12.3647 14.0741 12.14V9.44219C14.0741 9.21727 13.995 9.02639 13.8374 8.86925ZM10.6656 11.7101C10.5582 11.8167 10.4315 11.8702 10.285 11.8702C10.1385 11.8702 10.0112 11.8167 9.90429 11.7101C9.79736 11.603 9.74363 11.4767 9.74363 11.3306C9.74363 11.1846 9.79736 11.0579 9.90429 10.9513C10.0112 10.8446 10.138 10.791 10.285 10.791C10.4321 10.791 10.5582 10.8446 10.6656 10.9513C10.7727 11.0579 10.8264 11.1846 10.8264 11.3306C10.8264 11.4767 10.7727 11.603 10.6656 11.7101ZM12.8307 11.7101C12.7237 11.8167 12.5964 11.8702 12.4499 11.8702C12.3034 11.8702 12.1768 11.8167 12.0693 11.7101C11.9624 11.603 11.9091 11.4767 11.9091 11.3306C11.9091 11.1846 11.9624 11.0579 12.0693 10.9513C12.1768 10.8446 12.3034 10.791 12.4499 10.791C12.5964 10.791 12.7237 10.8446 12.8307 10.9513C12.9376 11.0579 12.9913 11.1846 12.9913 11.3306C12.9913 11.4767 12.9381 11.603 12.8307 11.7101Z" fill="black"></path><path d="M6.65795 9.01143C6.75928 9.11813 6.88609 9.17168 7.03815 9.17168C7.19022 9.17168 7.31743 9.11813 7.41876 9.01143L11.2078 5.23497C11.3827 5.07177 11.4223 4.8753 11.3264 4.64493C11.2306 4.42559 11.0644 4.31602 10.8277 4.31602H8.66218V0.539477C8.66218 0.393574 8.60845 0.266708 8.50152 0.16013C8.39458 0.0535517 8.26729 0 8.12078 0H5.95589C5.80885 0 5.68209 0.0535517 5.57515 0.16013C5.46769 0.266708 5.41449 0.393574 5.41449 0.539477V4.31606H3.24899C3.01229 4.31606 2.84607 4.42559 2.75029 4.64497C2.65439 4.8753 2.69344 5.07177 2.86838 5.23501L6.65795 9.01147V9.01143Z" fill="black"></path><rect x="9.49609" y="10.3594" width="4.31604" height="1.72641" fill="black"></rect></svg></span>Download Results</button></a><div role="menuitemcheckbox" class="ColumnPicker_manageColumns__uetVu ResultActions_columnPickerButton__YyRek dropdown"><button type="button" aria-expanded="false" class="dropdown-toggle btn btn-primary"><svg width="16" height="16" viewBox="0 0 16 16" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_5645_5771)"><rect x="1" y="1" width="14" height="15" fill="white"></rect><path d="M0 1.5C0 1.10218 0.158035 0.720644 0.43934 0.43934C0.720644 0.158035 1.10218 0 1.5 0L14.5 0C14.8978 0 15.2794 0.158035 15.5607 0.43934C15.842 0.720644 16 1.10218 16 1.5V14.5C16 14.8978 15.842 15.2794 15.5607 15.5607C15.2794 15.842 14.8978 16 14.5 16H1.5C1.10218 16 0.720644 15.842 0.43934 15.5607C0.158035 15.2794 0 14.8978 0 14.5L0 1.5ZM1.5 1C1.36739 1 1.24021 1.05268 1.14645 1.14645C1.05268 1.24021 1 1.36739 1 1.5V14.5C1 14.6326 1.05268 14.7598 1.14645 14.8536C1.24021 14.9473 1.36739 15 1.5 15H5V1H1.5ZM10 15V1H6V15H10ZM11 15H14.5C14.6326 15 14.7598 14.9473 14.8536 14.8536C14.9473 14.7598 15 14.6326 15 14.5V1.5C15 1.36739 14.9473 1.24021 14.8536 1.14645C14.7598 1.05268 14.6326 1 14.5 1H11V15Z" fill="black"></path><rect x="1" y="1" width="14" height="3" fill="black"></rect></g><defs><clipPath id="clip0_5645_5771"><rect width="16" height="16" fill="white"></rect></clipPath></defs></svg> Manage Columns</button></div></div></div></div><div class="mb-4 ResultsSection_tableResults__ieY79"><div tabindex="0" class="undefined Table_container__Y2W_q"><table role="table" class="Table_table__b_0YI table table-sm table-striped table-bordered"><caption class="sr-only">Study Search Results Table</caption><thead><tr><th tabindex="0" colSpan="1" style="width:300px" class="Table_alignLeft__VdU8l"><div class=""><div class="Table_row__H0_2i"><div class="Table_sortTextHeader__PZjYh Table_textHeader__nU1f7">Study Name</div><div class="Table_sortHeader__M9mVA"><a tabindex="0"><svg width="17" height="14" viewBox="0 0 17 14" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_2495_34255)"><path d="M8.78516 4.46988L12.2503 1.46875L15.7419 4.46988" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M12.25 12.3402V2.34961" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M8.3111 9.31445L4.84596 12.3419L1.35437 9.31445" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M4.84302 1.46875V11.4594" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path></g><defs><clipPath id="clip0_2495_34255"><rect width="15.7651" height="13.663" fill="white" transform="translate(0.664429 0.0722656)"></rect></clipPath></defs></svg></a></div></div></div></th><th tabindex="0" colSpan="1" style="width:130px" class="Table_alignLeft__VdU8l"><div class=""><div class="Table_row__H0_2i"><div class="Table_sortTextHeader__PZjYh Table_textHeader__nU1f7">Study Acronym</div><div class="Table_sortHeader__M9mVA"><a tabindex="0"><svg width="17" height="14" viewBox="0 0 17 14" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_2495_34255)"><path d="M8.78516 4.46988L12.2503 1.46875L15.7419 4.46988" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M12.25 12.3402V2.34961" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M8.3111 9.31445L4.84596 12.3419L1.35437 9.31445" stroke="transparent" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M4.84302 1.46875V11.4594" stroke="transparent" stroke-width="1.8" stroke-miterlimit="10"></path></g><defs><clipPath id="clip0_2495_34255"><rect width="15.7651" height="13.663" fill="white" transform="translate(0.664429 0.0722656)"></rect></clipPath></defs></svg></a></div></div></div></th><th tabindex="0" colSpan="1" style="width:200px" class="Table_alignLeft__VdU8l"><div class=""><div class="Table_row__H0_2i"><div class="Table_sortTextHeader__PZjYh Table_textHeader__nU1f7">Research Area</div><div class="Table_sortHeader__M9mVA"><a tabindex="0"><svg width="17" height="14" viewBox="0 0 17 14" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_2495_34255)"><path d="M8.78516 4.46988L12.2503 1.46875L15.7419 4.46988" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M12.25 12.3402V2.34961" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M8.3111 9.31445L4.84596 12.3419L1.35437 9.31445" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M4.84302 1.46875V11.4594" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path></g><defs><clipPath id="clip0_2495_34255"><rect width="15.7651" height="13.663" fill="white" transform="translate(0.664429 0.0722656)"></rect></clipPath></defs></svg></a></div></div></div></th><th tabindex="0" colSpan="1" style="width:130px" class="Table_alignLeft__VdU8l"><div class=""><div class="Table_row__H0_2i"><div class="Table_sortTextHeader__PZjYh Table_textHeader__nU1f7">Data Availability</div><div class="Table_sortHeader__M9mVA"><a tabindex="0"><svg width="17" height="14" viewBox="0 0 17 14" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_2495_34255)"><path d="M8.78516 4.46988L12.2503 1.46875L15.7419 4.46988" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M12.25 12.3402V2.34961" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M8.3111 9.31445L4.84596 12.3419L1.35437 9.31445" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M4.84302 1.46875V11.4594" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path></g><defs><clipPath id="clip0_2495_34255"><rect width="15.7651" height="13.663" fill="white" transform="translate(0.664429 0.0722656)"></rect></clipPath></defs></svg></a></div></div></div></th><th tabindex="0" colSpan="1" style="width:140px" class="Table_alignLeft__VdU8l"><div class=""><div class="Table_row__H0_2i"><div class="Table_sortTextHeader__PZjYh Table_textHeader__nU1f7">Specimen Availability</div><div class="Table_sortHeader__M9mVA"><a tabindex="0"><svg width="17" height="14" viewBox="0 0 17 14" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_2495_34255)"><path d="M8.78516 4.46988L12.2503 1.46875L15.7419 4.46988" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M12.25 12.3402V2.34961" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M8.3111 9.31445L4.84596 12.3419L1.35437 9.31445" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M4.84302 1.46875V11.4594" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path></g><defs><clipPath id="clip0_2495_34255"><rect width="15.7651" height="13.663" fill="white" transform="translate(0.664429 0.0722656)"></rect></clipPath></defs></svg></a></div></div></div></th><th tabindex="0" colSpan="1" style="width:130px" class="Table_alignLeft__VdU8l"><div class=""><div class="Table_row__H0_2i"><div class="Table_sortTextHeader__PZjYh Table_textHeader__nU1f7">Network</div><div class="Table_sortHeader__M9mVA"><a tabindex="0"><svg width="17" height="14" viewBox="0 0 17 14" fill="none" xmlns="http://www.w3.org/2000/svg"><g clip-path="url(#clip0_2495_34255)"><path d="M8.78516 4.46988L12.2503 1.46875L15.7419 4.46988" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M12.25 12.3402V2.34961" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M8.3111 9.31445L4.84596 12.3419L1.35437 9.31445" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path><path d="M4.84302 1.46875V11.4594" stroke="white" stroke-width="1.8" stroke-miterlimit="10"></path></g><defs><clipPath id="clip0_2495_34255"><rect width="15.7651" height="13.663" fill="white" transform="translate(0.664429 0.0722656)"></rect></clipPath></defs></svg></a></div></div></div></th></tr></thead><tbody><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/27">Adult Living Donor Liver Transplantation Studies</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">A2ALL</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Adult Living Donor Liver Transplantation Studies (A2ALL Network)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/46">Acute Liver Failure Study Group: Adult Acute Liver Failure Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">AALF</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Acute Liver Failure Study Group (ALFSG)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/139">African American Study of Kidney Disease and Hypertension Cohort Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">AASK Cohort</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">African American Study of Kidney Disease Study Group (AASK)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/56">African American Study of Kidney Disease and Hypertension Study (Clinical Trial)</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">AASK Trial</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">African American Study of Kidney Disease Study Group (AASK)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/172">NIDDK Reference Calibrators for Islet Autoantibody Measurements</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">AAb Calibrators</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/111">A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ACTIVE/ADIPOSE</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Obesity; Kidney Disease; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/122">Autosomal Dominant Polycystic Kidney Disease Genetic Modifier Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ADPKD</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Expected</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/189">Assessing Long Term Outcomes in Living Kidney Donors</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ALTOLD</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/117">Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">APRON</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Digestive Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Gastroparesis Clinical Research Consortium (GpCRC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/74">Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ASSESS-AKI</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Acute Kidney Injury Network (AKI)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/105">Acute Renal Failure Trial Network</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ATN</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/19">Boston Area Community Health Survey</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">BACH</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/29">Biliary Atresia Research Consortium</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">BARC</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ChiLDReN Network (ChiLDReN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/183">Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">BASE</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Chronic Kidney Disease Consortium (CKD)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/90">Biliary Atresia Study in Infants and Children</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">BASIC</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ChiLDReN Network (ChiLDReN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/119">Behavior Enhances Drug Reduction of Incontinence</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">BE-DRI</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urinary Incontinence Research Network (UITN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/270">Beta Cell Restoration Through Fat Mitigation</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">BetaFat</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Obesity; Multidisciplinary Research; Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">The RISE Consortium (RISE)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/23">Complementary and Alternative Medicine for Urological Symptoms</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CAMUS</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/66">Comprehensive Dialysis Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CDS</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease; Nutrition; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/102">Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CFLD PUSH</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease; Multidisciplinary Research; Pancreatic Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ChiLDReN Network (ChiLDReN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/191">Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-01</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/93">Strategies to Improve Long Term Islet Graft Survival and Extended Follow Up after Islet Transplantation in Type 1 Diabetes</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-02/08</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/94">Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes and Extended Follow Up after Islet Transplantation in Type 1 Diabetes</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-03/08</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/95">Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-04/08</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/96">B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-05/08</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/97">Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-06/08</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/92">Islet Transplantation in Type 1 Diabetes</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CIT-07/08</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Clinical Islet Transplantation Consortium (CITC)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/121">CKD Biomarkers Consortium</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CKD Biocon</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/39">The Chronic Kidney Disease in Children Cohort Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CKiD</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Multidisciplinary Research; Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/55">Cholestatic Liver Disease Consortium</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CLiC</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ChiLDReN Network (ChiLDReN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/176">The CKD Optimal Management With BInders and NicotinamidE</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">COMBINE</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Multidisciplinary Research; Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Chronic Kidney Disease Consortium (CKD)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/304">Caring for OutPatiEnts after Acute Kidney Injury</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">COPE-AKI</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Expected</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Expected</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/170">Clinical Outcomes Research Initiative</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CORI</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Digestive Diseases; Pancreatic Disease; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/13">Chronic Prostatitis Collaborative Research Network Cohort Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CPCRN Cohort</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Chronic Prostatitis Collaborative Research Network (CPCRN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/14">Chronic Prostatitis Collaborative Research Network Clinical Trial - Ciprofloxacin and Tamsulosin</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CPCRN RCT #1</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Chronic Prostatitis Collaborative Research Network (CPCRN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/129">Chronic Prostatitis Collaborative Research Network Clinical Trial - Alfuzosin</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CPCRN2 RCT#1</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Chronic Prostatitis Collaborative Research Network (CPCRN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/130">Chronic Prostatitis Collaborative Research Network Clinical Trial - Pregabalin</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CPCRN2 RCT#2</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Chronic Prostatitis Collaborative Research Network (CPCRN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/15">Chronic Renal Insufficiency Cohort Study</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CRIC</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes; Kidney Disease; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/10">Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CRISP</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP Network)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/167">Careful Urinary Tract Infection Evaluation</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CUTIE</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Urologic Diseases; Kidney Disease; Multidisciplinary Research</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">RIVUR Network (RIVUR Network)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/303">ChiLDReN Genetic Collection Protocol</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ChiLDReN-Genetics</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease; Multidisciplinary Research; Endocrine Diseases and Metabolic Diseases</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Expected</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">ChiLDReN Network (ChiLDReN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/171">Cure Glomerulonephropathy</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CureGN</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Kidney Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Requires Collaboration with Parent Study</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Cure Glomerulonephropathy (CureGN Network)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/148">Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">CyNCh</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Nonalcoholic Steatohepatitis Clinical Research Network (NASH)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/206">Diabetes Autoimmunity Study in the Young</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DAISY</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/16">Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DCCT/EDIC</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Multidisciplinary Research; Kidney Disease; Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/292">The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DCLP3</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/293">The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas in Pediatrics - A Study of t:slim X2 with Control-IQ Technology</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DCLP5</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Diabetes</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Not Available</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/163">DILIN: Prospective</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DILIN Pro</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Drug-Induced Liver Injury Network (DILIN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/160">DILIN: Retrospective</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DILIN Retro</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Liver Disease</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Drug-Induced Liver Injury Network (DILIN)</span></td></tr><tr class=""><td tabindex="0" class="Table_alignLeft__VdU8l"><a class="StudyExplorer_bold__8hb6s" href="/study/38">Diabetes Prevention Program</a></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">DPP</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Multidisciplinary Research; Diabetes; Nutrition; Obesity</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Data Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s">Specimens Available for Request</span></td><td tabindex="0" class="Table_alignLeft__VdU8l"><span class="StudyExplorer_bold__8hb6s"></span></td></tr></tbody></table></div></div><div class="mb-3 narrowTextBackground ResultActions_tableFunctionsContainer__uJZSc row"><div class="ResultActions_rowAlign__E7AmY"><div class="ResultActions_results__KOZPu undefined"><div class="Pagination_row__Gm3hz"><ul class="Pagination_pagination__BG_HW pagination"><li class="page-item disabled"><span class="page-link"><span aria-hidden="true">‹</span><span class="visually-hidden">Previous</span></span></li><li class="page-item active"><span class="page-link">1<span class="visually-hidden">(current)</span></span></li><li class="page-item"><a class="page-link" role="button" tabindex="0" href="#">2</a></li><li class="page-item disabled"><span class="page-link"><span aria-hidden="true">…</span><span class="visually-hidden">More</span></span></li><li class="page-item"><a class="page-link" role="button" tabindex="0" href="#">4</a></li><li class="page-item"><a class="page-link" role="button" tabindex="0" href="#"><span aria-hidden="true">›</span><span class="visually-hidden">Next</span></a></li></ul><span class="Pagination_text__gNN4K">Page</span></div></div></div></div></div></div></div></div><footer class="Footer_footer__ylvxI"><div class="Footer_footerBackground__oz0ra Footer_colorful__6nhIt "></div><div class="Footer_content__kdMvs"><div class="container"><div class="Footer_footerHeader__BQGGW row">NIH... Turning Discovery into Health ®</div><div class="mb-2 row"><div class="Footer_column__P3enx undefined col-sm-3"><p class="Footer_columnTitle__wFePf Footer_gray__JEbav"><a href="/pages/repository">Repository Resources</a></p><a href="/search/study">Studies</a><a href="/search/counts">Material Counts</a><a href="/requests/approved/data">List of Approved Requestors</a><a href="/publications">Publications</a></div><div class="Footer_column__P3enx col-sm-3"><p class="Footer_columnTitle__wFePf Footer_teal__of3yb"><a href="/pages/helpful_information">Helpful Information</a></p><a href="/pages/general_information">General Information</a><a href="/pages/for_requestors">For Requestors</a><a href="/pages/for_submitters">For Submitters</a><a href="/pages/instructional_materials">Educational/Instructional Information</a><a href="/pages/data_challenges">Data Challenges</a><a href="/pages/externa_links">External Links</a></div><div class="Footer_column__P3enx col-sm-3"><p class="Footer_columnTitle__wFePf Footer_blue__h5Qmd"><a href="/pages/requests">Requests</a></p><a href="/requests/reuse/data-request">Data Request</a><a href="/requests/biospecimen_types">Specimen Request</a></div><div class="Footer_column__P3enx col-sm-3"><p class="Footer_columnTitle__wFePf Footer_blue__h5Qmd"><a href="/pages/about_niddk_cr">About NIDDK-CR</a></p><a href="/pages/about">About NIDDK-CR</a><a href="/news">R4R News</a><a href="/faq">Frequently Asked Questions</a><a href="/pages/site_map">Site Navigation Map</a><a href="/pages/definitions">Definitions</a><a href="/contact">Contact the NIDDK-CR</a></div></div></div></div><div class="Footer_blackFooter__dTd_Q"><div class="Footer_blackFooterContainer__eegTA container"><div class="Footer_footerLinks__5nXNj row"><ul><li>v. 02.0.1</li><li><a href="/pages/privacy/">Privacy Policy</a></li><li><a href="https://www.niddk.nih.gov/freedom-information-act">Freedom of Information Act</a></li><li><a href="/pages/accessibility/">Accessibility</a></li><li><a href="https://www.niddk.nih.gov/disclaimers">Disclaimers</a></li><li><a href="https://www.niddk.nih.gov/copyright">Copyright</a></li><li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html">Vulnerability Disclosure Policy</a></li><li><a href="/pages/site_map/">Site Map</a></li></ul><ul><li><a href="https://www.hhs.gov/"><span>U.S. Department of Health and Human Services</span></a></li><li itemProp="memberOf" itemType="http://schema.org/GovernmentOrganization"><a href="https://www.nih.gov/" itemProp="url"><span itemProp="name">National Institutes of Health</span></a></li><li><a href="https://www.niddk.nih.gov/">NIDDK Home</a></li></ul></div><div class="Footer_ctsContainer__dnT05 row"><a href="https://doi.org/10.34894/NOYYSF" target="_blank" rel="noopener noreferrer"><img src="/images/CoreTrustSeal-logo-transparent.png" class="Footer_ctsLogo__nRZwO" alt="Core Trust Seal Logo"/></a><div><a href="https://amt.coretrustseal.org/certificates">Core Trustworthy Data Repository</a></div></div></div></div></footer></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"searchResults":{"took":24,"timed_out":false,"_shards":{"total":5,"successful":5,"skipped":0,"failed":0},"hits":{"total":{"value":187,"relation":"eq"},"max_score":null,"hits":[{"_index":"study_v001","_id":"SMK1bpMBHb0XhPer5t3W","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"A comparison of the mortality of AALDLT patients to the mortality of patients who have not yet received AALDLT was used as the primary outcome measure. The survival and rejection episodes for AALDLT vs. cadaveric recipients from time of transplant were also compared.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-07-23T00:34:23.169Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Adult Living Donor Liver Transplantation Studies[(V3) https://doi.org/10.58020/wyz7-0r97] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.135Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Transplant Patients","Adults"],"study_condition_array":["Hepatocellular Carcinoma","Cirrhosis of Liver","Cancer"],"study_image_types_array":null,"study_medication":null,"objective":"The primary study objective of the A2ALL Retrospective Cohort Study is to determine whether the decision to undergo adult-to-adult living donor liver transplant is beneficial for the patients who choose this type of transplant. The principal hypothesis was that receipt of a living liver allograft leads to better long term outcomes for liver transplant candidates than pursuit of cadaveric transplant. Secondary objectives included addressing selected biological and clinical issues in transplantation structured around the comparison between DDLT and AALDLT.","study_id":27,"study_keywords_array":["Liver Disease","Allograft","Liver Replacement","Deceased Donor Liver Transplant","Liver Transplant"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/study/NCT01619475,http://www.clinicaltrials.gov/show/NCT00096733}","network_id":220,"study_website":null,"created_at":"2004-03-29T20:18:37.000Z","selection_criteria":"The eligibility criteria for recipients included:\r\n\r\n- Potential recipient listed for single organ (liver) transplantation\r\n- Eligible for AALDLT\r\n- At least 18 years of age at the time of donor history and physical exam\r\n- Indication for transplant of non-fulminant liver disease\r\n- Potential donor identified and scheduled for evaluation (history and physical examination) within four weeks\r\n\r\nThe eligibility criteria for donors included:\r\n\r\n- Met donor criteria of the transplant center\r\n- At least 18 years of age at the time of donation\r\n- Evaluated with a history and physical examination at the transplantation center","doi":"https://doi.org/10.58020/wyz7-0r97","study_network":"Adult Living Donor Liver Transplantation Studies (A2ALL Network)","study_condition":"Hepatocellular Carcinoma; Cirrhosis of Liver; Cancer","study_keywords":"Liver Disease; Allograft; Liver Replacement; Deceased Donor Liver Transplant; Liver Transplant","study_citation":"Merion, Robert (2019). Adult Living Donor Liver Transplantation Studies(V3) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/wyz7-0r97","study_end_date":"2014-08","study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"a2all1","outcome":"The A2ALL study showed evidence that AALDLT is a viable option for liver replacement. The donor characteristics associated with acceptance were younger age and cold ischemia time of the right lobe graft. Additionally, data demonstrated that AALDLT is a procedure in which center experience plays a significant role in outcome, with outcomes that improve with experience.","study_start_date":"2003-02","acronym":"A2ALL","resource_use_acknowledgment":"The Adult Living Donor Liver Transplantation Studies (A2ALL) was conducted by the A2ALL Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the A2ALL (https://doi.org/10.58020/wyz7-0r97) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the A2ALL study and does not necessarily reflect the opinions or views of the A2ALL study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Transplant Patients; Adults","name":"Adult Living Donor Liver Transplantation Studies","study_specimen_types_array":null,"study_sites_number":"9","specimen_availability":"Specimens Available for Request","division":"DDN"},"sort":["A2ALL"]},{"_index":"study_v001","_id":"kv21bpMBC2xkvCSB5Bnh","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was overall survival of participants.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-11-21T20:13:25.751Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Acute Liver Failure Study Group: Adult Acute Liver Failure Study[(V2) https://doi.org/10.58020/9n48-q075] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.138Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Acute Liver Failure"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objectives were to collect clinical and epidemiological data as well as biospecimens (serum, plasma, urine, tissue, DNA) from participants with ALF, ALI, or those with coagulopathy but did not reach the threshold of encephalopathy.","study_id":46,"study_keywords_array":["Acute","Liver Failure","Liver Disease","Liver Transplant","Acute Liver Failure","Acute Liver Injury (ALI)"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00518440,https://www.clinicaltrials.gov/ct2/show/NCT02786836}","network_id":225,"study_website":"https://www.utsouthwestern.edu/labs/acute-liver/","created_at":"2005-11-08T23:17:46.000Z","selection_criteria":"ALF inclusion criteria:\u003cul\u003e\r\n\u003cli\u003eAltered mentation of any degree (encephalopathy)\u003c/li\u003e\r\n\u003cli\u003eEvidence of moderately severe coagulopathy (INR ≥ 1.5)\u003c/li\u003e\r\n\u003cli\u003eA presumed acute illness onset of less than 26 weeks\u003c/li\u003e\u003c/ul\u003e\r\nALF exclusion criteria:\u003cul\u003e\r\n\u003cli\u003eCirrhosis patients\u003c/li\u003e\r\n\u003cli\u003eAlcohol induced liver failure\u003c/li\u003e\r\n\u003cli\u003eKnown pre-existing chronic liver disease\u003c/li\u003e\u003c/ul\u003e\r\nALI inclusion criteria:\u003cul\u003e\r\n\u003cli\u003eAcetaminophen (APAP) etiology: Acute illness \u003c 2 weeks\u003c/li\u003e\r\n\u003cli\u003eNon-acetaminophen etiology: Acute illness \u003c 26 weeks\u003c/li\u003e\r\n\u003cli\u003eINR ≥ 2.0, ALT ≥ 10X ULN, TBili ≥ 3 mg/dL\u003c/li\u003e\u003c/ul\u003e\r\nALI exclusion criteria:\u003cul\u003e\r\n\u003cli\u003eAltered mentation of any degree (encephalopathy)\u003c/li\u003e\u003c/ul\u003e","doi":"https://doi.org/10.58020/9n48-q075","study_network":"Acute Liver Failure Study Group (ALFSG)","study_condition":"Acute Liver Failure","study_keywords":"Acute; Liver Failure; Liver Disease; Liver Transplant; Acute Liver Failure; Acute Liver Injury (ALI)","study_citation":"Lee, William (2024). Acute Liver Failure Study Group: Adult Acute Liver Failure Study(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/9n48-q075","study_end_date":"2019-09","study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"aalf","outcome":"While the severity of illness did not decline over the course of the study, improvements in outcomes were observed. For example, the numbers requiring listing for transplantation, those receiving transplant, and those dying of ALF all declined during the study period. Participants with acetaminophen toxicity listed for transplantation were more severely ill and less likely to receive a liver transplant than those with any other etiology. Furthermore, participants with acetaminophen overdoses had an outcome by day 4 following admission, emphasizing how rapid deterioration can occur as well as recovery.","study_start_date":"1998-01","acronym":"AALF","resource_use_acknowledgment":"The Acute Liver Failure Study Group: Adult Acute Liver Failure Study (AALF) was conducted by the AALF Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the AALF (https://doi.org/10.58020/9n48-q075) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the AALF study and does not necessarily reflect the opinions or views of the AALF study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Adults; Transplant Patients","name":"Acute Liver Failure Study Group: Adult Acute Liver Failure Study","study_specimen_types_array":null,"study_sites_number":"15","specimen_availability":"Specimens Available for Request","division":"DDN"},"sort":["AALF"]},{"_index":"study_v001","_id":"U8K1bpMBHb0XhPer590Z","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary renal outcome measure was a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Cardiovascular events were also measured as a major outcome of interest.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-13T18:30:19.606Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the African American Study of Kidney Disease and Hypertension Cohort Study[(V2) https://doi.org/10.58020/7wvm-dg50] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.135Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Chronic Kidney Disease","Hypertensive Disorder","Cardiovascular Disorder"],"study_image_types_array":null,"study_medication":null,"objective":"The overall objective of the AASK Cohort Study was to determine prospectively the long-term course of kidney function and risk factors for chronic kidney disease (CKD) progression in African-Americans with hypertension-related CKD receiving recommended antihypertensive drug therapy within the setting of a low blood pressure goal. A secondary objective was to determine the occurrence of cardiovascular disease and assess its risk factors in the setting of hypertension-related CKD.","study_id":139,"study_keywords_array":["Hypertension","Cardiovascular Disease","Kidney Disease","Renal Insufficiency","Anti-Hypertension Drug Therapy","Blood Pressure Goal","Chronic Kidney Disease (CKD)","Ramipril","Renin-Angiotensin System (RAAS)"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":222,"study_website":null,"created_at":"2012-06-08T18:39:35.000Z","selection_criteria":"The eligible study population of the AASK Cohort Study consisted of all randomized individuals in the AASK trial who did not reach ESRD by the end of the trial. Participants were eligible for the trial if they were self-identified African Americans, aged 18 to 70 years, with hypertensive CKD as defined by a diastolic BP higher than 95 mm Hg and a GFR between 20 mL/min/1.73 m\u003csup\u003e2\u003c/sup\u003e and 65 mL/min/1.73 m\u003csup\u003e2\u003c/sup\u003e.","doi":"https://doi.org/10.58020/7wvm-dg50","study_network":"African American Study of Kidney Disease Study Group (AASK)","study_condition":"Chronic Kidney Disease; Hypertensive Disorder; Cardiovascular Disorder","study_keywords":"Hypertension; Cardiovascular Disease; Kidney Disease; Renal Insufficiency; Anti-Hypertension Drug Therapy; Blood Pressure Goal; Chronic Kidney Disease (CKD); Ramipril; Renin-Angiotensin System (RAAS)","study_citation":"Gassman, Jennifer (2016). African American Study of Kidney Disease and Hypertension Cohort Study(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/7wvm-dg50","study_end_date":"2007-06","study_procedure":null,"study_research_area_array":["Kidney Disease","Multidisciplinary Research"],"@version":"1","slug":"aask-cohort","outcome":"African Americans with hypertensive CKD who were treated with currently recommended BP therapy (drugs and level of blood pressure continued to progress during the long-term.","study_start_date":"2002-04","acronym":"AASK Cohort","resource_use_acknowledgment":"The African American Study of Kidney Disease and Hypertension Cohort Study (AASK Cohort) was conducted by the AASK Cohort Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the AASK Cohort (https://doi.org/10.58020/7wvm-dg50) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the AASK Cohort study and does not necessarily reflect the opinions or views of the AASK Cohort study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease; Multidisciplinary Research","study_target_population":"Adults","name":"African American Study of Kidney Disease and Hypertension Cohort Study","study_specimen_types_array":null,"study_sites_number":"21","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["AASK Cohort"]},{"_index":"study_v001","_id":"dsK1bpMBHb0XhPer591m","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was change in GFR as determined by iothalamate clearance. Secondary outcome measures included a time-to-event analysis of reduction in GFR by 50% or by 25 ml/min/1.73m2, end-stage renal disease (ESRD), and death to determine the clinical impact of the interventions.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-07-23T00:52:46.610Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the African American Study of Kidney Disease and Hypertension Study (Clinical Trial)[(V8) https://doi.org/10.58020/jtkq-h450] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.136Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Hypertensive Disorder","Cardiovascular Disorder","Chronic Kidney Disease"],"study_image_types_array":null,"study_medication":null,"objective":"The AASK study aimed to determine the effects of a lower than usual level of blood pressure control and the use of specific antihypertensive regimens on the progression of renal insufficiency that was clinically attributed to the effects of hypertension on the kidney. Two levels of BP control and 3 different antihypertensive regimens were tested for efficacy in slowing the rate of decline of renal function.","study_id":56,"study_keywords_array":["Blood Pressure Control","MAP","Glomerular Filtration Rate (GFR)","Kidney Disease","Hypertension","Cardiovascular Disease","Renal Insufficiency","Chronic Kidney Disease (CKD)","Drug Therapy","Mean Arterial Pressure"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/study/NCT04364139}","network_id":222,"study_website":null,"created_at":"2007-08-10T01:10:58.000Z","selection_criteria":"The study enrolled African-American men and women between 18 and 70 years of age who presented with hypertension (defined as a sitting diastolic blood pressure of 95 mmHg or more) and reduced renal function (defined as a pre-randomization 125I-iothalamate glomerular filtration rate between 20 65 ml/min/1.73m2).\r\n \r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/jtkq-h450","study_network":"African American Study of Kidney Disease Study Group (AASK)","study_condition":"Hypertensive Disorder; Cardiovascular Disorder; Chronic Kidney Disease","study_keywords":"Blood Pressure Control; MAP; Glomerular Filtration Rate (GFR); Kidney Disease; Hypertension; Cardiovascular Disease; Renal Insufficiency; Chronic Kidney Disease (CKD); Drug Therapy; Mean Arterial Pressure","study_citation":"Gassman, Jennifer (2020). African American Study of Kidney Disease and Hypertension Study (Clinical Trial)(V8) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/jtkq-h450","study_end_date":"2007-06","study_procedure":null,"study_research_area_array":["Kidney Disease","Multidisciplinary Research"],"@version":"1","slug":"aask-trial","outcome":"Results of the AASK study showed that the angiotensin-converting enzyme inhibitor ramipril was was more effective than the beta blocker metoprolol or the dihydropyridine calcium channel blocker amlodipine in slowing the rate of glomerular filtration rate decline in African American patients with mild to moderate renal insufficiency. Notably, there was no significant difference in the rate of decline in kidney function between the 92 mmHg or less and the 102-107 mmHg MAP groups. The study suggests that reduction in blood pressure to levels below those currently advocated for cardiovascular risk reduction does not provide readily identifiable benefits to African Americans with hypertensive nephrosclerosis. While this study provides the basis for the primary use of angiotensin-converting enzyme inhibitors in an African American population, it is undetermined if this represents a class effect for all angiotensin-converting enzyme inhibitors.","study_start_date":"1995-02","acronym":"AASK Trial","resource_use_acknowledgment":"The African American Study of Kidney Disease and Hypertension Study (Clinical Trial) (AASK Trial) was conducted by the AASK Trial Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the AASK Trial (https://doi.org/10.58020/jtkq-h450) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the AASK Trial study and does not necessarily reflect the opinions or views of the AASK Trial study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease; Multidisciplinary Research","study_target_population":"Adults","name":"African American Study of Kidney Disease and Hypertension Study (Clinical Trial)","study_specimen_types_array":null,"study_sites_number":"21","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["AASK Trial"]},{"_index":"study_v001","_id":"esK1bpMBHb0XhPer591m","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Not Available","modified_at":"2024-08-17T00:01:47.076Z","study_type":null,"study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.174Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":null,"study_id":172,"study_keywords_array":["Diabetes Mellitus, Type 1","Islet Autoantibody"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":null,"created_at":"2015-06-02T05:42:08.894Z","selection_criteria":null,"doi":null,"study_network":null,"study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Diabetes Mellitus, Type 1; Islet Autoantibody","study_citation":null,"study_end_date":null,"study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"aab-calibrators","outcome":null,"study_start_date":null,"acronym":"AAb Calibrators","resource_use_acknowledgment":"The NIDDK Reference Calibrators for Islet Autoantibody Measurements (AAb Calibrators) was conducted by the AAb Calibrators Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The biospecimens from the AAb Calibrators reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the AAb Calibrators study and does not necessarily reflect the opinions or views of the AAb Calibrators study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults","name":"NIDDK Reference Calibrators for Islet Autoantibody Measurements","study_specimen_types_array":null,"study_sites_number":null,"specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["AAb Calibrators"]},{"_index":"study_v001","_id":"3f21bpMBC2xkvCSB5RkX","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Logistic regression models were used to determine the associations between nutrition, cardiovascular, and rehabilitation factors with the frailty phenotype.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:42:48.120Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD[(V1) https://doi.org/10.58020/4nz9-tq14] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.180Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Dialysis Patients","Adults"],"study_condition_array":["End Stage Renal Failure","Cardiovascular Disorder","Chronic Kidney Disease"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the ACTIVE/ADIPOSE study is to characterize the prevalence and progression of frailty among patients undergoing hemodialysis for end-stage renal disease.","study_id":111,"study_keywords_array":["Renal Insufficiency","Kidney Disease","End-Stage Renal Disease"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":"https://www.usrds.org/2013/view/v2_09.aspx","created_at":"2010-09-27T21:46:42.000Z","selection_criteria":"Patients of at least 18 years of age who spoke either English or Spanish, were on hemodialysis for at least three months, and gave informed consent were enrolled in the study.","doi":"https://doi.org/10.58020/4nz9-tq14","study_network":null,"study_condition":"End Stage Renal Failure; Cardiovascular Disorder; Chronic Kidney Disease","study_keywords":"Renal Insufficiency; Kidney Disease; End-Stage Renal Disease","study_citation":"Kaysen, George (2016). A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/4nz9-tq14","study_end_date":"2013-09","study_procedure":null,"study_research_area_array":["Obesity","Kidney Disease","Multidisciplinary Research"],"@version":"1","slug":"activeadipose","outcome":"Analyses showed that peripheral vascular disease and cardiac diseases, such as dysrhythmia, atrial fibrillation, tachycardia, pericarditis, and cardiac arrest, were associated with higher odds for frailty. In contrast, black race and higher serum albumin concentration were associated with lower odds for frailty. Among patients who met the Fried definition of frailty, 78% scored as frail on walk speed and 56% scored as frail on grip strength, the 2 physical performance measures. The association of these sociodemographic and clinical risk factors with wasting in this cohort provides evidence for the prevalence of frailty in hemodialysis patients. There is a need for prospective testing of interventions to address wasting or other components of the frailty syndrome to determine whether frailty can be reversed and whether improvements in frailty are associated with improved survival.","study_start_date":"2009-07","acronym":"ACTIVE/ADIPOSE","resource_use_acknowledgment":"The A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD (ACTIVE/ADIPOSE) was conducted by the ACTIVE/ADIPOSE Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the ACTIVE/ADIPOSE (https://doi.org/10.58020/4nz9-tq14) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the ACTIVE/ADIPOSE study and does not necessarily reflect the opinions or views of the ACTIVE/ADIPOSE study, NIDDK-CR, or NIDDK.","study_research_area":"Obesity; Kidney Disease; Multidisciplinary Research","study_target_population":"Dialysis Patients; Adults","name":"A Cohort Study to Investigate the Value of Exercise in ESRD/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD","study_specimen_types_array":null,"study_sites_number":"14","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["ACTIVE/ADIPOSE"]},{"_index":"study_v001","_id":"xf21bpMBC2xkvCSB5Bn5","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Expected","modified_at":"2024-07-26T20:45:45.049Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.178Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Dialysis Patients","Children"],"study_condition_array":["Polycystic Kidney Disease","Cystic Kidney Disease"],"study_image_types_array":null,"study_medication":null,"objective":"The ADPKD Genetic Modifier study aims to identify genetic factors that influence the severity of kidney disease in ADPKD patients through genome-wide association studies of family members of PKD patients.","study_id":122,"study_keywords_array":["Polycystic Kidney Disease","Hypertension","Kidney Disease"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":null,"created_at":"2011-09-29T17:11:11.000Z","selection_criteria":"Participants and family members of HALT-PKD clinical trial and CRISP observational study participants are eligible to participate in the ADPKD Genetic Modifier study, along with other ADPKD patients from recruitment sites and from collaborating sites.","doi":null,"study_network":null,"study_condition":"Polycystic Kidney Disease; Cystic Kidney Disease","study_keywords":"Polycystic Kidney Disease; Hypertension; Kidney Disease","study_citation":null,"study_end_date":null,"study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"adpkd","outcome":"This study is ongoing.","study_start_date":null,"acronym":"ADPKD","resource_use_acknowledgment":"The Autosomal Dominant Polycystic Kidney Disease Genetic Modifier Study (ADPKD) was conducted by the ADPKD Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The biospecimens from the ADPKD reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the ADPKD study and does not necessarily reflect the opinions or views of the ADPKD study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Adults; Dialysis Patients; Children","name":"Autosomal Dominant Polycystic Kidney Disease Genetic Modifier Study","study_specimen_types_array":null,"study_sites_number":"4","specimen_availability":"Requires Collaboration with Parent Study","division":"KUH"},"sort":["ADPKD"]},{"_index":"study_v001","_id":"3P21bpMBC2xkvCSB5RkX","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome of this study is the difference between donors and controls in the slope of the mGFR measured by iohexol clearance between 6 and 36 months after donations.\r\n\r\nSecondary outcomes include medical history, vital signs, glomerular filtration rate, and other measurements at 6, 12, 24, and 36 months after donation.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-12T02:12:52.303Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Assessing Long Term Outcomes in Living Kidney Donors[(V1) https://doi.org/10.58020/rn2a-m312] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.172Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Transplant Patients","Adults"],"study_condition_array":["Chronic Kidney Disease"],"study_image_types_array":null,"study_medication":null,"objective":"The study aims to examine the pathophysiological effects of kidney donation, assess donor safety, and understand the effects of kidney donation on kidney function compared to healthy individuals.","study_id":189,"study_keywords_array":["Glomerular Filtration Rate (GFR)","Cardiovascular Disease (CVD)","Kidney Disease","Renal Insufficiency","Kidney Transplant"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":null,"created_at":"2017-05-24T23:53:54.472Z","selection_criteria":"Donors were any potential living kidney donor. Controls were any healthy individual who could theoretically be a donor at the study site. Both donors and controls had to be willing to give informed consent and be at least 18 years old. \r\n\r\nDonors and controls were excluded if they were allergic to intravenous radiocontrast or seafood, had evidence of kidney disease (especially proteinuria), invasive cancer, active infection, cardiovascular disease, diabetes, and psychiatric disorders.","doi":"https://doi.org/10.58020/rn2a-m312","study_network":null,"study_condition":"Chronic Kidney Disease","study_keywords":"Glomerular Filtration Rate (GFR); Cardiovascular Disease (CVD); Kidney Disease; Renal Insufficiency; Kidney Transplant","study_citation":"Kasiske, Bertram (2017). Assessing Long Term Outcomes in Living Kidney Donors(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/rn2a-m312","study_end_date":"2018-06","study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"altold","outcome":"The study is still ongoing. However, preliminary results at 36 months show that GFR slopes increased between 6 and 36 months in donors versus controls, which suggests that kidney function continues to improve in donors while controls have expected age-related declines in function.","study_start_date":"2006-07","acronym":"ALTOLD","resource_use_acknowledgment":"The Assessing Long Term Outcomes in Living Kidney Donors (ALTOLD) was conducted by the ALTOLD Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the ALTOLD reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the ALTOLD study and does not necessarily reflect the opinions or views of the ALTOLD study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Transplant Patients; Adults","name":"Assessing Long Term Outcomes in Living Kidney Donors","study_specimen_types_array":null,"study_sites_number":"8","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["ALTOLD"]},{"_index":"study_v001","_id":"m_21bpMBC2xkvCSB5Bnm","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure is improvement in VAS scores from baseline to through the course of treatment, as defined by a 25 mm or more reduction in mean VAS or attaining a mean VAS during the treatment period of \u003c 25 mm. Secondary outcome measures include improvement in other gastrointestinal symptoms, as measured by Gastroparesis Cardinal Symptom Index Daily Diary (GCSIDD), an overall relief of symptom questionnaire, and patient perception of improvement. Safety will be assessed through satiety tests, electrogastrography for measuring of EGG dysrhythmias, and monitoring of side effects.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:42:57.291Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial[(V1) https://doi.org/10.58020/khy5-1135] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.103Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Gastroparesis"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objective of the APRON study is to test the efficacy of aprepitant as compared to placebo in improving the symptoms of chronic nausea and vomiting of presumed gastric origin. In addition, the study aims to investigate the how aprepitant affects the symptoms of fullness, hunger, bloating, and abdominal pain, as well as to assess safety.","study_id":117,"study_keywords_array":["Gastroparesis Cardinal Symptom Index Daily Diary (GCSIDD)","Aprepitant","Visual Analog Scale (VAS)","Gastroparesis","Gastrointestinal Disease"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT01149369}","network_id":49,"study_website":null,"created_at":"2011-02-14T19:41:47.000Z","selection_criteria":"Patients of at least 18 years of age who met the following criteria were eligible for enrollment:\r\n\r\n- Gastric emptying scintigraphy within 2 years of registration\r\n- Normal upper endoscopy or upper GI series within 2 years of registration\r\n- Symptoms of chronic nausea or vomiting compatible with gastroparesis or other functional gastric disorder for at least 6 months (does not have to be contiguous) prior to registration with a Gastroparesis Cardinal Symptom Index score of ≥ 21\r\n- Significant nausea defined with a VAS score of ≥ 25 mm on a 0 to 100 mm scale","doi":"https://doi.org/10.58020/khy5-1135","study_network":"Gastroparesis Clinical Research Consortium (GpCRC)","study_condition":"Gastroparesis","study_keywords":"Gastroparesis Cardinal Symptom Index Daily Diary (GCSIDD); Aprepitant; Visual Analog Scale (VAS); Gastroparesis; Gastrointestinal Disease","study_citation":"Tonascia, James (2020). Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/khy5-1135","study_end_date":"2015-09","study_procedure":null,"study_research_area_array":["Digestive Diseases"],"@version":"1","slug":"apron","outcome":null,"study_start_date":"2013-04","acronym":"APRON","resource_use_acknowledgment":"The Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial (APRON) was conducted by the APRON Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the APRON (https://doi.org/10.58020/khy5-1135) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the APRON study and does not necessarily reflect the opinions or views of the APRON study, NIDDK-CR, or NIDDK.","study_research_area":"Digestive Diseases","study_target_population":"Adults","name":"Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial","study_specimen_types_array":null,"study_sites_number":"8","specimen_availability":"Specimens Available for Request","division":"DDN"},"sort":["APRON"]},{"_index":"study_v001","_id":"gcK1bpMBHb0XhPer591n","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Renal outcomes (including change in kidney function, time to development of incident CKD, progression of CKD, development of ESRD, and incident or recurrent episodes of AKI), cardiovascular outcomes (including coronary heart disease, heart failure, and arrhythmias and ECG abnormalities), cebrovascular outcomes, peripheral arterial disease outcomes, and mortality will be monitored.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-09-25T04:33:04.511Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury[(V2) https://doi.org/10.58020/js2k-9d54] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.137Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Children"],"study_condition_array":["Chronic Kidney Disease","Acute Kidney Injury","Cardiovascular Disorder"],"study_image_types_array":null,"study_medication":null,"objective":"The primary goals of the ASSESS-AKI study are to characterize the short-term and long-term natural history of AKI, evaluate the incremental utility of novel blood and urine biomarkers to refine the diagnosis and prognosis of AKI, and identify a subset of high-risk patients who could be targeted for future clinical trials to improve outcomes after AKI.","study_id":74,"study_keywords_array":["Acute Kidney Injury (AKI)","Glomerular Filtration Rate (GFR)"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":224,"study_website":"https://kri.washington.edu/completed-research-studies","created_at":"2009-07-23T22:54:20.000Z","selection_criteria":"Participants are divided into two groups: adult (aged 18 years to 89 years) and children (aged greater than 1 month to less than 18 years). To participate, all patients must have a documented baseline serum creatinine value, which is then used to estimate glomerular filtration rate (eGFR). For hospitalized patients, baseline serum creatinine is defined as the outpatient, non-emergency department test value nearest to the index hospitalization within 7 and 365 days prior to admission using an IDMS-traceable serum creatinine assay; for patients undergoing surgery, this baseline value is defined as pre-operative serum creatinine results from an IDMS-traceable assay obtained within seven days before cardiac surgery. For pediatric participants, a pre-operative serum creatinine concentration measured in the local hospital clinical laboratory can be used as a baseline.","doi":"https://doi.org/10.58020/js2k-9d54","study_network":"Acute Kidney Injury Network (AKI)","study_condition":"Chronic Kidney Disease; Acute Kidney Injury; Cardiovascular Disorder","study_keywords":"Acute Kidney Injury (AKI); Glomerular Filtration Rate (GFR)","study_citation":"Chinchilli, Vernon (2022). Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/js2k-9d54","study_end_date":"2020-06","study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"assess-aki","outcome":"This study is ongoing.","study_start_date":"2009-12","acronym":"ASSESS-AKI","resource_use_acknowledgment":"The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) was conducted by the ASSESS-AKI Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the ASSESS-AKI (https://doi.org/10.58020/js2k-9d54) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the ASSESS-AKI study and does not necessarily reflect the opinions or views of the ASSESS-AKI study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Adults; Children","name":"Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury","study_specimen_types_array":null,"study_sites_number":"4","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["ASSESS-AKI"]},{"_index":"study_v001","_id":"ksK1bpMBHb0XhPer591v","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was death from any cause by day 60. Secondary outcome measures included in-hospital death, recovery of kidney function (defined as lack of need for continuing dialysis support, with a minimum creatinine clearance of 20 ml/minute), the duration of renal-replacement therapy, lengths of stay in the intensive care unit (ICU) and hospital, days free of nonrenal organ failure (defined as days on which individual Sequential Organ Failure Assessment (SOFA) organ system scores were 0 to 2), and whether the patients returned to their previous living situation and did not require dialysis by day 60.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-14T04:04:27.871Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Acute Renal Failure Trial Network[(V3) https://doi.org/10.58020/9y3c-s862] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.180Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Dialysis Patients","Adults"],"study_condition_array":["Acute Kidney Injury"],"study_image_types_array":null,"study_medication":null,"objective":"The study investigated whether more intensive renal-replacement therapy decreases mortality among critically ill patients with acute kidney injury.","study_id":105,"study_keywords_array":["Kidney Disease","Renal-Replacement Therapy","Acute Kidney Injury (AKI)"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00076219}","network_id":null,"study_website":null,"created_at":"2010-04-21T22:00:54.000Z","selection_criteria":"Patients ages 18 years or older who met the following criteria were eligible for enrollment:\r\n- Acute kidney injury clinically consistent with acute tubular necrosis\r\n- Plan for renal-replacement therapy\r\n- Failure of one or more nonrenal organ systems, defined as a nonrenal SOFA organ system score ≥ 2 (range, 0 to 4, with a higher score indicating more severe organ dysfunction), or sepsis\r\n\r\nPatients were excluded if they had undergone more than one session of intermittent hemodialysis or sustained low-efficiency dialysis or had received more than 24 hours of continuous renal-replacement therapy prior to enrollment. Detailed exclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/9y3c-s862","study_network":null,"study_condition":"Acute Kidney Injury","study_keywords":"Kidney Disease; Renal-Replacement Therapy; Acute Kidney Injury (AKI)","study_citation":"Palevsky, Paul (2016). Acute Renal Failure Trial Network(V3) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/9y3c-s862","study_end_date":"2008-07","study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"atn","outcome":"Results showed that the primary outcome measure, death from any cause by day 60, did not differ between the two groups. Intensive renal support in critically ill patients with acute kidney injury did not improve recovery of renal function or reduce the rate of nonrenal organ failure as compared with less-intensive therapy. The study found no added benefit from an intensive (high-dose) treatment strategy as compared with the more conventional, less-intensive treatment strategy.","study_start_date":"2003-10","acronym":"ATN","resource_use_acknowledgment":"The Acute Renal Failure Trial Network (ATN) Study was conducted by the ATN Investigators and supported by the Cooperative Studies Program (CSP) of the Department of Veterans Affairs Office of Research and Development (VA) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the ATN study were supplied by NIDDK Central Repository (NIDDK-CR). This manuscript was not prepared under the auspices of the ATN study and does not necessarily reflect the opinions or views of the ATN study, the VA, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Dialysis Patients; Adults","name":"Acute Renal Failure Trial Network","study_specimen_types_array":null,"study_sites_number":"27","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["ATN"]},{"_index":"study_v001","_id":"0v21bpMBC2xkvCSB5RkM","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Information concerning the following was collected from participants: urologic symptoms, medications, lifestyle, medical history, morbidity, alcohol use, nutrition, and sociodemographics.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-06-27T20:14:57.310Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Boston Area Community Health Survey[(V5) https://doi.org/10.58020/e5cx-za20] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.191Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Erectile Dysfunction","Interstitial Cystitis","Urinary Incontinence","Benign Prostatic Hyperplasia","Prostatitis","Hypogonadism"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the BACH study was to estimate the prevalence of urologic conditions such as interstitial cystitis (IC), urinary incontinence, benign prostatic hyperplasia, prostatitis, hypogonadism, and impaired sexual function by race/ethnicity, age, sex, and socioeconomic status (SES). Other objectives included assessing risk factors for these symptoms, evaluating impact of symptoms on quality of life, and establishing a collection of data for use in future studies.","study_id":19,"study_keywords_array":["Urogenital Disease","Urologic Symptom","Urinary Incontinence","Impaired Sexual Function","Benign Prostatic Hyperplasia","Prostatic Disease","Prostatitis","Hypogonadism","Interstitial Cystitis (IC)"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":null,"created_at":"2004-03-27T03:20:43.000Z","selection_criteria":"The cohort consisted of a representative community-based sample of men and women aged 30 to 79 years, divided proportionately according to race/ethnicity by Hispanic, African American, and Caucasian identification.","doi":"https://doi.org/10.58020/e5cx-za20","study_network":null,"study_condition":"Erectile Dysfunction; Interstitial Cystitis; Urinary Incontinence; Benign Prostatic Hyperplasia; Prostatitis; Hypogonadism","study_keywords":"Urogenital Disease; Urologic Symptom; Urinary Incontinence; Impaired Sexual Function; Benign Prostatic Hyperplasia; Prostatic Disease; Prostatitis; Hypogonadism; Interstitial Cystitis (IC)","study_citation":"Brewer, Jessica (2016). Boston Area Community Health Survey(V5) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/e5cx-za20","study_end_date":"2012-03","study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"bach","outcome":"The BACH Survey contributed greatly to the knowledge of the prevalence of urologic conditions, which was shown to be greater than previously estimated. The study succeeded in creating a large, racially-diverse sample to provide both cross sectional and longitudinal data to explore urologic questions. Findings from the survey have been used to identify sex, and racial/ethnic differences for a number of urologic symptoms.","study_start_date":"2002-04","acronym":"BACH","resource_use_acknowledgment":"The Boston Area Community Health Survey (BACH) was conducted by the BACH Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the BACH reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the BACH study and does not necessarily reflect the opinions or views of the BACH study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Boston Area Community Health Survey","study_specimen_types_array":null,"study_sites_number":"1","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["BACH"]},{"_index":"study_v001","_id":"jcK1bpMBHb0XhPer591v","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Survival, transplant status, and serum bilirubin levels were used to measure outcome. Good outcome was defined as alive with native liver and total serum bilirubin level \u003c 6.0 mg/dL at age 24 months; poor outcome was defined as either death or liver transplantation before age 24 months; and indeterminate outcome was defined as alive with native liver but with serum total bilirubin level \u003e 6.0 mg/dL.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:43:09.861Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Biliary Atresia Research Consortium[(V1) https://doi.org/10.58020/2jbe-2m91] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.134Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Transplant Patients"],"study_condition_array":["Bile Duct Disorder","Biliary Atresia"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the BARC study was to collect and correlate data about the presentation, diagnostic interventions, and medical and surgical management of infants with biliary atresia in order to identify risk factors that affect outcomes at two years of age.","study_id":29,"study_keywords_array":["Bile Duct Disease","Liver Transplant","Hepatoportoenterostomy (HPE)","Liver Disease","Biliary Tract Disease","Biliary Atresia"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":177,"study_website":"https://childrennetwork.org/Clinical-Studies","created_at":"2004-03-29T20:36:18.000Z","selection_criteria":"The study analyzed the case records of children born between January 1, 1997 and December 31, 2000 who were diagnosed with biliary atresia and had hepatopotoenterostomy (HPE) performed as surgical therapy. Children with a diagnosis of choledochal cyst or of an additional disease manifesting as cholestatic liver disease were excluded from the study.","doi":"https://doi.org/10.58020/2jbe-2m91","study_network":"ChiLDReN Network (ChiLDReN)","study_condition":"Bile Duct Disorder; Biliary Atresia","study_keywords":"Bile Duct Disease; Liver Transplant; Hepatoportoenterostomy (HPE); Liver Disease; Biliary Tract Disease; Biliary Atresia","study_citation":"Brown, Morton (2015). Biliary Atresia Research Consortium(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/2jbe-2m91","study_end_date":null,"study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"barc","outcome":"The study found that contemporary management of biliary atresia in the 9 US centers resulted in outcomes equivalent to those reported from Western Europe and Japan despite significant variability in the approaches to diagnosis and management among the BARC centers and differences in approach with respect to other countries. Total serum bilirubin level measured at 3 months post-HPE appeared to be a biomarker that was predictive of subsequent outcome. Additionally, the data showed that the coexistence of splenic malformations with biliary atresia (BASM syndrome) had negative implications with regard to outcome.","study_start_date":null,"acronym":"BARC","resource_use_acknowledgment":"The Biliary Atresia Research Consortium (BARC) was conducted by the BARC Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the BARC (https://doi.org/10.58020/2jbe-2m91) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the BARC study and does not necessarily reflect the opinions or views of the BARC study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Children; Transplant Patients","name":"Biliary Atresia Research Consortium","study_specimen_types_array":null,"study_sites_number":"9","specimen_availability":"Requires Collaboration with Parent Study","division":"DDN"},"sort":["BARC"]},{"_index":"study_v001","_id":"X8K1bpMBHb0XhPer590g","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Primary Outcome Measures:\r\n\r\n- Percentage of participants in each dose arm who are prescribed (i) full randomized sodium bicarbonate dose per protocol at end of 28 weeks and (ii) at least 25% of randomized sodium bicarbonate dose per protocol at end of 28 weeks.\r\n\r\nSecondary Outcome Measures:\r\n\r\n- Change in Urinary ammonium excretion from baseline to 28 weeks","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:43:08.448Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)[(V1) https://doi.org/10.58020/agds-b607] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.139Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Chronic Kidney Disease"],"study_image_types_array":null,"study_medication":null,"objective":"To determine the best dose of sodium bicarbonate to prescribe (in a future study) that will test the long-term safety and efficacy of sodium bicarbonate as a treatment to in individuals with chronic kidney disease.","study_id":183,"study_keywords_array":["Cronic Kidney Disease (CKD)","Sodium Bicarconate","Kidney Disease","Estimated Glomerular Filtration Rate (EGFR)"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT02521181}","network_id":232,"study_website":null,"created_at":"2016-05-25T21:46:18.843Z","selection_criteria":"Inclusion Criteria:\r\n\r\n- Patients must be 18 years or older with moderate to severe chronic kidney disease at the time of screening to participate in this study.\r\n\r\nExclusion Criteria:\r\n\r\n- Patients less than 18 years or older and/or do not have severe chronic kidney disease at the time of screening may not participate in this study.","doi":"https://doi.org/10.58020/agds-b607","study_network":"Chronic Kidney Disease Consortium (CKD)","study_condition":"Chronic Kidney Disease","study_keywords":"Cronic Kidney Disease (CKD); Sodium Bicarconate; Kidney Disease; Estimated Glomerular Filtration Rate (EGFR)","study_citation":"Gassman, Jennifer (2020). Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/agds-b607","study_end_date":"2018-06","study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"base","outcome":"This study is ongoing.","study_start_date":"2015-10","acronym":"BASE","resource_use_acknowledgment":"The Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR) (BASE) was conducted by the BASE Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the BASE (https://doi.org/10.58020/agds-b607) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the BASE study and does not necessarily reflect the opinions or views of the BASE study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Adults","name":"Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)","study_specimen_types_array":null,"study_sites_number":"7","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["BASE"]},{"_index":"study_v001","_id":"qv21bpMBC2xkvCSB5Bnq","_score":null,"_source":{"dbgap_link":"{https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003356.v1.p1}","main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-09-13T00:51:29.109Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Biliary Atresia Study in Infants and Children[(V1) ] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.132Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Transplant Patients","Children"],"study_condition_array":["Bile Duct Disorder","Biliary Atresia","Cholestasis"],"study_image_types_array":null,"study_medication":null,"objective":"Specific aims of the study include identifying the gene(s) implicated in the etiology of biliary atresia, identifying the polymorphisms that may influence disease progression, and characterizing the natural history of the older, non-transplanted patients with biliary atresia.","study_id":90,"study_keywords_array":["Liver Disease","Biliary Atresia","Cholestasis","Liver Transplant","Polymorphism"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00345553}","network_id":177,"study_website":"https://childrennetwork.org/Clinical-Studies","created_at":"2010-02-11T23:49:02.000Z","selection_criteria":"Patients between the ages of 6 months and 20 years who meet the following criteria are eligible for enrollment:\u003cul\u003e\r\n\u003cli\u003eHave a confirmed diagnosis of biliary atresia determined chart review, including review of pertinent diagnostic biopsy reports, radiologic reports, and/or surgical reports\u003c/li\u003e\r\n\u003cli\u003eHave their native liver or have a confirmed liver transplantation\u003c/li\u003e\u003c/ul\u003e\u003c/ul\u003e\r\nExclusion criteria:\u003cul\u003e\r\n\u003cli\u003eCurrently participating in the ChiLDReN study PROBE\u003c/li\u003e\r\n\u003cli\u003eInability to confirm original diagnostic evaluation of biliary atresia\u003c/li\u003e \r\n\u003cli\u003eInability or unwillingness of family or participant to participate in all scheduled visits\u003c/li\u003e\u003c/ul\u003e","doi":null,"study_network":"ChiLDReN Network (ChiLDReN)","study_condition":"Bile Duct Disorder; Biliary Atresia; Cholestasis","study_keywords":"Liver Disease; Biliary Atresia; Cholestasis; Liver Transplant; Polymorphism","study_citation":"Brown, Morton (2024). Biliary Atresia Study in Infants and Children(V1) [Dataset] NIDDK Central Repository. ","study_end_date":"2029-05","study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"basic","outcome":"This study is ongoing.","study_start_date":"2006-05","acronym":"BASIC","resource_use_acknowledgment":"The Biliary Atresia Study in Infants and Children (BASIC) was conducted by the BASIC Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the BASIC reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the BASIC study and does not necessarily reflect the opinions or views of the BASIC study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Transplant Patients; Children","name":"Biliary Atresia Study in Infants and Children","study_specimen_types_array":null,"study_sites_number":"16","specimen_availability":"Requires Collaboration with Parent Study","division":"DDN"},"sort":["BASIC"]},{"_index":"study_v001","_id":"w_21bpMBC2xkvCSB5Bn5","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure, which was assessed at 8 months, was a composite of two endpoints: (1) successful drug withdrawal (i.e. not requesting any other treatment for incontinence) and (2) achieving and maintaining ≥ 70% reduction from baseline in the frequency of incontinence episodes reported on a bladder diary. \r\n\r\nSecondary outcome measures included reduction in incontinence, self-reported satisfaction and improvement, and scores on validated questionnaires measuring symptom distress and health-related quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-06-27T20:05:29.937Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Behavior Enhances Drug Reduction of Incontinence[(V1) https://doi.org/10.58020/sjgp-bq76] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.160Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Urinary Incontinence"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the study was to determine whether combining antimuscarinic drug therapy with supervised behavioral training, compared with drug therapy alone, improves the ability of women with urge incontinence to achieve clinically important reductions in incontinence episodes and to sustain these improvements after discontinuing drug therapy.","study_id":119,"study_keywords_array":["Antimuscarinic Drug Therapy","Urinary Incontinence","Urge Incontinence","Behavioral Training","Urogenital Disease"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00090584}","network_id":284,"study_website":null,"created_at":"2011-06-07T19:17:23.000Z","selection_criteria":"Women with urge incontinence only or predominant urge incontinence (defined as urge symptom index \u003e stress symptom index on the Medical Epidemiological, and Social Aspects of Aging Questionnaire) who met the following criteria were eligible for the study:\r\n\r\n- At least 7 episodes of incontinence reported in a 7-day bladder diary\r\n- Persistent incontinence for at least 3 months\r\n- No current use of antimuscarinics or other medications that could impact urinary incontinence\r\n- No evidence that incontinence was secondary to neurologic or other systemic diseases.","doi":"https://doi.org/10.58020/sjgp-bq76","study_network":"Urinary Incontinence Research Network (UITN)","study_condition":"Urinary Incontinence","study_keywords":"Antimuscarinic Drug Therapy; Urinary Incontinence; Urge Incontinence; Behavioral Training; Urogenital Disease","study_citation":"Tennstedt, Sharon (2008). Behavior Enhances Drug Reduction of Incontinence(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/sjgp-bq76","study_end_date":"2006-08","study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"be-dri","outcome":"Results showed that the rate of successful discontinuation of therapy at 8 months was the same in the combination therapy and drug therapy alone groups, although a higher proportion of participants who received combination therapy than drug therapy alone achieved a 70% or greater reduction in incontinence at 10 weeks. Combination therapy yielded better outcomes over time for patient satisfaction and perceived improvement but not health-related quality of life.\r\n\r\nThe study concluded that the addition of behavioral training to drug therapy may reduce incontinence frequency during active treatment but does not improve the ability to discontinue drug therapy and maintain improvement in urinary incontinence. Combination therapy was shown to have a beneficial effect on patient satisfaction, perceived improvement, and reduction of other bladder symptoms.","study_start_date":"2004-08","acronym":"BE-DRI","resource_use_acknowledgment":"The Behavior Enhances Drug Reduction of Incontinence (BE-DRI) was conducted by the BE-DRI Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the BE-DRI reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the BE-DRI study and does not necessarily reflect the opinions or views of the BE-DRI study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Behavior Enhances Drug Reduction of Incontinence","study_specimen_types_array":null,"study_sites_number":"9","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["BE-DRI"]},{"_index":"study_v001","_id":"mMK1bpMBHb0XhPer7t17","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Primary Outcome Measure:\r\nStudy participants were assessed for change in steady-state beta-cell compensation for insulin resistance from baseline to 24 months. The results were compared between the treatment groups.\r\n\r\nSecondary Outcome Measure:\r\nParticipants were also evaluated for change in blood glucose levels during the study period.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-08-14T21:26:58.266Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Beta Cell Restoration Through Fat Mitigation[(V1) https://doi.org/10.58020/7nt7-nf08] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.116Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Prediabetes Syndrome","Type 2 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"The aim of the BetaFat study was to determine whether gastric banding would be better than metformin at maintaining or restoring beta-cell function in mildly to moderately obese individuals with prediabetes or recently diagnosed type 2 diabetes.","study_id":270,"study_keywords_array":["Beta-Cell Function","Restoring Insulin Secretion","Gastric Banding","Metformin","Prediabetic State","Diabetes Mellitus, Type 2"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT01763346}","network_id":158,"study_website":null,"created_at":"2020-09-19T05:09:44.780Z","selection_criteria":"Inclusion Criteria:\r\nStudy participants were age 22 – 65 years; had prediabetes or diabetes for less than one year and did not receive any glucose-lowering medication, except during pregnancy; body mass index 30 – 40 kg/m2; participated in a diet, exercise, and lifestyle intervention program for at least two months within two years prior to screening; and met the glucose and HbA1c requirements.\r\n\r\nExclusion Criteria:\r\nIndividuals were excluded from participation if they were anemic or had known coagulopathy; had contraindications to gastric binding and MRI; excessive alcohol consumption; thyroid disease that was not sufficiently treated; cardiovascular disease; serum AST more than three times the upper limit of normal; renal disease or serum potassium abnormality; active infection; or an underlying disease or condition that would affect glucose metabolism, limit life span, increase the risk of intervention, prevent or limit study participation, or interfere with study procedures and/or outcomes.","doi":"https://doi.org/10.58020/7nt7-nf08","study_network":"The RISE Consortium (RISE)","study_condition":"Prediabetes Syndrome; Type 2 Diabetes Mellitus","study_keywords":"Beta-Cell Function; Restoring Insulin Secretion; Gastric Banding; Metformin; Prediabetic State; Diabetes Mellitus, Type 2","study_citation":"Braffett, Barbara (2021). Beta Cell Restoration Through Fat Mitigation(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/7nt7-nf08","study_end_date":"2018-06","study_procedure":null,"study_research_area_array":["Obesity","Multidisciplinary Research","Diabetes"],"@version":"1","slug":"rise_betafat","outcome":"Study outcomes show that metformin and gastric banding had comparable effects in improving insulin sensitivity in patients with prediabetes or recently diagnosed type 2 diabetes. Both treatment groups exhibited some improvements in beta-cell function and glycemia during the study period. Also, those in the gastric banding group lost more weight and experienced faster weight loss than the patients in the metformin group. Although both treatment groups had similar results with reducing the progression of type 2 diabetes over the two-year study period, additional studies are needed to determine the long-term benefits of gastric banding versus metformin treatment.","study_start_date":"2013-06","acronym":"BetaFat","resource_use_acknowledgment":"The Beta Cell Restoration Through Fat Mitigation (BetaFat) was conducted by the BetaFat Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the BetaFat (https://doi.org/10.58020/7nt7-nf08) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the BetaFat study and does not necessarily reflect the opinions or views of the BetaFat study, NIDDK-CR, or NIDDK.","study_research_area":"Obesity; Multidisciplinary Research; Diabetes","study_target_population":"Adults","name":"Beta Cell Restoration Through Fat Mitigation","study_specimen_types_array":null,"study_sites_number":"1","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["BetaFat"]},{"_index":"study_v001","_id":"h8K1bpMBHb0XhPer591n","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the change in AUASI, which is a self-administered 7 item index assessing frequency of lower urinary tract symptoms, scored from baseline to 72 weeks. Participants were seen at baseline and at 12, 24, 36, 48, 60, and 72 weeks for outcome assessments. They were assessed for side effects with blood counts, basic blood chemistries, coagulation tests, electrocardiograms, and urinalyses 4 weeks after each dose increase and at end of study, including a query about adverse effects occurring within 30 days of treatment discontinuation.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-12T02:12:56.468Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Complementary and Alternative Medicine for Urological Symptoms[(V2) https://doi.org/10.58020/cezb-xp64] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.190Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Benign Prostatic Hyperplasia"],"study_image_types_array":null,"study_medication":null,"objective":"The overall goal of the CAMUS study was to compare the efficacy of a widely available phytotherapy, extract of Serenoa repens, with placebo on lower urinary tract symptoms in men with BPH.","study_id":23,"study_keywords_array":["Benign Prostatic Hyperplasia (BPH)","Prostatic Hyperplasia","Urogenital Disease","Saw Palmetto Extract","Urinry Tract Symptom","American Urological Associate Symptom Index (AUASI)"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00603304}","network_id":null,"study_website":null,"created_at":"2004-03-29T19:54:11.000Z","selection_criteria":"Participants included males at least 45 years of age who met the following criteria: (1) peak urinary flow rate at least 4 mL/s with a voided volume of at least 125 mL and (2) AUASI score of between 8 and 24 at both screening visits.","doi":"https://doi.org/10.58020/cezb-xp64","study_network":null,"study_condition":"Benign Prostatic Hyperplasia","study_keywords":"Benign Prostatic Hyperplasia (BPH); Prostatic Hyperplasia; Urogenital Disease; Saw Palmetto Extract; Urinry Tract Symptom; American Urological Associate Symptom Index (AUASI)","study_citation":"Lee, Jeannette (2021). Complementary and Alternative Medicine for Urological Symptoms(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/cezb-xp64","study_end_date":"2010-12","study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"camus","outcome":"The CAMUS study found that saw palmetto extract used at up to three times the standard daily dose, while safe and with no attributable side effects, did not reduce lower urinary symptoms or other outcomes related to BPH compared to placebo.","study_start_date":"2008-02","acronym":"CAMUS","resource_use_acknowledgment":"The Complementary and Alternative Medicine for Urological Symptoms (CAMUS) was conducted by the CAMUS Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CAMUS (https://doi.org/10.58020/cezb-xp64) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CAMUS study and does not necessarily reflect the opinions or views of the CAMUS study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Complementary and Alternative Medicine for Urological Symptoms","study_specimen_types_array":null,"study_sites_number":"11","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["CAMUS"]},{"_index":"study_v001","_id":"hsK1bpMBHb0XhPer591n","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Outcome measures included a patient questionnaire completed by all study participants to collect baseline information. Patients from a pre-identified subset of dialysis units were also asked to provide data for a nutrition sub-study by completing the Block 2000-Brief Food Questionnaire (FQ), and serum samples were requested from dialysis units for these patients. Patients in the sub-study were also asked to complete both the patient and food questionnaire at 12 months after baseline data collection.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:43:20.634Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Comprehensive Dialysis Study[(V4) https://doi.org/10.58020/zv2g-cy49] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.182Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Dialysis Patients","Adults"],"study_condition_array":["End Stage Renal Failure"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objective of the CDS study was to better understand interrelations among patients’ general health, nutritional status, physical function and health-related quality of life.","study_id":66,"study_keywords_array":["Work/Disability","End Stage Renal Disease","Protein Energy Malnutrition","Nutrition","Dialysis","United States Renal Data System","Social Determinants of Health (SDoH)","Physical Activity","Health-Related Quality of Life"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":null,"created_at":"2008-07-21T18:19:57.000Z","selection_criteria":"Participants were enrolled who met the following inclusion criteria:\r\n\r\n- On dialysis for no more than 6 months\r\n- Able to speak English or Spanish\r\n- Able to provide voluntary written informed consent","doi":"https://doi.org/10.58020/zv2g-cy49","study_network":null,"study_condition":"End Stage Renal Failure","study_keywords":"Work/Disability; End Stage Renal Disease; Protein Energy Malnutrition; Nutrition; Dialysis; United States Renal Data System; Social Determinants of Health (SDoH); Physical Activity; Health-Related Quality of Life","study_citation":"Kaysen, George (2016). Comprehensive Dialysis Study(V4) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/zv2g-cy49","study_end_date":null,"study_procedure":null,"study_research_area_array":["Kidney Disease","Nutrition","Multidisciplinary Research"],"@version":"1","slug":"cds","outcome":"The CDS contains detailed information on health-related quality of life, self-reported physical activity, and macronutrient intake and represents one of few cohorts in which laboratory proxies of nutrition and inflammatory status were measured simultaneously. Information reported by CDS participants was linked with patient-specific modality history, mortality, hospitalization, and cost information in USRDS files. The CDS therefore provides a unique resource from which to inform the design of interventions addressing several related conditions that affect longevity and health status in ESRD.","study_start_date":null,"acronym":"CDS","resource_use_acknowledgment":"The Comprehensive Dialysis Study (CDS) was conducted by the CDS Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CDS (https://doi.org/10.58020/zv2g-cy49) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CDS study and does not necessarily reflect the opinions or views of the CDS study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease; Nutrition; Multidisciplinary Research","study_target_population":"Dialysis Patients; Adults","name":"Comprehensive Dialysis Study","study_specimen_types_array":null,"study_sites_number":"335","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["CDS"]},{"_index":"study_v001","_id":"hv21bpMBC2xkvCSB5BmZ","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Primary Outcome Measures:\r\nDuring a five year period subjects will be monitored for the development of cirrhosis.\r\n\r\nSecondary Outcome Measures:\r\nDuring a five year period the effects on associated pulmonary and nutritional issues will be documented.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:44:45.532Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease[(V1) https://doi.org/10.58020/vj16-wz20] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.129Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children"],"study_condition_array":["Pancreatic Insufficiency","Cystic Fibrosis","Cirrhosis of Liver"],"study_image_types_array":null,"study_medication":null,"objective":"The objective of the PUSH study is to determine the usefulness of abdominal ultrasound when attempting to predict the development of cirrhosis in subjects with cystic fibrosis.","study_id":102,"study_keywords_array":["Cystic Fibrosis","Advanced Liver Disease","Abdominal Ultrasound","Pancreatic Insufficiency","Cirrhosis","Liver Disease"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT01144507}","network_id":177,"study_website":"https://childrennetwork.org/Clinical-Studies","created_at":"2010-03-01T21:04:35.000Z","selection_criteria":"Inclusion Criteria: \r\nParticipants must be age 3-12 years; diagnosed with Cystic Fibrosis and pancreatic insufficiency; and be enrolled in the CFF registry study or Toronto CF Registry.\r\n\r\nExclusion Criteria: \r\nIndividuals will be excluded if they have cirrhosis; presence of Burkholderia cepacia; short bowel syndrome; or a serious disease that would prevent participation.","doi":"https://doi.org/10.58020/vj16-wz20","study_network":"ChiLDReN Network (ChiLDReN)","study_condition":"Pancreatic Insufficiency; Cystic Fibrosis; Cirrhosis of Liver","study_keywords":"Cystic Fibrosis; Advanced Liver Disease; Abdominal Ultrasound; Pancreatic Insufficiency; Cirrhosis; Liver Disease","study_citation":"Magee, John (2020). Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/vj16-wz20","study_end_date":"2023-06","study_procedure":null,"study_research_area_array":["Liver Disease","Multidisciplinary Research","Pancreatic Disease"],"@version":"1","slug":"cfld-push","outcome":"This study is ongoing, but not recruiting participants.","study_start_date":"2010-01","acronym":"CFLD PUSH","resource_use_acknowledgment":"The Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease (CFLD PUSH) was conducted by the CFLD PUSH Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CFLD PUSH (https://doi.org/10.58020/vj16-wz20) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CFLD PUSH study and does not necessarily reflect the opinions or views of the CFLD PUSH study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease; Multidisciplinary Research; Pancreatic Disease","study_target_population":"Children","name":"Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis Liver Disease","study_specimen_types_array":null,"study_sites_number":"11","specimen_availability":"Requires Collaboration with Parent Study","division":"DDN"},"sort":["CFLD PUSH"]},{"_index":"study_v001","_id":"qP21bpMBC2xkvCSB5Bnq","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The level of stimulated c-peptide at 90-minutes derived from the mixed-meal tolerance test (MMTT) at 75+/-5 days following the first islet infusion.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:24:36.888Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation[(V1) https://doi.org/10.58020/v6zz-1r31] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.106Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Transplant Patients","Adults"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objective is to evaluate the safety and efficacy of Low Molecular Weight Dextran Sulfate (LMW-DS) to enhance engraftment and prevent IBMIR in islet transplantation to Type 1 diabetic subjects. The secondary objective is to gather additional safety and efficacy information about the combination of Low Molecular Weight Sulfated Dextran with islet transplantation.","study_id":191,"study_keywords_array":["Sirolimus","Etanercept","Diabetes Mellitus, Type 1","Tacrolimus","Islet Cell Transplantation","Low Molecular Weight Sulfated Dextran (LMW-SD)","Basiliximab"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT00789308}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2018-12-18T00:41:08.339Z","selection_criteria":null,"doi":"https://doi.org/10.58020/v6zz-1r31","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Sirolimus; Etanercept; Diabetes Mellitus, Type 1; Tacrolimus; Islet Cell Transplantation; Low Molecular Weight Sulfated Dextran (LMW-SD); Basiliximab","study_citation":"Clarke, William (2019). Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/v6zz-1r31","study_end_date":"2014-08","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-01","outcome":"This study has ended.","study_start_date":"2008-07","acronym":"CIT-01","resource_use_acknowledgment":"The Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01) was conducted by the CIT-01 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CIT-01 reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-01 study and does not necessarily reflect the opinions or views of the CIT-01 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Transplant Patients; Adults","name":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","study_specimen_types_array":null,"study_sites_number":null,"specimen_availability":"Specimens Not Available","division":"DEM"},"sort":["CIT-01"]},{"_index":"study_v001","_id":"dMK1bpMBHb0XhPer591m","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the proportion of participants with insulin independence at 75 days following the first transplant infusion. Secondary outcome measures included reduction in insulin requirements, mean amplitude of glycemic excursions, HbA1c levels, and assessment of quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:26:25.227Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Strategies to Improve Long Term Islet Graft Survival and Extended Follow Up after Islet Transplantation in Type 1 Diabetes[(V1) https://doi.org/10.58020/vpj2-xq84] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.108Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"CIT-02: The primary objective is to determine the proportion of subjects who are insulin independent after a single islet transplant at 75 +/- 5 days post-transplant in subjects treated with Lisofylline added to a standard islet transplant regimen who enroll at the same sites as the CIT-02 subjects. \r\n\r\nCIT-08: The primary objective is to provide extended follow-up for safety and efficacy and to support continued islet graft function to participants previously enrolled in CIT02, CIT03, CIT04, CIT05, CIT06, or CIT07.","study_id":93,"study_keywords_array":["Exenatide","Rabbit Anti-Thymocyte Globulin","Basiliximab","Etanercept","Sirolimus","Immunosuppresive Medication Regimen","Tacrolimus","Lisofylline","Diabetes Mellitus, Type 1","Islet Cell Transplant","Normal Kidney Function","Intractable Hypoglycemia"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00464555}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2010-03-01T20:18:15.000Z","selection_criteria":"Individuals who met the following criteria were eligible for the study: \r\n- Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28\r\n- Absent stimulated C-peptide (less than 0.3 ng/mL) 60 and 90 minutes post-mixed-meal tolerance test\r\n- Involvement of intensive diabetes management, defined as: (1) Self-monitoring of glucose values no less than a mean of three times each day averaged over each week; (2) Administration of three or more insulin injections each day or insulin pump therapy; (3) Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three evaluations during the 12 months prior to study enrollment\r\n- At least one episode of severe hypoglycemia in the past 12 months prior to study enrollment\r\n- Reduced awareness of hypoglycemia. More information about this criterion, including specific definition of hypoglycemia unawareness, is in the protocol\r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/vpj2-xq84","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Exenatide; Rabbit Anti-Thymocyte Globulin; Basiliximab; Etanercept; Sirolimus; Immunosuppresive Medication Regimen; Tacrolimus; Lisofylline; Diabetes Mellitus, Type 1; Islet Cell Transplant; Normal Kidney Function; Intractable Hypoglycemia","study_citation":"Clarke, William (2020). Strategies to Improve Long Term Islet Graft Survival and Extended Follow Up after Islet Transplantation in Type 1 Diabetes(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/vpj2-xq84","study_end_date":"2014-02","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-02","outcome":"This study has been concluded, but results have not yet been published.","study_start_date":"2006-12","acronym":"CIT-02/08","resource_use_acknowledgment":"The Strategies to Improve Long Term Islet Graft Survival and Extended Follow Up after Islet Transplantation in Type 1 Diabetes (CIT-02/08) was conducted by the CIT-02/08 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CIT-02/08 (https://doi.org/10.58020/vpj2-xq84) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-02/08 study and does not necessarily reflect the opinions or views of the CIT-02/08 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults; Transplant Patients","name":"Strategies to Improve Long Term Islet Graft Survival and Extended Follow Up after Islet Transplantation in Type 1 Diabetes","study_specimen_types_array":null,"study_sites_number":"2","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["CIT-02/08"]},{"_index":"study_v001","_id":"UcK1bpMBHb0XhPer590Z","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the proportion of participants with insulin independence at 75 days following the first transplant infusion. Secondary outcome measures included reduction in insulin requirements, mean amplitude of glycemic excursions, HbA1c levels, incidence of immune sensitization (defined by detected anti-HLA antibodies not present prior to transplantation), and quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:27:45.124Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes and Extended Follow Up after Islet Transplantation in Type 1 Diabetes[(V1) https://doi.org/10.58020/djpt-4d91] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.108Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"CIT-03: The primary objective of this protocol is to assess the safety and efficacy of an immunosuppressive regimen consisting of ATG (1st transplant only), basiliximab (subsequent transplants only), etanercept, DSG, sirolimus, and low-dose tacrolimus on post-transplant islet function in subjects with T1D. \r\n\r\nCIT-08: The primary objective is to provide extended follow-up for safety and efficacy and to support continued islet graft function to participants previously enrolled in CIT02, CIT03, CIT04, CIT05, CIT06, or CIT07.","study_id":94,"study_keywords_array":["Diabetes Mellitus, Type1","Immunosuppresive Medication Regimen","Deoxyspergualin","Islet Cell Transplant","Normal Kidney Function","Intractable Hypoglycemia","Tacrolimus","Basiliximab","Sirolimus","Rabbit Anti-Thymocyte Globulin","Etanercept"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00434850}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2010-03-01T20:19:11.000Z","selection_criteria":"Individuals who met the following criteria were eligible for enrollment:\r\n\r\n- Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28\r\n- Absent stimulated C-peptide (less than 0.3 ng/mL) 60 and 90 minutes post-mixed-meal tolerance test\r\n- Involvement of intensive diabetes management, defined as: (1) Self-monitoring of glucose values no less than a mean of three times each day averaged over each week; (2) Administration of three or more insulin injections each day or insulin pump therapy; (3) Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three evaluations during the 12 months prior to study enrollment\r\n- At least one episode of severe hypoglycemia in the 12 months prior to study enrollment\r\n- Reduced awareness of hypoglycemia. \r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/djpt-4d91","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Diabetes Mellitus, Type1; Immunosuppresive Medication Regimen; Deoxyspergualin; Islet Cell Transplant; Normal Kidney Function; Intractable Hypoglycemia; Tacrolimus; Basiliximab; Sirolimus; Rabbit Anti-Thymocyte Globulin; Etanercept","study_citation":"Clarke, William (2020). Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes and Extended Follow Up after Islet Transplantation in Type 1 Diabetes(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/djpt-4d91","study_end_date":"2013-11","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-03","outcome":"This study has been concluded, but results have not yet been published.","study_start_date":"2006-10","acronym":"CIT-03/08","resource_use_acknowledgment":"The Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes and Extended Follow Up after Islet Transplantation in Type 1 Diabetes (CIT-03/08) was conducted by the CIT-03/08 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CIT-03/08 (https://doi.org/10.58020/djpt-4d91) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-03/08 study and does not necessarily reflect the opinions or views of the CIT-03/08 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults; Transplant Patients","name":"Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes and Extended Follow Up after Islet Transplantation in Type 1 Diabetes","study_specimen_types_array":null,"study_sites_number":"3","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["CIT-03/08"]},{"_index":"study_v001","_id":"RsK1bpMBHb0XhPer5t3W","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the proportion of participants with insulin independence at 75 days following the first transplant infusion. Secondary outcome measures included reduction in insulin requirements, mean amplitude of glycemic excursions, HbA1c levels, incidence of immune sensitization (defined by detected anti-HLA antibodies not present prior to transplantation), and quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:32:56.249Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy[(V1) https://doi.org/10.58020/c22t-jh71] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.107Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"CIT-04: The primary objective of this protocol is to assess the safety and efficacy of an immunosuppressive medication consisting of a monoclonal antibody IL-2 receptor blocker (basiliximab), belatacept and mycophenolate mofetil in islet transplantation. The primary efficacy measure will be the proportion of insulin-independent subjects at day 75 (+/- 5 days) following the first isletL transplant. The secondary objective is to assess islet graft function in the absence of calcineurin inhibitor drugs, with determination of success being the proportion of patients attaining and maintaining insulin independence after receiving a maximum of 3 islet transplants. \r\n\r\nCIT-08: The primary objective is to provide extended follow-up for safety and efficacy and to support continued islet graft function to participants previously enrolled in CIT02, CIT03, CIT04, CIT05, CIT06, or CIT07.","study_id":95,"study_keywords_array":["Intractable Hypoglycemia","Normal Kidney Function","Islet Cell Transplant","Belatacept","Immunosuppresive Medication Regimen","Diabetes Mellitus, Type 1","Myocophenolate Mofetil","Basiliximab","Rabbit Anti-Thymocyte Globulin"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00468403}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2010-03-01T20:20:23.000Z","selection_criteria":"Individuals who met the following criteria were eligible for enrollment:\r\n\r\n- Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28\r\n- Absent stimulated C-peptide (less than 0.3 ng/mL) 60 and 90 minutes post-mixed-meal tolerance test\r\n- Involvement of intensive diabetes management, defined as: (1) Self-monitoring of glucose values no less than a mean of three times each day averaged over each week; (2) Administration of three or more insulin injections each day or insulin pump therapy; (3) Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three evaluations during the 12 months prior to study enrollment\r\n- At least one episode of severe hypoglycemia in the 12 months prior to study enrollment\r\n- Reduced awareness of hypoglycemia. \r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/c22t-jh71","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Intractable Hypoglycemia; Normal Kidney Function; Islet Cell Transplant; Belatacept; Immunosuppresive Medication Regimen; Diabetes Mellitus, Type 1; Myocophenolate Mofetil; Basiliximab; Rabbit Anti-Thymocyte Globulin","study_citation":"Clarke, William (2020). Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/c22t-jh71","study_end_date":"2013-04","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-04","outcome":"This study has been concluded, but results have not yet been published.","study_start_date":"2008-10","acronym":"CIT-04/08","resource_use_acknowledgment":"The Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy (CIT-04/08) was conducted by the CIT-04/08 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CIT-04/08 (https://doi.org/10.58020/c22t-jh71) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-04/08 study and does not necessarily reflect the opinions or views of the CIT-04/08 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults; Transplant Patients","name":"Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy","study_specimen_types_array":null,"study_sites_number":"2","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["CIT-04/08"]},{"_index":"study_v001","_id":"i8K1bpMBHb0XhPer591v","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the proportion of participants with insulin independence at 75 days following the first transplant infusion. Secondary outcome measures included reduction in insulin requirements, mean amplitude of glycemic excursions, HbA1c levels, incidence of immune sensitization (defined by detected anti-HLA antibodies not present prior to transplantation), and quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:37:30.284Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression[(V1) https://doi.org/10.58020/t68y-hk43] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.107Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"CIT-05: The primary objective is to determine the proportion of subjects who are insulin independent at 75 +/- 5 days following the first islet transplant among subjects treated with an experimental islet transplant immunosuppression regimen which includes rituximab and excludes tacrolimus. This group will be compared, as a secondary analysis, to subjects in a concurrent protocol, CIT-07, which uses a standard immunosuppressive regimen. \r\n\r\nCIT-08: The primary objective is to provide extended follow-up for safety and efficacy and to support continued islet graft function to participants previously enrolled in CIT02, CIT03, CIT04, CIT05, CIT06, or CIT07.","study_id":96,"study_keywords_array":["Intractable Hypoglycemia","Rutiximab","Sirolimus","Daclizumab","ATG","Immunosuppresive Medication Regimen","Rabbit Anti-Thymocyte Globulin","Islet Cell Transplant","Normal Kidney Function","Anti-CD20 Agent Rutiximab","Diabetes Mellitus, Type 1"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00468442}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2010-03-01T20:24:41.000Z","selection_criteria":"Individuals who met the following criteria were eligible for enrollment:\r\n\r\n- Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28\r\n\r\n- Absent stimulated C-peptide (less than 0.3 ng/mL) 60 and 90 minutes post-mixed-meal tolerance test\r\n\r\n- Involvement of intensive diabetes management, defined as: (1) Self-monitoring of glucose values no less than a mean of three times each day averaged over each week; (2) Administration of three or more insulin injections each day or insulin pump therapy; (3) Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three evaluations during the 12 months prior to study enrollment\r\n\r\n- At least one episode of severe hypoglycemia in the 12 months prior to study enrollment\r\n\r\n- Reduced awareness of hypoglycemia. \r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/t68y-hk43","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Intractable Hypoglycemia; Rutiximab; Sirolimus; Daclizumab; ATG; Immunosuppresive Medication Regimen; Rabbit Anti-Thymocyte Globulin; Islet Cell Transplant; Normal Kidney Function; Anti-CD20 Agent Rutiximab; Diabetes Mellitus, Type 1","study_citation":"Clarke, William (2020). B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/t68y-hk43","study_end_date":"2011-09","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-0501","outcome":"This study was terminated for lack of efficacy.","study_start_date":"2006-11","acronym":"CIT-05/08","resource_use_acknowledgment":"The B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression (CIT-05/08) was conducted by the CIT-05/08 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CIT-05/08 (https://doi.org/10.58020/t68y-hk43) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-05/08 study and does not necessarily reflect the opinions or views of the CIT-05/08 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults; Transplant Patients","name":"B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression","study_specimen_types_array":null,"study_sites_number":"1","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["CIT-05/08"]},{"_index":"study_v001","_id":"1v21bpMBC2xkvCSB5RkX","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the proportion of participants with an absence of severe hypoglycemic events and either a reduction in HbAc1 of at least 1 point or HbAc1 of at most 6.5%, assessed at 1 year after the first islet transfusion. Secondary outcome measures included reduction in insulin requirements, mean amplitude of glycemic excursions, renal and cardiovascular impact, and quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:39:08.654Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation[(V1) https://doi.org/10.58020/3rma-wx55] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.107Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"CIT-06: The primary objective is to test the hypothesis that islet transplantation in patients with established kidney transplants leads to a reduced risk of diabetes-related complications as assessed by improved metabolic control measured by serial HbA1c levels and/or reduced occurrence of hypoglycemic events compared with IIT. Secondary objectives of this study will assess whether successful islet transplantation leads to improved QOL, improved metabolic control and reduced risk of cardiovascular and renal complications from diabetes. \r\n\r\nCIT-08: The primary objective is to provide extended follow-up for safety and efficacy and to support continued islet graft function to participants previously enrolled in CIT02, CIT03, CIT04, CIT05, CIT06, or CIT07.","study_id":97,"study_keywords_array":["ATG","Daclizumab","Normal Kidney Function","Intractable Hypoglycemia","Maintenance Immunosuppresion","Rabbit Anti-Thymocyte Globulin","Diabetes Mellitus, Type 1","Basiliximab","Islet Transplantation","Etanercept","Kidney Transplant"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00468117}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2010-03-01T20:25:48.000Z","selection_criteria":"Individuals who met the following criteria were eligible for enrollment:\r\n\r\n- Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28\r\n- Absent stimulated C-peptide (less than 0.3 ng/mL) 60 and 90 minutes post-mixed-meal tolerance test\r\n- Received kidney transplant for ESRD and are taking appropriate calcineurin inhibitor (CNI)-based maintenance immunosuppressive therapy\r\n- Stable renal function (defined as creatinine of no more than one-third greater than the average creatinine determination performed in the 3 previous months prior to islet transplantation)\r\n- Intensive diabetes management followed by reduced awareness of hypoglycemia or HbAc1 ≥ 7.5%.\r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/3rma-wx55","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"ATG; Daclizumab; Normal Kidney Function; Intractable Hypoglycemia; Maintenance Immunosuppresion; Rabbit Anti-Thymocyte Globulin; Diabetes Mellitus, Type 1; Basiliximab; Islet Transplantation; Etanercept; Kidney Transplant","study_citation":"Clarke, William (2020). Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/3rma-wx55","study_end_date":"2017-07","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-06","outcome":"The study has concluded.","study_start_date":"2007-01","acronym":"CIT-06/08","resource_use_acknowledgment":"The Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation (CIT-06/08) was conducted by the CIT-06/08 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CIT-06/08 (https://doi.org/10.58020/3rma-wx55) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-06/08 study and does not necessarily reflect the opinions or views of the CIT-06/08 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults; Transplant Patients","name":"Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation","study_specimen_types_array":null,"study_sites_number":"10","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["CIT-06/08"]},{"_index":"study_v001","_id":"f8K1bpMBHb0XhPer591n","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the proportion of participants with an absence of severe hypoglycemic events and HbA1c less than 7.0%, assessed at 1 year after the first islet infusion. Secondary outcome measures included reduction in insulin requirements, mean amplitude of glycemic excursions, the incidence and severity of adverse events, and quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T18:40:39.553Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Islet Transplantation in Type 1 Diabetes[(V2) https://doi.org/10.58020/qx8b-gk69] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.109Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Transplant Patients"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"The study aimed to determine the safety and efficacy of islet transplantation when combined with an immunosuppressive medication regimen in treating patients with type 1 diabetes and hypoglycemia unawareness.","study_id":92,"study_keywords_array":["Islet Cell Transplant","Normal Kidney Function","Intractable Hypoglycemia","Rabbit Anti-Thymocyte Globulin","Basiliximab","Etanercept","Sirolimus","Tacrolimus","Purified Human Pancreatic Islet (PHPI)","Impaired Awareness of Hypoglycemia","Diabetes Mellitus, Type 1","Islet Transplantation","Severe Hypoglycemic Event"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00434811}","network_id":58,"study_website":"https://www.citisletstudy.org/studies.html","created_at":"2010-03-01T20:15:36.000Z","selection_criteria":"Individuals who met the following criteria were eligible for enrollment:\r\n\r\n- Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28\r\n- Absent stimulated C-peptide (less than 0.3 ng/mL) 60 and 90 minutes post-mixed-meal tolerance test\r\n- Involvement of intensive diabetes management, defined as: (1) Self-monitoring of glucose values no less than a mean of three times each day averaged over each week; (2) Administration of three or more insulin injections each day or insulin pump therapy; (3) Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three evaluations during the 12 months prior to study enrollment\r\n- At least one episode of severe hypoglycemia in the 12 months prior to study enrollment\r\n- Reduced awareness of hypoglycemia. \r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/qx8b-gk69","study_network":"Clinical Islet Transplantation Consortium (CITC)","study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Islet Cell Transplant; Normal Kidney Function; Intractable Hypoglycemia; Rabbit Anti-Thymocyte Globulin; Basiliximab; Etanercept; Sirolimus; Tacrolimus; Purified Human Pancreatic Islet (PHPI); Impaired Awareness of Hypoglycemia; Diabetes Mellitus, Type 1; Islet Transplantation; Severe Hypoglycemic Event","study_citation":"Clarke, William (2018). Islet Transplantation in Type 1 Diabetes(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/qx8b-gk69","study_end_date":"2014-05","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"cit-07","outcome":"Transplanted purified human pancreatic islets (PHPI) provided glycemic control, restoration of hypoglycemia awareness, and protection from severe hypoglycemic events (SHEs) in subjects with intractable impaired awareness of hypoglycemic (IAH) and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.\r\n\r\nData associated with the primary publication only are available on the Immune Tolerance Network Trial Share website through the following link: \u003ca href=\"https://www.itntrialshare.org/project/CIT/CIT-07PUBLIC/begin.view?pageId=study.DATA_ANALYSIS\"\u003eCIT-07 Public Data\u003c/a\u003e","study_start_date":"2006-10","acronym":"CIT-07/08","resource_use_acknowledgment":"The Islet Transplantation in Type 1 Diabetes (CIT-07/08) was conducted by the CIT-07/08 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CIT-07/08 (https://doi.org/10.58020/qx8b-gk69) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CIT-07/08 study and does not necessarily reflect the opinions or views of the CIT-07/08 study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Adults; Transplant Patients","name":"Islet Transplantation in Type 1 Diabetes","study_specimen_types_array":null,"study_sites_number":"8","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["CIT-07/08"]},{"_index":"study_v001","_id":"nsK1bpMBHb0XhPer7t17","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Not Available","modified_at":"2020-09-19T01:04:54.350Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.179Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Chronic Kidney Disease"],"study_image_types_array":null,"study_medication":null,"objective":"The CKD Biomarkers Consortium was established to pursue the discovery and validation of novel biomarkers for CKD to advance research into the causes and outcomes of the disease.","study_id":121,"study_keywords_array":["Chronic Renal Insufficiency","Biomarkers","Kidney Disease"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":"https://www.ckdbiomarkersconsortium.org/","created_at":"2011-07-21T23:30:53.000Z","selection_criteria":"Participant criteria vary by study and the cohort(s) used for analysis.","doi":null,"study_network":null,"study_condition":"Chronic Kidney Disease","study_keywords":"Chronic Renal Insufficiency; Biomarkers; Kidney Disease","study_citation":null,"study_end_date":null,"study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"ckd-biocon","outcome":"This study is ongoing.","study_start_date":null,"acronym":"CKD Biocon","resource_use_acknowledgment":null,"study_research_area":"Kidney Disease","study_target_population":"Adults","name":"CKD Biomarkers Consortium","study_specimen_types_array":null,"study_sites_number":"6","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["CKD Biocon"]},{"_index":"study_v001","_id":"n8K1bpMBHb0XhPer7t17","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure is the rate of decline of GFR, which is measured repeatedly over time in cohort participants. \r\n\r\nThe time to ESRD, defined by transplantation, dialysis, or a 50% decrease in GFR, is a secondary outcome measure. Measures of neurodevelopment, cognitive ability and growth, and cardiovascular disease risk factors are also assessed.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-09-28T00:22:07.384Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the The Chronic Kidney Disease in Children Cohort Study[(V7) https://doi.org/10.58020/dzq8-ct80] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.187Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Dialysis Patients","Transplant Patients"],"study_condition_array":["Cardiovascular Disorder","Chronic Kidney Disease","End Stage Renal Failure"],"study_image_types_array":null,"study_medication":null,"objective":"The CKiD study had various objectives, including: (1) identifying and quantifying novel and traditional risk factors for progression of CKD; (2) characterizing how CKD progression effects neurodevelopment, cognitive abilities, and behavior; (3) describing the prevalence of cardiovascular disease and associated risk factors; and (4) examining the effects of declining kidney function on growth in children with CKD.","study_id":39,"study_keywords_array":["Cardiovascular Disease Risk Factors","Glomerular Filtration Rate","Kidney Disease","Chronic Renal Insufficiency","Kidney Transplant","End-Stage Renal Disease (ESRD)"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00327860}","network_id":null,"study_website":null,"created_at":"2005-05-26T23:27:17.000Z","selection_criteria":"Inclusion criteria:\r\n\r\n- For cohort 1, children between the ages of 1 and 16 years were enrolled if they had an estimated GFR (based on the Schwartz formula) between 30 and 90 ml/min/1.73m\u003csup\u003e2\u003c/sup\u003e.\r\n- For cohort 2, children between the ages of 1 and 16 years were enrolled if they had an estimated GFR (based on the Schwartz formula) between 45 and 90 ml/min/1.73m\u003csup\u003e2\u003c/sup\u003e.\r\n\r\nExclusion criteria: \r\n\r\n- Renal, other solid organ, bone marrow, or stem cell transplantation\r\n- Dialysis treatment within the past three months\r\n- Cancer diagnosis or HIV diagnosis/treatment within last 12 months\r\n- Current pregnancy or pregnancy within past 12 months\r\n- Inability to complete major data collection procedures\r\n- Current enrollment in a randomized clinical trial in which the specific treatment is unknown\r\n- Not fluent in English or Spanish\r\n- Plans to move out of area of any participating CKiD site\r\n- History of structural heart disease\r\n- Genetic syndromes involving the central nervous system (e.g., Down syndrome)\r\n- History of severe to profound mental retardation (i.e., intelligence quotient (IQ) \u003c 40, significant impairment in adaptive function and/or inability to independently execute self-care skills)","doi":"https://doi.org/10.58020/dzq8-ct80","study_network":null,"study_condition":"Cardiovascular Disorder; Chronic Kidney Disease; End Stage Renal Failure","study_keywords":"Cardiovascular Disease Risk Factors; Glomerular Filtration Rate; Kidney Disease; Chronic Renal Insufficiency; Kidney Transplant; End-Stage Renal Disease (ESRD)","study_citation":"Ng, Derek (2021). The Chronic Kidney Disease in Children Cohort Study(V7) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/dzq8-ct80","study_end_date":"2028-07","study_procedure":null,"study_research_area_array":["Multidisciplinary Research","Kidney Disease"],"@version":"1","slug":"ckid","outcome":"Results from the CKiD study have generated over 140 publications to date (https://statepi.jhsph.edu/ckid/publications/). Cross-sectional and longitudinal analysis of CKiD data has revealed valuable information that better defines the prevalence and impact of comorbid conditions and associated risk factors, including hypertension, LVH, dyslipidemia, anemia, poor growth, and abnormal neurocognitive development, that accompany CKD. To date, CKiD data has facilitated the development of more accurate estimating equations for GFR (https://ckid-gfrcalculator.shinyapps.io/eGFR/), which allows clinicians to monitor changes in kidney function of children over time. Longitudinal follow-up of the cohort is ongoing and will continue to provide insight on the progression of CKD (https://www.kidney.org/professionals/kdoqi/gfr_calculatorPedRisk).","study_start_date":"2003-10","acronym":"CKiD","resource_use_acknowledgment":"The Chronic Kidney Disease in Children Cohort Study (CKiD) was conducted by the CKiD Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with additional funding from the National Institute of Child Health and Human Development (NICHD), and the National Heart, Lung, and Blood Institute (NHLBI) under grants U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK-66116. The data and biospecimens from the CKiD study reported here were supplied by NIDDK Central Repository (NIDDK-CR). This manuscript does not necessarily reflect the opinions or views of the CKiD study, NIDDK-CR, or NIH.","study_research_area":"Multidisciplinary Research; Kidney Disease","study_target_population":"Children; Dialysis Patients; Transplant Patients","name":"The Chronic Kidney Disease in Children Cohort Study","study_specimen_types_array":null,"study_sites_number":"50","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["CKiD"]},{"_index":"study_v001","_id":"2P21bpMBC2xkvCSB5RkX","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Not Available","modified_at":"2020-09-19T00:31:56.431Z","study_type":null,"study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.133Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children"],"study_condition_array":["Bile Duct Disorder","Biliary Atresia","Cholestasis"],"study_image_types_array":null,"study_medication":null,"objective":null,"study_id":55,"study_keywords_array":["Cystic Fibrosis Liver Disease","Biliary Tract Disease","Childhood Liver Disease Research and Education Network","ChiLDREN","Cholestasis","Rare Pediatric Liver Diseases","Bile Duct Disease"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":177,"study_website":"https://childrennetwork.org/Clinical-Studies","created_at":"2007-08-08T00:15:20.000Z","selection_criteria":null,"doi":null,"study_network":"ChiLDReN Network (ChiLDReN)","study_condition":"Bile Duct Disorder; Biliary Atresia; Cholestasis","study_keywords":"Cystic Fibrosis Liver Disease; Biliary Tract Disease; Childhood Liver Disease Research and Education Network; ChiLDREN; Cholestasis; Rare Pediatric Liver Diseases; Bile Duct Disease","study_citation":null,"study_end_date":null,"study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"clic","outcome":null,"study_start_date":null,"acronym":"CLiC","resource_use_acknowledgment":"The Cholestatic Liver Disease Consortium (CLiC) was conducted by the CLiC Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The biospecimens from the CLiC reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CLiC study and does not necessarily reflect the opinions or views of the CLiC study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Children","name":"Cholestatic Liver Disease Consortium","study_specimen_types_array":null,"study_sites_number":null,"specimen_availability":"Requires Collaboration with Parent Study","division":"DDN"},"sort":["CLiC"]},{"_index":"study_v001","_id":"h_21bpMBC2xkvCSB5BmZ","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"As a pilot study, the primary outcome measure is feasibility. The clinical outcome measure is change from baseline to 12 months in serum phosphate and FGF23 levels.\r\n\r\nSecondary Outcome Measures:\r\n\r\n- Change from baseline in bone and mineral metabolism markers.\r\n\r\n- Change from baseline in surrogate measures of cardiovascular disease (CVD) risk over 12 months.\r\n\r\n- Change from baseline in surrogate measures of CKD progression and inflammation, by changes in intra-renal oxygenation and fibrosis over 12 months \r\n\r\nOther outcome measures are documented in the Clinical Trials URL.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:45:10.000Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the The CKD Optimal Management With BInders and NicotinamidE[(V1) https://doi.org/10.58020/e4nx-6v60] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.140Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Chronic Kidney Disease","Cardiovascular Disorder"],"study_image_types_array":null,"study_medication":null,"objective":"- To test the effectiveness of the study drugs, nicotinamide and lanthanum carbonate, either individually or in combination, to lower blood levels of phosphorus and FGF23.\r\n- To determine the tolerability and safety of the study drugs, nicotinamide and lanthanum carbonate, either individually or in combination, over 12 months in patients with chronic kidney disease.\r\n- To perform cardiac and renal MRI scans without contrast to evaluate the intrinsic renal function and chambers of the heart in response to study procedures.","study_id":176,"study_keywords_array":["Nicotinamide","Cardiovascular Disease (CVD) Risk","Chronic Kidney Disease (CKD)","Parathyroid Hormone (PTH)","Kidney Disease","Fibroblast Growth Factor 23 (FGF23)","Lanthanum Carbonate"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT02258074}","network_id":232,"study_website":null,"created_at":"2015-10-14T23:04:10.249Z","selection_criteria":"\u003cb\u003eInclusion Criteria:\u003c/b\u003e \r\nAdults between the ages of 18 and 85 years old, with an estimated glomerular filtration rate (eGFR) 20-45 ml/min/1.73m2, a serum phosphate ≥ 2.8 mg/dL, a platelet count ≥ 125,000/mm3, and able to eat at least two meals a day. \r\n\r\n\u003cb\u003eExclusion Criteria:\u003c/b\u003e \r\n\r\nAdults with a history of allergic reaction to nicotinamide, niacin, multivitamin preparations, or lanthum carbonate; creatinine kinase concentrations \u003e 2 times the upper limit of the local laboratory reference range; major hemorrhagic event within the past six months requiring in-patient admission; blood or platelet transfusion within the past six months; secondary hyperparathyroidism or currently taking cinacalcet; anemia; serum albumin \u003c 2.5 mg/dl; current, clinically significant malabsorption; anticipated initiation of dialysis or kidney transplantation with 12 months; use of immunosuppressive medications; active abuse of alcohol or drugs; malignancy requiring therapy within 2 years; currently taking investigational drugs; currently participating in another clinical trial or interventional research; current or recent treatment with phosphate binder or niacin/nicotinamide; recent initiation or change in dose of treatment with 1,25 (OH)2 vitamin D or active vitamin D analogues (paricalcitol or hectorol); liver disease, defined as known cirrhosis by imaging or physician diagnosis, documented alcohol use \u003e 14 drinks/week, or aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or total bilirubin concentrations \u003e 2 times the upper limit of the local laboratory reference range; and institutionalized individuals.","doi":"https://doi.org/10.58020/e4nx-6v60","study_network":"Chronic Kidney Disease Consortium (CKD)","study_condition":"Chronic Kidney Disease; Cardiovascular Disorder","study_keywords":"Nicotinamide; Cardiovascular Disease (CVD) Risk; Chronic Kidney Disease (CKD); Parathyroid Hormone (PTH); Kidney Disease; Fibroblast Growth Factor 23 (FGF23); Lanthanum Carbonate","study_citation":"Gassman, Jennifer (2020). The CKD Optimal Management With BInders and NicotinamidE(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/e4nx-6v60","study_end_date":"2019-09","study_procedure":null,"study_research_area_array":["Multidisciplinary Research","Kidney Disease"],"@version":"1","slug":"combine","outcome":"This study is ongoing.","study_start_date":"2015-03","acronym":"COMBINE","resource_use_acknowledgment":"The The CKD Optimal Management With BInders and NicotinamidE (COMBINE) was conducted by the COMBINE Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the COMBINE (https://doi.org/10.58020/e4nx-6v60) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the COMBINE study and does not necessarily reflect the opinions or views of the COMBINE study, NIDDK-CR, or NIDDK.","study_research_area":"Multidisciplinary Research; Kidney Disease","study_target_population":"Adults","name":"The CKD Optimal Management With BInders and NicotinamidE","study_specimen_types_array":null,"study_sites_number":"7","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["COMBINE"]},{"_index":"study_v001","_id":"ecK1bpMBHb0XhPer591m","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure is computed as hospital-free days through day 90, and is defined as 90 minus the number of calendar days in the hospital as either an inpatient or on observation status.\r\n\r\nSecondary outcome measures are as follows:\u003cul\u003e\r\n\u003cli\u003eRate of MAKE at 180 days\u003c/li\u003e\r\n\u003cli\u003eRecurrent AKI hospitalization at 180 days\u003c/li\u003e\r\n\u003cli\u003eChange from baseline in global health-related quality of life (HR-QoL) at 180 days\u003c/li\u003e\r\n\u003cli\u003eChange from baseline in AKI-specific health-related quality of life (HR-QoL) at 180 days\u003c/li\u003e\r\n\u003cli\u003eChange from baseline in interactions with providers at 180 days\u003c/li\u003e\r\n\u003cli\u003eChange from baseline in social support at 180 days\u003c/li\u003e\u003c/ul\u003e","study_population_size":null,"study_image_types":null,"has_data":"Data Expected","modified_at":"2024-07-11T20:01:34.974Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.165Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Acute Kidney Injury"],"study_image_types_array":null,"study_medication":null,"objective":"The primary study objective is hospital-free days through 90 days of follow up, defined as 90 minus the number of calendar days in the hospital as either an inpatient or on observation status, based on the determination made by the corresponding hospital. \r\n\r\nKey secondary objectives include rates of Major Adverse Kidney Events (MAKE) (measured at 90, 180, and 365 days), rates of recurrent AKI (90, 180, and 365 days), and four participant reported outcomes: global health-related quality of life, AKI-specific health-related quality of life, provider interactions, and social support (30, 90, 180, and 365 days).","study_id":304,"study_keywords_array":["Enhanced Care Team","Major Adverse Kidney Events (MAKE)","Randomized Kidney Trial","Acute Kidney Injury (AKI)"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/study/NCT05805709}","network_id":null,"study_website":null,"created_at":"2022-12-14T01:57:44.997Z","selection_criteria":"Inclusion criteria:\u003cul\u003e\r\n\u003cli\u003eAge ≥ 18 years\u003c/li\u003e\r\n\u003cli\u003eKidney Disease Improving Global Outcomes (KDIGO) Stage 2/3 AKI with evidence of persistent AKI (defined as meeting Stage 2+ AKI for 2 consecutive days with serum creatinine concentration measurements \u003e 12 hours apart)\u003c/li\u003e\u003c/ul\u003e\r\nExclusion criteria:\u003cul\u003e\r\n\u003cli\u003eAKI due to primary glomerulonephritis, renal vasculitis, or thrombotic microangiopathy\u003c/li\u003e\r\n\u003cli\u003eDiagnosis of end-stage kidney disease (ESKD) at the time of admission, defined as:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eBaseline estimated glomerular filtration rate (eGFR) \u003c 15 mL/min/1.73 m2\u003c/li\u003e\r\n\u003cli\u003ePrevious kidney transplant recipient\u003c/li\u003e\r\n\u003cli\u003eOn chronic dialysis\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eAcute urinary obstruction with rapid kidney function improvement following relief of obstruction\u003c/li\u003e\r\n\u003cli\u003eIndex hospitalization involving nephrectomy\u003c/li\u003e\r\n\u003cli\u003eIndex hospitalization involving solid organ transplant or stem cell/bone marrow transplant\u003c/li\u003e\r\n\u003cli\u003eContinued dialysis dependence at time of discharge\u003c/li\u003e\r\n\u003cli\u003ePrevious (within 6 months) or new referral to a nephrologist for care specifically for:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003ePrevious or new diagnosis of glomerulonephritis\u003c/li\u003e\r\n\u003cli\u003ePrimary electrolyte imbalance disorders unrelated to AKI (e.g., syndrome of inappropriate antidiuretic hormone secretion, Bartter syndrome)\u003c/li\u003e\r\n\u003cli\u003eActive treatment for acute interstitial nephritis\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eNon-kidney end-organ failure:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eClass IV congestive heart failure\u003c/li\u003e\r\n\u003cli\u003eDecompensated cirrhosis with Model for End-Stage Liver Disease (MELD) \u003e 30 or those with a diagnosis of hepatorenal syndrome by the clinical teams\u003c/li\u003e\r\n\u003cli\u003eEnd-stage pulmonary disease (advanced stage chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, pulmonary hypertension)\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eMetastatic malignancy or malignancy requiring active treatment (chemotherapy, immunotherapy), such as multiple myeloma\u003c/li\u003e\r\n\u003cli\u003ePrimary goal of care is palliation: life expectancy \u003c 6 months\u003c/li\u003e\r\n\u003cli\u003ePregnancy\u003c/li\u003e\r\n\u003cli\u003eVulnerable populations\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003ePersons incarcerated\u003c/li\u003e\r\n\u003cli\u003ePersons institutionalized\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eInability to provide informed consent\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eImpaired cognition as demonstrated by the Brief Confusion Assessment Method (bCAM)\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eConcurrent enrollment in a separate greater than minimal risk interventional trial\u003c/li\u003e\r\n\u003cli\u003eInability to participate in either in-person or remote visits\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eInability to participate as determined by the research team at time of discharge based on disposition (versus uniform decision across site about exclusion based on skilled nursing facility)\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eDischarge to long-term acute care facility or other hospital-based location\u003c/li\u003e\u003c/ul\u003e","doi":null,"study_network":null,"study_condition":"Acute Kidney Injury","study_keywords":"Enhanced Care Team; Major Adverse Kidney Events (MAKE); Randomized Kidney Trial; Acute Kidney Injury (AKI)","study_citation":null,"study_end_date":null,"study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"cope-aki","outcome":"The study is ongoing.","study_start_date":null,"acronym":"COPE-AKI","resource_use_acknowledgment":null,"study_research_area":"Kidney Disease","study_target_population":"Adults","name":"Caring for OutPatiEnts after Acute Kidney Injury","study_specimen_types_array":null,"study_sites_number":"7","specimen_availability":"Specimens Expected","division":"KUH"},"sort":["COPE-AKI"]},{"_index":"study_v001","_id":"hcK1bpMBHb0XhPer591n","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:43:19.244Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Clinical Outcomes Research Initiative[(V3) https://doi.org/10.58020/4tmh-xc10] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.174Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Children"],"study_condition_array":["Cancer","Pancreatitis","Cholelithiasis"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objectives of the CORI project are to study outcomes of gastrointestinal endoscopic procedures in varied clinical settings and examine endoscopic practice patterns.","study_id":170,"study_keywords_array":["National Endoscopic Database (NED)","Gastrointestinal Disease","Gastrointestinal Endoscopic Procedures","American Society for Gastrointestinal Endoscopy (ASGE)"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":null,"study_website":null,"created_at":"2014-10-07T18:26:07.818Z","selection_criteria":null,"doi":"https://doi.org/10.58020/4tmh-xc10","study_network":null,"study_condition":"Cancer; Pancreatitis; Cholelithiasis","study_keywords":"National Endoscopic Database (NED); Gastrointestinal Disease; Gastrointestinal Endoscopic Procedures; American Society for Gastrointestinal Endoscopy (ASGE)","study_citation":"Lieberman, David (2018). Clinical Outcomes Research Initiative(V3) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/4tmh-xc10","study_end_date":null,"study_procedure":null,"study_research_area_array":["Digestive Diseases","Pancreatic Disease","Multidisciplinary Research"],"@version":"1","slug":"cori","outcome":null,"study_start_date":null,"acronym":"CORI","resource_use_acknowledgment":"The Clinical Outcomes Research Initiative (CORI) was conducted by the CORI Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CORI reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CORI study and does not necessarily reflect the opinions or views of the CORI study, NIDDK-CR, or NIDDK.","study_research_area":"Digestive Diseases; Pancreatic Disease; Multidisciplinary Research","study_target_population":"Adults; Children","name":"Clinical Outcomes Research Initiative","study_specimen_types_array":null,"study_sites_number":"70","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["CORI"]},{"_index":"study_v001","_id":"msK1bpMBHb0XhPer7t17","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Clinical and laboratory values from physical examination and laboratory studies, the NIH Chronic Prostatitis Symptom Index (NIH-CPSI), and quality of life assessments were used as outcome measures.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-06-27T20:08:20.883Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Chronic Prostatitis Collaborative Research Network Cohort Study[(V2) https://doi.org/10.58020/y7xf-s477] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.143Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Prostatitis"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objective of the study was to characterize CP/CPPS by examining the diagnosis, symptoms, and quality of life in affected men and assessing the economic impact of the condition.","study_id":13,"study_keywords_array":["Urogenital Disease","Prostatic Disease","Chronic Prostatitis","Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)","NIH Chronic Prostatitis Symptom Index (NIH-CPSI)","Pelvic Pain"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":233,"study_website":null,"created_at":"2004-03-27T03:11:39.000Z","selection_criteria":"Participants included men of all ages who had experienced symptoms of discomfort or pain in the pelvic region for at least 3 of the 6 months prior to the baseline screening visit. Men who had used antimicrobial agents, had an active genitourinary infection, or a prostate biopsy within the past three months were deferred for 3 months, and at that time they were allowed to enter into the study.\r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/y7xf-s477","study_network":"Chronic Prostatitis Collaborative Research Network (CPCRN)","study_condition":"Prostatitis","study_keywords":"Urogenital Disease; Prostatic Disease; Chronic Prostatitis; Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS); NIH Chronic Prostatitis Symptom Index (NIH-CPSI); Pelvic Pain","study_citation":"Landis, Richard (2021). Chronic Prostatitis Collaborative Research Network Cohort Study(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/y7xf-s477","study_end_date":null,"study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"cpcrn-cs","outcome":"The study found that CP/CPPS is a multifactorial problem affecting men of all ages and demographics. The condition is characterized by substantial variation in symptoms within and among subjects. There is no evidence that the disorder worsens significantly during 2 years of follow-up, and for about a third of men with long-standing symptoms there may be moderate to marked improvement during this period. Men with chronic prostatitis experience impairment in the mental and physical domains of general health related quality of life, and many have benefited only minimally from empirical, goal-directed therapy. The CPCRN has conducted numerous clinical trials to investigate the safety and efficacy of numerous treatments for CP/CPPS, for which more details are available on the NIDDK Repository website.","study_start_date":null,"acronym":"CPCRN Cohort","resource_use_acknowledgment":"The Chronic Prostatitis Collaborative Research Network Cohort Study (CPCRN Cohort) was conducted by the CPCRN Cohort Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CPCRN Cohort reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CPCRN Cohort study and does not necessarily reflect the opinions or views of the CPCRN Cohort study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Chronic Prostatitis Collaborative Research Network Cohort Study","study_specimen_types_array":null,"study_sites_number":"6","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["CPCRN Cohort"]},{"_index":"study_v001","_id":"wf21bpMBC2xkvCSB5Bn5","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score from baseline to 6 weeks. Secondary outcome measures included changes in the pain, voiding, and quality-of-life subscales of the NIH-CPSI; physical and mental summary scores on the Medical Outcomes Study 12-Item Short-Form Health Survey; and a 7-point patient-reported global response assessment. All adverse events were monitored and analyzed.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-08-29T05:08:34.919Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Chronic Prostatitis Collaborative Research Network Clinical Trial - Ciprofloxacin and Tamsulosin[(V2) https://doi.org/10.58020/g34k-9585] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.141Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Prostatitis"],"study_image_types_array":null,"study_medication":null,"objective":"This CPCRN study was designed to evaluate whether ciprofloxacin or tamsulosin reduces symptoms of long-standing CP/CPPS of at least moderate severity. The primary purpose of the trial was to test the most common prescription treatments given to men with CP/CPPS.","study_id":14,"study_keywords_array":["Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)","Pelvic Pain","Prostatic Disease","Urogenital Disease","Ciprofloxacin","Tamsulosin"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/ct2/show/NCT04552431}","network_id":233,"study_website":null,"created_at":"2004-03-27T03:12:19.000Z","selection_criteria":"Participants with CP/CPPS were referred from their providers. The primary criterion for eligibility was pain or discomfort in the pelvic region for at least 3 months in the previous 6 months. Exclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/g34k-9585","study_network":"Chronic Prostatitis Collaborative Research Network (CPCRN)","study_condition":"Prostatitis","study_keywords":"Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS); Pelvic Pain; Prostatic Disease; Urogenital Disease; Ciprofloxacin; Tamsulosin","study_citation":"Landis, Richard (2014). Chronic Prostatitis Collaborative Research Network Clinical Trial - Ciprofloxacin and Tamsulosin(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/g34k-9585","study_end_date":"2003-08","study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"cpcrn-rct-1","outcome":"The study found that neither ciprofloxacin nor tamsulosin significantly reduced the NIH-CPSI total score over 6 weeks compared with placebo. Moreover, neither treatment showed a significant benefit among a wide range of secondary outcomes related to symptoms and quality of life. Analyses of outcomes at 12 weeks demonstrated that additional changes after the end of treatment at 6 weeks were minimal. Findings do not support the use of these agents as therapy for men with long-standing CP/CPPS and at least moderate symptoms.","study_start_date":"1997-09","acronym":"CPCRN RCT #1","resource_use_acknowledgment":"The Chronic Prostatitis Collaborative Research Network Clinical Trial - Ciprofloxacin and Tamsulosin (CPCRN RCT #1) was conducted by the CPCRN RCT #1 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CPCRN RCT #1 reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CPCRN RCT #1 study and does not necessarily reflect the opinions or views of the CPCRN RCT #1 study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Chronic Prostatitis Collaborative Research Network Clinical Trial - Ciprofloxacin and Tamsulosin","study_specimen_types_array":null,"study_sites_number":"11","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["CPCRN RCT #1"]},{"_index":"study_v001","_id":"a8K1bpMBHb0XhPer590q","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure was a decrease (improvement) in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) of at least 4 points from baseline to 12 weeks, which is the minimal clinically significant difference in the score. \r\n\r\nSecondary outcome measures included assessment of general pain and urinary urgency on a Likert scale and the McGill Pain Questionnaire; the Medical Outcomes Study Short Form Health Survey; the Hospital Anxiety and Depression Scale; the International Index of Erectile Function; and the Male Sexual Health Questionnaire. Toxicity was assessed for each subject both overall and within each body system.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-08-29T05:08:18.172Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Chronic Prostatitis Collaborative Research Network Clinical Trial - Alfuzosin[(V2) https://doi.org/10.58020/801k-fj90] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.141Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Prostatitis"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the study was to evaluate the efficacy and safety of the alpha-adrenergic blocker Alfuzosin (Uroxatral) in men who had recently received a diagnosis of CP/CPPS and who had not previously been treated with this class of drug.","study_id":129,"study_keywords_array":["Alfuzosin","Urogenital Disease","Prostatic Disease","National Institutes of Health Chronic Prostatitis Symptom Index","Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)","NIH-CPSI","Alpha-Adrenergic Blocker","Uroxatral","Pelvic Pain"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT00103402}","network_id":233,"study_website":null,"created_at":"2012-01-27T23:38:17.000Z","selection_criteria":"Men of at least 18 years of age who exhibited: (1) symptoms bothersome enough to prompt a physician visit within the previous two years, (2) symptoms of pain or discomfort in the pelvic region for at least 6 weeks, and (3) a total score of at least 12 on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) were eligible for the study. \r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/801k-fj90","study_network":"Chronic Prostatitis Collaborative Research Network (CPCRN)","study_condition":"Prostatitis","study_keywords":"Alfuzosin; Urogenital Disease; Prostatic Disease; National Institutes of Health Chronic Prostatitis Symptom Index; Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS); NIH-CPSI; Alpha-Adrenergic Blocker; Uroxatral; Pelvic Pain","study_citation":"Landis, Richard (2014). Chronic Prostatitis Collaborative Research Network Clinical Trial - Alfuzosin(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/801k-fj90","study_end_date":"2008-01","study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"cpcrn2-rct1","outcome":"The study found no difference between placebo and alfuzosin in the proportion of men with an improvement of at least four points in the NIH-CPSI score. Similarly, there was no significant difference between the alfuzosin and placebo groups in multiple secondary outcomes, including the results of the global response assessment and measures of quality of life, depression, sexual function, and pain. These findings do not support the use of alfuzosin to reduce the symptoms of CP/CPPS in men who have not received prior treatment with an alpha-blocker.","study_start_date":"2005-02","acronym":"CPCRN2 RCT#1","resource_use_acknowledgment":"The Chronic Prostatitis Collaborative Research Network Clinical Trial - Alfuzosin (CPCRN2 RCT#1) was conducted by the CPCRN2 RCT#1 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CPCRN2 RCT#1 reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CPCRN2 RCT#1 study and does not necessarily reflect the opinions or views of the CPCRN2 RCT#1 study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Chronic Prostatitis Collaborative Research Network Clinical Trial - Alfuzosin","study_specimen_types_array":null,"study_sites_number":"11","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["CPCRN2 RCT#1"]},{"_index":"study_v001","_id":"nv21bpMBC2xkvCSB5Bnm","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome was a decrease (improvement) in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score of at least 6 points from baseline to week 6. A 6-point decrease in NIHCPSI score has been shown to be clinically important in previous clinical trials of men with CP/CPPS.\r\n\r\nSeveral secondary outcome measures were assessed, including the subscores of the NIH-CPSI, the Global Response Assessment (GRA, a self-reported assessment that measures perception of change in symptoms), the Medical Outcomes Study 12-Item Short Form Health Survey, the Hospital Anxiety and Depression Scale, and the Sexual Health Inventory for Men.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-08-29T05:08:45.864Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Chronic Prostatitis Collaborative Research Network Clinical Trial - Pregabalin[(V2) https://doi.org/10.58020/hamh-fh56] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.140Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Prostatitis"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the study was to determine whether pregabalin, which has been proved effective in other chronic pain conditions, was effective in reducing symptoms in men with CP/CPPS.","study_id":130,"study_keywords_array":["Urogenital Disease","Pregabalin","Pelvic Pain","Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)","National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)","Prostatic Disease"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00371033}","network_id":233,"study_website":null,"created_at":"2012-01-27T23:39:04.000Z","selection_criteria":"Men were eligible for the study if they were at least 18 years, they reported symptoms of discomfort or pain in the pelvic region during at least 3 of the previous 6 months, and they had a total score of at least 15 of 43 on the NIH-CPSI at both screening and randomization visits approximately 2 weeks apart. \r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/hamh-fh56","study_network":"Chronic Prostatitis Collaborative Research Network (CPCRN)","study_condition":"Prostatitis","study_keywords":"Urogenital Disease; Pregabalin; Pelvic Pain; Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS); National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI); Prostatic Disease","study_citation":"Landis, Richard (2014). Chronic Prostatitis Collaborative Research Network Clinical Trial - Pregabalin(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/hamh-fh56","study_end_date":"2008-01","study_procedure":null,"study_research_area_array":["Urologic Diseases"],"@version":"1","slug":"cpcrn2-rct2","outcome":"The study found no a clinically significant (6-point) decrease in the NIH-CPSI in men treated with pregabalin compared to men assigned to placebo. The GRA response rate was significantly higher in men treated with pregabalin compared with placebo.","study_start_date":"2006-03","acronym":"CPCRN2 RCT#2","resource_use_acknowledgment":"The Chronic Prostatitis Collaborative Research Network Clinical Trial - Pregabalin (CPCRN2 RCT#2) was conducted by the CPCRN2 RCT#2 Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the CPCRN2 RCT#2 reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CPCRN2 RCT#2 study and does not necessarily reflect the opinions or views of the CPCRN2 RCT#2 study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases","study_target_population":"Adults","name":"Chronic Prostatitis Collaborative Research Network Clinical Trial - Pregabalin","study_specimen_types_array":null,"study_sites_number":"10","specimen_availability":"Specimens Not Available","division":"KUH"},"sort":["CPCRN2 RCT#2"]},{"_index":"study_v001","_id":"ZcK1bpMBHb0XhPer590g","_score":null,"_source":{"dbgap_link":"{http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000524.v1.p1}","main_outcome_measures":"The primary renal outcome measure was reduction in estimated GFR. Renal events were defined as the need for renal replacement therapy (ESRD), an estimated halving of GFR, and/or a 25 ml/min per 1.73 m2 decline in GFR from baseline.\r\n\r\nEvaluation of subclinical CVD was also used as a study outcome measure. Additionally, clinical cardiovascular outcomes (including acute myocardial infarction, heart failure, arrhythmias, stroke, and peripheral arterial disease [PAD]) were ascertained.","study_population_size":null,"study_image_types":"Retinal Images","has_data":"Data Available for Request","modified_at":"2024-01-12T07:51:54.768Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Chronic Renal Insufficiency Cohort Study[(V12) https://doi.org/10.58020/6dxf-ed78] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.192Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Cardiovascular Disorder","Type 2 Diabetes Mellitus","Chronic Kidney Disease","Type 1 Diabetes Mellitus","End Stage Renal Failure"],"study_image_types_array":["Retinal Images"],"study_medication":null,"objective":"The primary objectives of the CRIC Study were to examine risk factors for progression of CKD and CVD among patients with established CKD. Additionally, the study aimed to develop predictive models to identify high-risk subgroups, informing future treatment trials, and examine the effect of ongoing clinical management on outcomes.","study_id":15,"study_keywords_array":["Diabetes Mellitus","Cardiovascular Outcomes","Cardiovascular Disease (CVD)","End-Stage Renal Disease (ESRD)","Glomerular Filtration Rate (GFR)","Chronic Kidney Disease (CKD)","Chronic Renal Insufficiency (CRI)"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00304148}","network_id":null,"study_website":"http://cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/","created_at":"2004-03-27T03:13:28.000Z","selection_criteria":"The study enrolled participants with CKD aged 21 to 74 years. About one-half of the study participants were diagnosed with diabetes mellitus. Age-related entry criteria for GFR were established to limit the proportion of older individuals recruited with age-related diminutions of GFR, but otherwise nonprogressive CRI. The estimated GFR to define eligibility was based on the simplified MDRD estimating equation. \r\nPatients diagnosed with polycystic kidney disease or on active immunosuppression for glomerulonephritis were excluded from the study.","doi":"https://doi.org/10.58020/6dxf-ed78","study_network":null,"study_condition":"Cardiovascular Disorder; Type 2 Diabetes Mellitus; Chronic Kidney Disease; Type 1 Diabetes Mellitus; End Stage Renal Failure","study_keywords":"Diabetes Mellitus; Cardiovascular Outcomes; Cardiovascular Disease (CVD); End-Stage Renal Disease (ESRD); Glomerular Filtration Rate (GFR); Chronic Kidney Disease (CKD); Chronic Renal Insufficiency (CRI)","study_citation":"Feldman, Harold ; Dember, Laura (2023). Chronic Renal Insufficiency Cohort Study(V12) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/6dxf-ed78","study_end_date":"2028-06","study_procedure":null,"study_research_area_array":["Diabetes","Kidney Disease","Multidisciplinary Research"],"@version":"1","slug":"cric","outcome":"Major outcomes include loss of kidney function (estimated GFR, measured GFR in a subset of study participants, occurrence of end-stage renal disease-ESRD) and occurrence of cardiovascular disease (CVD). See \u003ca href=http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/ \u003e http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/ \u003c/a\u003e for additional information.","study_start_date":"2003-07","acronym":"CRIC","resource_use_acknowledgment":"The Chronic Renal Insufficiency Cohort Study (CRIC) was conducted by the CRIC Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CRIC (https://doi.org/10.58020/6dxf-ed78) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CRIC study and does not necessarily reflect the opinions or views of the CRIC study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes; Kidney Disease; Multidisciplinary Research","study_target_population":"Adults","name":"Chronic Renal Insufficiency Cohort Study","study_specimen_types_array":null,"study_sites_number":"7 (with total of 13 recruiting sites)","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["CRIC"]},{"_index":"study_v001","_id":"q_21bpMBC2xkvCSB5Bnq","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Increased renal volume, cyst volume, and % cyst volume were primary endpoints of the study. Changes in glomerular filtration rate (GFR), serum creatinine level, the reciprocal of serum creatinine, and blood urea nitrogen between baseline and termination of the study were also measured.\r\n\r\nThe outcome measure of the molecular analysis was UCVs in the PKD1 and PKD2 genes.","study_population_size":null,"study_image_types":"Magnetic Resonance Imaging (MRI)","has_data":"Data Available for Request","modified_at":"2024-08-03T02:16:21.238Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease[(V9) https://doi.org/10.58020/956q-m463] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.143Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Adults"],"study_condition_array":["Cystic Kidney Disease","Polycystic Kidney Disease"],"study_image_types_array":["Magnetic Resonance Imaging (MRI)"],"study_medication":null,"objective":"The primary goal of the CRISP study group was to make prospective, longitudinal measurements of cyst and kidney growth in a large cohort of patients with ADPKD.\r\n\r\nThe objective of the mutation-based molecular analysis was to screen and evaluate UCVs in the ADPKD population.","study_id":10,"study_keywords_array":["PKD2 Gene","Glomerular Filtration Rate (GFR)","PKD1 Gene","Unclassified Variants (UCV)","Kidney Growth","Cyst Growth","Magnetic Resonance Imaging (MRI)","Autosomal-Dominant Polycystic Kidney Disease (ADPKD)"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/study/NCT01039987}","network_id":235,"study_website":null,"created_at":"2004-03-27T03:05:18.000Z","selection_criteria":"The study enrolled participants ages 15 to 46 years who met the following criteria:\r\n\u003cul\u003e\r\n\u003cli\u003eDiagnosis of ADPKD\u003c/li\u003e\r\n\u003cli\u003eActual or estimated creatinine clearance of at least 70 mL/min\u003c/li\u003e\r\n\u003cli\u003eSerum creatinine level of ≤ 1.6 mg/deciliter for men and ≤ 1.4 mg/deciliter for women\u003c/ul\u003e\u003c/li\u003e\r\n\r\nPatients were ineligible if they had other medical conditions besides hypertension that could affect renal function (e.g., diabetes mellitus).","doi":"https://doi.org/10.58020/956q-m463","study_network":"Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP Network)","study_condition":"Cystic Kidney Disease; Polycystic Kidney Disease","study_keywords":"PKD2 Gene; Glomerular Filtration Rate (GFR); PKD1 Gene; Unclassified Variants (UCV); Kidney Growth; Cyst Growth; Magnetic Resonance Imaging (MRI); Autosomal-Dominant Polycystic Kidney Disease (ADPKD)","study_citation":"Bae, Kyongtae (2022). Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease(V9) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/956q-m463","study_end_date":null,"study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"crisp1","outcome":"The study showed that MR measures of renal and cyst volume are reliable and accurate in patients with ADPKD. Findings indicated that renal-cyst and kidney enlargement is a continuous process in most patients with ADPKD and that the kidneys behaved as though the cysts within them enlarged at a steady rate specific to the patient.\r\n\r\nResults showed a strong relationship between kidney volume at the beginning of the study and the subsequent change in the GFR, which provides support for the view that enlarging cysts have an important role in promoting the ultimate decline in GFR and renal function.\r\n\r\nIn the molecular analysis of the CRISP cohort, mutations were identified in 180 probands, of which 153 were in PKD1 and 27 were in PKD2, and 30% of the mutations were recurrent. These results demonstrate the potential for molecular diagnostics in ADPKD.","study_start_date":"1999-09","acronym":"CRISP","resource_use_acknowledgment":"The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was conducted by the CRISP Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CRISP (https://doi.org/10.58020/956q-m463) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CRISP study and does not necessarily reflect the opinions or views of the CRISP study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Children; Adults","name":"Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease","study_specimen_types_array":null,"study_sites_number":"4","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["CRISP"]},{"_index":"study_v001","_id":"j8K1bpMBHb0XhPer591v","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Medical history, quality of life, kidney function, and development of kidney damage were measured to the determine risk factors for renal scarring.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-09-03T22:58:46.782Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Careful Urinary Tract Infection Evaluation[(V3) https://doi.org/10.58020/6gqa-cn96] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.152Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children"],"study_condition_array":["Vesicoureteral Reflux","Urinary Tract Infection"],"study_image_types_array":null,"study_medication":null,"objective":"The primary aim of the study was to determine the risk factors for developing renal scarring in children as a result of a UTI.","study_id":167,"study_keywords_array":["Kidney Scar","Renal Scarring","Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR)","Recurrent UTI","Persistent UTI","Urinary Tract Infection (UTI)","Urogenital Disease"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":271,"study_website":null,"created_at":"2014-07-28T23:26:01.911Z","selection_criteria":"Children between 2 months and 6 years of age were eligible for the study if they meet the following criteria:\r\n\u003cul\u003e\r\n\u003cli\u003eHas had no more than 2 UTIs with either fever or symptoms\u003c/li\u003e\r\n\u003cli\u003eWas treated for the first UTI for at least seven days with an effective antibiotic\u003c/li\u003e\r\n\u003cli\u003eNo history of VUR\u003c/li\u003e\r\n\u003cli\u003eNo history of other renal injury or serious disease\u003c/li\u003e\r\n\u003cli\u003eNo allergies to sulfa medications\u003c/li\u003e\u003c/ul\u003e","doi":"https://doi.org/10.58020/6gqa-cn96","study_network":"RIVUR Network (RIVUR Network)","study_condition":"Vesicoureteral Reflux; Urinary Tract Infection","study_keywords":"Kidney Scar; Renal Scarring; Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR); Recurrent UTI; Persistent UTI; Urinary Tract Infection (UTI); Urogenital Disease","study_citation":"Carpenter, Myra (2024). Careful Urinary Tract Infection Evaluation(V3) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/6gqa-cn96","study_end_date":null,"study_procedure":null,"study_research_area_array":["Urologic Diseases","Kidney Disease","Multidisciplinary Research"],"@version":"1","slug":"cutie","outcome":"VUR and BBD were risk factors for recurrent UTI, especially when they appeared in combination. Strategies for preventing recurrent UTI include antimicrobial prophylaxis and treatment of BBD.","study_start_date":null,"acronym":"CUTIE","resource_use_acknowledgment":"The Careful Urinary Tract Infection Evaluation (CUTIE) was conducted by the CUTIE Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CUTIE (https://doi.org/10.58020/6gqa-cn96) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CUTIE study and does not necessarily reflect the opinions or views of the CUTIE study, NIDDK-CR, or NIDDK.","study_research_area":"Urologic Diseases; Kidney Disease; Multidisciplinary Research","study_target_population":"Children","name":"Careful Urinary Tract Infection Evaluation","study_specimen_types_array":null,"study_sites_number":"3","specimen_availability":"Specimens Available for Request","division":"KUH"},"sort":["CUTIE"]},{"_index":"study_v001","_id":"jMK1bpMBHb0XhPer591v","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"None","study_population_size":null,"study_image_types":null,"has_data":"Data Expected","modified_at":"2024-08-03T00:00:09.027Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.118Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Adults"],"study_condition_array":["Cholestasis","Biliary Atresia","Mitochondrial Disease","Bile Duct Disorder","Alpha 1-Antitrypsin Deficiency","Alagille Syndrome"],"study_image_types_array":null,"study_medication":null,"objective":"The major objective of this protocol is to augment a repository of DNA from participants and their biological parents previously enrolled into clinical research but for whom a DNA biosample was not previously collected. The acquisition and storage of DNA from participants and their biological parents will make available an important resource for future and ongoing studies that may evaluate etiology, pathogenesis, biomarkers, pharmacogenomics, and genetic modifiers of these rare disorders.","study_id":303,"study_keywords_array":["PROBE","Neonatal Hepatitis","Mitochondrial Hepatopathies","Bile Acid Synthesis Defects (BASD)","Progressive Familial Intrahepatic Cholestasis (PFIC)","Biliary Atresia","Alpha 1-Antitrypsin Deficiency (α1-AT)","Alagille Syndrome (ALGS)","Rare Cholestatic Liver Diseases of Childhood","MITOHEP","LOGIC","BASIC"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/study/NCT05272319}","network_id":177,"study_website":null,"created_at":"2022-12-14T01:54:47.502Z","selection_criteria":"Inclusion criteria:\u003cul\u003e\r\n\u003cli\u003eFor child participants:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003ePrevious enrollment in PROBE, BASIC, LOGIC, or MITOHEP\u003c/li\u003e\r\n\u003cli\u003eExited from one of the aforementioned studies\u003c/li\u003e\r\n\u003cli\u003eConsent for DNA sample collection obtained during enrollment during enrollment to one of the aforementioned studies but sample not previously collected\u003c/li\u003e\r\n\u003cli\u003eStill followed at the clinical site\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eFor biological parent participants:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eBiological parents of previously consented child participant without collection of a parental DNA biospecimen\u003c/li\u003e\r\n\u003cli\u003eChild still followed at the clinical site\u003c/li\u003e\u003c/ul\u003e\u003c/ul\u003e\r\n\r\nExclusion criteria:\u003cul\u003e\r\n\u003cli\u003eFor child participants:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eParticipant is deceased\u003c/li\u003e\r\n\u003cli\u003eParticipant exited from prior study due to violating eligibility criteria\u003c/li\u003e\r\n\u003cli\u003eParticipant cannot be contacted\u003c/li\u003e\u003c/ul\u003e\r\n\u003cli\u003eFor biological parent participants:\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eNon-biological parent\u003c/li\u003e\r\n\u003cli\u003eChild DNA was not previously collected and will not be collected in this study\u003c/li\u003e\u003c/ul\u003e\u003c/ul\u003e","doi":null,"study_network":"ChiLDReN Network (ChiLDReN)","study_condition":"Cholestasis; Biliary Atresia; Mitochondrial Disease; Bile Duct Disorder; Alpha 1-Antitrypsin Deficiency; Alagille Syndrome","study_keywords":"PROBE; Neonatal Hepatitis; Mitochondrial Hepatopathies; Bile Acid Synthesis Defects (BASD); Progressive Familial Intrahepatic Cholestasis (PFIC); Biliary Atresia; Alpha 1-Antitrypsin Deficiency (α1-AT); Alagille Syndrome (ALGS); Rare Cholestatic Liver Diseases of Childhood; MITOHEP; LOGIC; BASIC","study_citation":null,"study_end_date":"2029-05","study_procedure":null,"study_research_area_array":["Liver Disease","Multidisciplinary Research","Endocrine Diseases and Metabolic Diseases"],"@version":"1","slug":"children-genetics","outcome":"This study is ongoing.","study_start_date":"2022-04","acronym":"ChiLDReN-Genetics","resource_use_acknowledgment":"The ChiLDReN Genetic Collection Protocol (ChiLDReN-Genetics) was conducted by the ChiLDReN-Genetics Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The biospecimens from the ChiLDReN-Genetics reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the ChiLDReN-Genetics study and does not necessarily reflect the opinions or views of the ChiLDReN-Genetics study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease; Multidisciplinary Research; Endocrine Diseases and Metabolic Diseases","study_target_population":"Children; Adults","name":"ChiLDReN Genetic Collection Protocol","study_specimen_types_array":null,"study_sites_number":"14","specimen_availability":"Requires Collaboration with Parent Study","division":"DDN"},"sort":["ChiLDReN-Genetics"]},{"_index":"study_v001","_id":"2f21bpMBC2xkvCSB5RkX","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Participants will undergo periodic assessments for disease progression; measure of kidney function; patient reported outcome measures; time to cause-specific events; and time to end stage kidney disease or death.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T19:16:09.254Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Cure Glomerulonephropathy[(V1) https://doi.org/10.58020/9g61-6226] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.143Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Children"],"study_condition_array":["IgA Glomerulonephritis","Membranous Glomerulonephritis","Focal Segmental Glomerulosclerosis","Glomerular Disorder","Glomerulonephritis","Lipoid Nephrosis"],"study_image_types_array":null,"study_medication":null,"objective":"The objective of the CureGN study is to advance the diagnosis and care of patients with glomerular diseases.","study_id":171,"study_keywords_array":["Glomerular Disease","Fical Segmental Glomerulosclerosis (FSGS)","Membranous Nephropathy (MN)","Immunoglobulin A Nephropathy (IgAN)","Kidney Biopsy","Glomerulonephritis","Glomerulosclerosis","Focal Segmental","Minimal Change Disease (MCD)"],"study_genomic_types_array":null,"clinical_trials_url":null,"network_id":238,"study_website":null,"created_at":"2015-05-01T17:58:15.224Z","selection_criteria":"Inclusion Criteria:\r\nParticipants of the study must be diagnosed with MCD, FSGS, MN, or IgAN via diagnostic kidney biopsy within 5 years of study enrollment. Additionally, participants must have access to the results and/or slides of their first kidney biopsy.\r\n\r\nExclusion Criteria:\r\nIndividuals will be excluded from the study if they are an institutionalized patient; an organ or bone marrow transplant recipient; have end stage kidney disease; or have diagnosed cancer, Hepatitis B, Hepatitis C, HIV, diabetes mellitus, or systemic lupus erythematosus.","doi":"https://doi.org/10.58020/9g61-6226","study_network":"Cure Glomerulonephropathy (CureGN Network)","study_condition":"IgA Glomerulonephritis; Membranous Glomerulonephritis; Focal Segmental Glomerulosclerosis; Glomerular Disorder; Glomerulonephritis; Lipoid Nephrosis","study_keywords":"Glomerular Disease; Fical Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy (MN); Immunoglobulin A Nephropathy (IgAN); Kidney Biopsy; Glomerulonephritis; Glomerulosclerosis; Focal Segmental; Minimal Change Disease (MCD)","study_citation":"Kretzler, Matthias (2019). Cure Glomerulonephropathy(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/9g61-6226","study_end_date":null,"study_procedure":null,"study_research_area_array":["Kidney Disease"],"@version":"1","slug":"curegn_prime","outcome":"This study is ongoing.","study_start_date":null,"acronym":"CureGN","resource_use_acknowledgment":"The Cure Glomerulonephropathy (CureGN) was conducted by the CureGN Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CureGN (https://doi.org/10.58020/9g61-6226) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CureGN study and does not necessarily reflect the opinions or views of the CureGN study, NIDDK-CR, or NIDDK.","study_research_area":"Kidney Disease","study_target_population":"Adults; Children","name":"Cure Glomerulonephropathy","study_specimen_types_array":null,"study_sites_number":"61","specimen_availability":"Requires Collaboration with Parent Study","division":"KUH"},"sort":["CureGN"]},{"_index":"study_v001","_id":"p_21bpMBC2xkvCSB5Bnq","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure is improvement in NAFLD at 52 weeks, defined as a decrease in NAFLD Activity Score (NAS) of at least 2 and no worsening of fibrosis.\r\n \r\nSecondary outcome measures, also to be assessed at 52 weeks, include reduction in serum aminotransferase and gamma-glytamyl transpeptidase, reduction in MRI-determined hepatic fat fraction, changes in markers of oxidation and anti-oxidant status (malondialdehyde, F2alpha-isoprostane, total antioxidant capacity, oxidized LDL), changes in histology and symptoms, and quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:43:25.127Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children[(V2) https://doi.org/10.58020/637v-9r95] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.094Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children"],"study_condition_array":["Metabolic Dysfunction-Associated Steatotic Liver Disease","Fatty Liver Disease"],"study_image_types_array":null,"study_medication":null,"objective":"The CyNCh trial aims to determine whether treatment with delayed-release cysteamine bitartrate capsules results in improvement in NAFLD severity in children.","study_id":148,"study_keywords_array":["Serum Aminotransferase","Nonalcoholic Fatty Liver Disease (NAFLD)","Delayed-Release Cysteamine Bitartrate","NAFLD Activity Score (NAS)","Fibrosis","Cysteamine","Gamma-Glytamyl Transpeptidase","Heptic Fat Fraction","Liver Biopsy"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT01529268}","network_id":32,"study_website":null,"created_at":"2012-09-06T17:29:31.000Z","selection_criteria":"Children between the ages of 8 to 17 years who met the following criteria were eligible for enrollment:\r\n\r\n- Liver biopsy obtained within 90 days of screening visit and not more than 120 days before randomization\r\n- Clinical history and liver histology consistent with NAFLD\r\n- No evidence of any other liver disease by clinical history or histological evaluation\r\n- A histological severity of NAFLD Activity score ≥ 4\r\n\r\nExclusion criteria are documented in the study protocol.","doi":"https://doi.org/10.58020/637v-9r95","study_network":"Nonalcoholic Steatohepatitis Clinical Research Network (NASH)","study_condition":"Metabolic Dysfunction-Associated Steatotic Liver Disease; Fatty Liver Disease","study_keywords":"Serum Aminotransferase; Nonalcoholic Fatty Liver Disease (NAFLD); Delayed-Release Cysteamine Bitartrate; NAFLD Activity Score (NAS); Fibrosis; Cysteamine; Gamma-Glytamyl Transpeptidase; Heptic Fat Fraction; Liver Biopsy","study_citation":"Tonascia, James (2020). Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children(V2) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/637v-9r95","study_end_date":"2015-09","study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"cynch","outcome":"This study is ongoing.","study_start_date":"2012-06","acronym":"CyNCh","resource_use_acknowledgment":"The Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh) was conducted by the CyNCh Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the CyNCh (https://doi.org/10.58020/637v-9r95) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the CyNCh study and does not necessarily reflect the opinions or views of the CyNCh study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Children","name":"Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children","study_specimen_types_array":null,"study_sites_number":"10","specimen_availability":"Specimens Available for Request","division":"DDN"},"sort":["CyNCh"]},{"_index":"study_v001","_id":"of21bpMBC2xkvCSB5Bnm","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"The primary outcome measure is the diagnosis of T1D through participant assessments from birth until the date of first documentation of T1D or up to 30 years of age. Other outcome measures include the detection of islet autoantibodies and transglutaminase antibodies.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-06-20T19:25:07.304Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the Diabetes Autoimmunity Study in the Young[(V1) https://doi.org/10.58020/brsr-hp55] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.169Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Adults"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"The primary objective of the study is to estimate the overall burden of T1D and other autoimmune diseases in the general population by age 30.","study_id":206,"study_keywords_array":["T1D","Omics Data","T1D-Related Autoantibodies","Islet Autoimmunity (IA)","Diabetes Mellitus"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT03205865}","network_id":null,"study_website":null,"created_at":"2019-08-14T08:00:00.000Z","selection_criteria":"Inclusion criteria:\u003cul\u003e\r\n\r\n\u003cli\u003eGeneral population genetic screening and follow-up\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eChild born at St. Joseph Hospital between 1/1/1993 and 6/30/2006\u003c/li\u003e\r\n\u003cli\u003eInformed consent obtained\u003c/li\u003e\r\n\u003cli\u003eCord blood sample available\u003c/li\u003e\r\n\u003cli\u003eNo other severe co-existent condition\u003c/li\u003e\r\n\u003cli\u003eAt least one parent/guardian speaks English\u003c/li\u003e\r\n\u003cli\u003eInitial telephone interview at 3 months of age, initial blood draw at 9 months of age\u003c/li\u003e\r\n\u003cli\u003eHigh or moderate risk of T1D, as determined from genetic screening (300 low risk children also enrolled as a control group)\u003c/li\u003e\u003c/ul\u003e\r\n\r\n\u003cli\u003eFamily members\u003c/li\u003e\u003cul\u003e\r\n\u003cli\u003eInformed consent obtained\u003c/li\u003e\r\n\u003cli\u003eSiblings age \u003c 4 years (\u003c 7 years prior to 1997)\u003c/li\u003e\r\n\u003cli\u003eFirst degree relative of either a sibling/offspring participant or general population newborn participant ages 12 months to 65 years\u003c/li\u003e\r\n\u003cli\u003eNo other severe co-existent condition\u003c/li\u003e\r\n\u003cli\u003eOne clinic visit to obtain blood for genetic marker determination and islet autoantibody screening\u003c/li\u003e\u003c/ul\u003e\u003c/ul\u003e\r\n\r\nExclusion criteria:\u003cul\u003e\r\n\u003cli\u003eCord blood not available for genetic screening\u003c/li\u003e\r\n\u003cli\u003eOther severe co-morbidities indicated or T1D diagnosed\u003c/li\u003e\r\n\u003cli\u003eRefused consent and long-term storage of data and specimen samples\u003c/li\u003e\r\n\u003cli\u003eAt least one parent or legal guardian did not speak English\u003c/li\u003e\u003c/ul\u003e","doi":"https://doi.org/10.58020/brsr-hp55","study_network":null,"study_condition":"Type 1 Diabetes Mellitus","study_keywords":"T1D; Omics Data; T1D-Related Autoantibodies; Islet Autoimmunity (IA); Diabetes Mellitus","study_citation":"Rewers, Marian (2023). Diabetes Autoimmunity Study in the Young(V1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/brsr-hp55","study_end_date":"2025-04","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"daisy","outcome":"The study is ongoing.","study_start_date":"1993-12","acronym":"DAISY","resource_use_acknowledgment":"The Diabetes Autoimmunity Study in the Young (DAISY) was conducted by the DAISY Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the DAISY reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the DAISY study and does not necessarily reflect the opinions or views of the DAISY study, NIDDK-CR, or NIDDK.","study_research_area":"Diabetes","study_target_population":"Children; Adults","name":"Diabetes Autoimmunity Study in the Young","study_specimen_types_array":null,"study_sites_number":null,"specimen_availability":"Specimens Not Available","division":"DEM"},"sort":["DAISY"]},{"_index":"study_v001","_id":"u_21bpMBC2xkvCSB5Bn1","_score":null,"_source":{"dbgap_link":"{http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000086.v2.p1}","main_outcome_measures":"The primary outcome measure for the DCCT study was diabetic retinopathy, which was chosen because it can be reliably quantified and its rate of progression determined in a reasonable number of years. Blood glucose and hemoglobin A1c measurements were used as primary indicators of metabolic control. Other outcome measures included diabetic nephropathy, diabetic neuropathy, and cardiovascular events or their known or putative risk factors.\r\n\r\nThe primary outcome measure for the EDIC study was the time to the first of any cardiovascular disease event. Similar to the DCCT study, secondary outcome measures included assessment of retinopathy, neuropathy, and nephropathy in participants. Notably, as both studies track diabetic nephropathy as an outcome measure, the DCCT and EDIC studies are kidney-relevant.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-04-28T21:55:00.914Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications[(V21) https://doi.org/10.58020/mn8k-ms49] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.192Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults","Children"],"study_condition_array":["Diabetic Kidney Disease","Type 1 Diabetes Mellitus","Diabetic Neuropathy","Diabetic Retinopathy","Cardiovascular Disorder"],"study_image_types_array":null,"study_medication":null,"objective":"The DCCT study sought to determine the effects of intensive versus standard diabetes therapy on the development and progression of the early vascular and neurologic complications of type 1 diabetes. Intensive therapy was aimed to maintain blood glucose concentrations close to the normal range in diabetic patients, which was hypothesized to decrease the development and progression of diabetic complications.\r\n\r\nThe EDIC study aimed to determine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease.","study_id":16,"study_keywords_array":["Diabetic Retinopathy","Diabetic Nephropathy","Diabetic Neuropathy","Cardiovascular Complications","Diabetes Mellitus, Type 1 (T1D)","Microvascular Complications","Blood Glucose","Hemoglobin A1c"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/ct2/show/NCT00360893}","network_id":null,"study_website":"https://edic.bsc.gwu.edu/dcct-study","created_at":"2004-03-27T03:14:12.000Z","selection_criteria":"The EDIC study enrolled patients who had previously participated in the DCCT study. The DCCT study involved participants aged 13 to 39 years who had been diagnosed with diabetes for at least 1 but less than 15 years and who had no, or only early signs, of diabetic retinopathy.","doi":"https://doi.org/10.58020/mn8k-ms49","study_network":null,"study_condition":"Diabetic Kidney Disease; Type 1 Diabetes Mellitus; Diabetic Neuropathy; Diabetic Retinopathy; Cardiovascular Disorder","study_keywords":"Diabetic Retinopathy; Diabetic Nephropathy; Diabetic Neuropathy; Cardiovascular Complications; Diabetes Mellitus, Type 1 (T1D); Microvascular Complications; Blood Glucose; Hemoglobin A1c","study_citation":"Lachin, John ; Braffett, Barbara (2021). Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications(V21) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/mn8k-ms49","study_end_date":"2027-06","study_procedure":null,"study_research_area_array":["Multidisciplinary Research","Kidney Disease","Diabetes"],"@version":"1","slug":"edic","outcome":"The DCCT study showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of the eye, kidney, and nerve damage caused by diabetes. Furthermore, it demonstrated that any sustained lowering of blood glucose helps decrease the progression of complications, even if the patient has a history of poor control.\r\n\r\nFollowing the initial findings of the DCCT study, the EDIC study has found that intensive diabetes therapy had long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes and that the differences in outcomes between the intensive and conventional therapy groups persist after long-term study. The EDIC follow-up is ongoing. As of April 2021, 598 of the 711 participants in the DCCT study intensive group and 553 of the 730 participants in the DCCT study conventional group continue to be followed in EDIC. This represents 94% and 91% (respectively) of the living cohort members.","study_start_date":"1994-04","acronym":"DCCT/EDIC","resource_use_acknowledgment":"The Diabetes Control and Complications Trial (DCCT) and its follow-up the Epidemiology of Diabetes Interventions and Complications (EDIC) study were conducted by the DCCT/EDIC Research Group and supported by National Institute of Health (NIH) grants and contracts and by the General Clinical Research Center Program (GCRC), the National Center for Research Resources (NCRR). The data and biospecimens from the DCCT/EDIC study were supplied by NIDDK Central Repository (NIDDK-CR). This manuscript was not prepared under the auspices of the DCCT/EDIC study and does not represent analyses or conclusions of the DCCT/EDIC study group, NIDDK-CR, or NIH.","study_research_area":"Multidisciplinary Research; Kidney Disease; Diabetes","study_target_population":"Adults; Children","name":"Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications","study_specimen_types_array":null,"study_sites_number":"29","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["DCCT/EDIC"]},{"_index":"study_v001","_id":"z_21bpMBC2xkvCSB5RkM","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Primary outcome measure: Time in target range 70-180 mg/dL measured by CGM in CLC group versus SAP group.\r\n\r\nSecondary outcome measures (26-week time frame): \r\n\u003cul\u003e\r\n\u003cli\u003eCGM time above or below the target range\u003c/li\u003e\r\n\u003cli\u003eCGM mean glucose\u003c/li\u003e\r\n\u003cli\u003eStandard deviation of CGM\u003c/li\u003e\r\n\u003cli\u003eLow and high blood glucose index by CGM with higher index indicating higher risk of hypoglycemia\u003c/li\u003e\r\n\u003cli\u003eCGM hypoglycemia events\u003c/li\u003e\r\n\u003cli\u003eHbA1c levels\u003c/li\u003e\r\n\u003cli\u003eTotal daily insulin\u003c/li\u003e\r\n\u003cli\u003eBasal to bolus insulin ratio\u003c/li\u003e\r\n\u003cli\u003eWeight\u003c/li\u003e\r\n\u003cli\u003eBMI\u003c/ul\u003e\u003c/li\u003e","study_population_size":null,"study_image_types":null,"has_data":"Data Not Available","modified_at":"2023-05-23T19:12:15.281Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.166Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Adults"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"Primary objective: Assess the efficacy and safety of the Control-IQ closed loop system over a 6-month period.\r\n\r\nSecondary objective: Investigate longer term use of the system compared with switching to sensor-augmented pump therapy.","study_id":292,"study_keywords_array":["Continuous Glucose Monitoring (CGM)","Diabetes Mellitus, Type 1 (T1D)","Insulin Pump","Closed-Loop Control (CLC)","Sensor-Augmented Pump (SAP)","Control-IQ Medical Device"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT03563313}","network_id":null,"study_website":"https://www.jaeb.org/projects/","created_at":"2022-02-24T21:00:42.290Z","selection_criteria":"Inclusion criteria:\r\n\u003cul\u003e\r\n\u003cli\u003eClinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year\u003c/li\u003e\r\n\u003cli\u003eFamiliarity and use of a carbohydrate ratio for meal boluses\u003c/li\u003e\r\n\u003cli\u003eAge ≥ 14.0 years old\u003c/li\u003e\r\n\u003cli\u003eFor females, not currently pregnant and agree to use a form of contraception to prevent pregnancy while a participant in the study\u003c/li\u003e\r\n\u003cli\u003eWillingness to suspend use of any personal CGM for the duration of the clinical trial\u003c/li\u003e\r\n\u003cli\u003eWillingness to use a regular insulin pump during the study with no automatic insulin adjustment based on glucose level when assigned to participate in the SAP group\u003c/li\u003e\r\n\u003cli\u003eWillingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study\u003c/li\u003e\r\n\u003cli\u003eTotal daily insulin dose (TDD) at least 10 U/day\u003c/li\u003e\r\n\u003cli\u003eWillingness not to start any new non-insulin glucose-lowering agent during the course of the trial\u003c/ul\u003e\u003c/li\u003e\r\n\r\nExclusion criteria:\r\n\u003cul\u003e\r\n\u003cli\u003eConcurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)\u003c/li\u003e\r\n\u003cli\u003eHemophilia or any other bleeding disorder\u003c/li\u003e\r\n\u003cli\u003eParticipation in another pharmaceutical or device trial at the time of enrollment or during the study\u003c/ul\u003e\u003c/li\u003e","doi":null,"study_network":null,"study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Continuous Glucose Monitoring (CGM); Diabetes Mellitus, Type 1 (T1D); Insulin Pump; Closed-Loop Control (CLC); Sensor-Augmented Pump (SAP); Control-IQ Medical Device","study_citation":null,"study_end_date":"2019-04","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"dclp3","outcome":"At the end of the 6-month trial, the closed-loop group were found to have spent a greater percentage of time in the target glycemic range than the SAP group.\r\n\r\nData generated from this study are available externally outside of the NIDDK Central Repository. Please navigate to the external repository and follow the policies and procedures to access data associated with this study: \u003ca href=\"https://public.jaeb.org/dataset/573\" target=\"_blank\" rel=\"noopener noreferrer\"\u003ehttps://public.jaeb.org/dataset/573\u003c/a\u003e","study_start_date":"2018-06","acronym":"DCLP3","resource_use_acknowledgment":null,"study_research_area":"Diabetes","study_target_population":"Children; Adults","name":"The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas","study_specimen_types_array":null,"study_sites_number":"7","specimen_availability":"Specimens Not Available","division":"DEM"},"sort":["DCLP3"]},{"_index":"study_v001","_id":"hMK1bpMBHb0XhPer591n","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":"Primary outcome measure: Time in target range 70-180 mg/dL measured by CGM in CLC group versus control group.\r\n\r\nSecondary outcome measures: \r\n\u003cul\u003e\r\n\u003cli\u003eCGM-measured percent above or below the target range\u003c/li\u003e\r\n\u003cli\u003eCGM-measured mean glucose\u003c/li\u003e\r\n\u003cli\u003eHbA1c levels\u003c/li\u003e\r\n\u003cli\u003eGlucose variability measured with the coefficient of variation (CV)\u003c/ul\u003e\u003c/li\u003e","study_population_size":null,"study_image_types":null,"has_data":"Data Not Available","modified_at":"2023-05-23T19:12:26.675Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":null,"@timestamp":"2024-11-27T17:40:30.165Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children"],"study_condition_array":["Type 1 Diabetes Mellitus"],"study_image_types_array":null,"study_medication":null,"objective":"Primary objective: Assess the efficacy and safety of the closed loop system compared with the standard of care.","study_id":293,"study_keywords_array":["Closed Loop Control (CLC)","Insulin Pump","Continuous Glucose Monitoring (CGM)","Target Glucose Level","Control-IQ Medical Device","Diabetes Mellitus, Type 1 (T1D)"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/ct2/show/NCT03844789}","network_id":null,"study_website":"https://www.jaeb.org/projects/","created_at":"2022-02-24T21:08:37.185Z","selection_criteria":"Inclusion criteria:\r\n\u003cul\u003e\r\n\u003cli\u003eClinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 6 months\u003c/li\u003e\r\n\u003cli\u003eFamiliarity and use of a carbohydrate ratio for meal boluses\u003c/li\u003e\r\n\u003cli\u003eAge ≥ 6 and ≤ 13 years old\u003c/li\u003e\r\n\u003cli\u003eWeight ≥ 25 kg and ≤ 140 kg\u003c/li\u003e\r\n\u003cli\u003eWillingness to suspend use of any personal CGM for the duration of the clinical trial\u003c/li\u003e\r\n\u003cli\u003eWillingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study\u003c/li\u003e\r\n\u003cli\u003eTotal daily insulin dose (TDD) at least 10 U/day\u003c/li\u003e\r\n\u003cli\u003eWillingness not to start any new non-insulin glucose-lowering agent during the course of the trial\u003c/li\u003e\r\n\u003cli\u003eParticipant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff\u003c/ul\u003e\u003c/li\u003e\r\n\r\nExclusion criteria:\r\n\u003cul\u003e\r\n\u003cli\u003eConcurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)\u003c/li\u003e\r\n\u003cli\u003eHemophilia or any other bleeding disorder\u003c/li\u003e\r\n\u003cli\u003eParticipation in another pharmaceutical or device trial at the time of enrollment or during the study\u003c/ul\u003e\u003c/li\u003e","doi":null,"study_network":null,"study_condition":"Type 1 Diabetes Mellitus","study_keywords":"Closed Loop Control (CLC); Insulin Pump; Continuous Glucose Monitoring (CGM); Target Glucose Level; Control-IQ Medical Device; Diabetes Mellitus, Type 1 (T1D)","study_citation":null,"study_end_date":"2020-03","study_procedure":null,"study_research_area_array":["Diabetes"],"@version":"1","slug":"dclp5","outcome":"After completion of the 16-week trial involving children with type 1 diabetes, a greater percentage of time was spent in the target glucose level for those using the closed-loop system than those in the control group.\r\n\r\nData generated from this study are available externally outside of the NIDDK Central Repository. Please navigate to the external repository and follow the policies and procedures to access data associated with this study: \u003ca href=\"https://public.jaeb.org/dataset/535\" target=\"_blank\" rel=\"noopener noreferrer\"\u003ehttps://public.jaeb.org/dataset/535\u003c/a\u003e","study_start_date":"2019-06","acronym":"DCLP5","resource_use_acknowledgment":null,"study_research_area":"Diabetes","study_target_population":"Children","name":"The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas in Pediatrics - A Study of t:slim X2 with Control-IQ Technology","study_specimen_types_array":null,"study_sites_number":"4","specimen_availability":"Specimens Not Available","division":"DEM"},"sort":["DCLP5"]},{"_index":"study_v001","_id":"j_21bpMBC2xkvCSB5Bnh","_score":null,"_source":{"dbgap_link":"{https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000663.v3.p3}","main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-10-18T04:11:59.407Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the DILIN: Prospective[(V4) https://doi.org/10.58020/rs4w-6k77] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.100Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Dialysis Patients","Adults","Children"],"study_condition_array":["Drug-Induced Liver Injury"],"study_image_types_array":null,"study_medication":null,"objective":"The goals of this study are to develop a database of recent DILI cases, identify the clinical, environmental and genetic risk factors that predict DILI, develop standardized instruments and terminology and perform careful longitudinal follow-up of DILI subjects. Biological samples collected will be used in future studies of the mechanisms and genetics of DILI.","study_id":163,"study_keywords_array":["Complementary and Alternative Medications (CAM) Use","Liver Elastography (FibroScans)","Alkaline Phosphatase (Alk Phos)","Serum Aspartate Aminotransferase (AST)","Alanine Aminotransferase (ALT)","Non-Prescription Medication Use","Drug-Induced Liver Injury (DILI)"],"study_genomic_types_array":null,"clinical_trials_url":"{https://www.clinicaltrials.gov/ct2/show/NCT00345930}","network_id":33,"study_website":"https://dilin.org/for-practitioners/prospective-study/about-the-prospective-study/","created_at":"2014-03-05T02:08:03.536Z","selection_criteria":"\u003cul\u003e\u003cli\u003eAge \u003e 2 years at time of enrollment\u003c/li\u003e \u003cli\u003eEvidence of liver injury that is known or suspected to be related to consumption of a drug or CAM product in the 6-month period prior to enrollment.\u003c/li\u003e \u003cli\u003eDocumented clinically important DILI, defined as any of the following: \u003col type=\"A\"\u003e\u003cli\u003eALT or AST \u003e5 x ULN or A P’ase \u003e2 x ULN confirmed on at least 2 consecutive blood draws in patients with previously normal values \u003cli\u003eIf baseline (BL) ALT, AST or A P’ase are known to be elevated, then ALT or AST \u003e 5 x BL or A P’ase \u003e 2 x BL on at least 2 consecutive blood draws. “Baseline” is defined as the average of at least 2 measurements performed during the 12-month period prior to starting the DILI medication. \u003cli\u003eAny elevation of ALT, A P’ase, or AST, associated with (a) increased total bilirubin (≥ 2.5 mg/dL), in absence of prior diagnosis of liver disease, Gilbert’s syndrome, or evidence of hemolysis or (b) coagulopathy with INR \u003e 1.5 in absence of Coumadin therapy or known vitamin K deficiency\u003c/li\u003e\u003c/ol\u003e \u003cli\u003eExclusion: competing cause of acute liver injury, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, other chronic biliary tract diseases, acetaminophen hepatotoxicity, liver/bone marrow transplant prior to the development of drug or CAM induced liver injury\u003c/li\u003e\u003c/ul\u003e","doi":"https://doi.org/10.58020/rs4w-6k77","study_network":"Drug-Induced Liver Injury Network (DILIN)","study_condition":"Drug-Induced Liver Injury","study_keywords":"Complementary and Alternative Medications (CAM) Use; Liver Elastography (FibroScans); Alkaline Phosphatase (Alk Phos); Serum Aspartate Aminotransferase (AST); Alanine Aminotransferase (ALT); Non-Prescription Medication Use; Drug-Induced Liver Injury (DILI)","study_citation":"Barnhart, Huiman (2017). DILIN: Prospective(V4) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/rs4w-6k77","study_end_date":"2027-07","study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"dilin-pro","outcome":null,"study_start_date":"2004-09","acronym":"DILIN Pro","resource_use_acknowledgment":"The DILIN: Prospective (DILIN Pro) was conducted by the DILIN Pro Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the DILIN Pro (https://doi.org/10.58020/rs4w-6k77) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the DILIN Pro study and does not necessarily reflect the opinions or views of the DILIN Pro study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Dialysis Patients; Adults; Children","name":"DILIN: Prospective","study_specimen_types_array":null,"study_sites_number":"5 academic clinical centers","specimen_availability":"Specimens Available for Request","division":"DDN"},"sort":["DILIN Pro"]},{"_index":"study_v001","_id":"sv21bpMBC2xkvCSB5Bn1","_score":null,"_source":{"dbgap_link":null,"main_outcome_measures":null,"study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2023-01-13T23:43:36.281Z","study_type":"Observational","study_cohort_size_range":null,"data_availability_statement":"Data from the DILIN: Retrospective[(V3) https://doi.org/10.58020/2v81-5f48] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.101Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Children","Adults"],"study_condition_array":["Drug-Induced Liver Injury","Cirrhosis of Liver"],"study_image_types_array":null,"study_medication":null,"objective":"The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI caused by seven specific drugs (isoniazid, phenytoin, clavulanic acid / amoxicillin and valproic acid, nitrofurantoin, trimethoprim-sulfamethoxazole, minocycline) and one drug class (quinolone antibiotics); and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma. A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be re-contacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI. \u003cbr/\u003e An important goal of this study is to generate hypotheses for consideration in future studies. Type-II error, i.e., failing to find an interesting association when there is one, is an important consideration. Thus, as a compromise between type-I and type-II error, α = 0.01 will be applied to declare any effect statistically significant. Because the suspected DILI mechanism is thought to be different for each drug, statistical analysis will be performed separately for each medication. The conditional logistic regression model will be the primary analytic model. Stratification variables, and any other covariates (other than the matching variables) known or suspected to distinguish cases from controls will be included as covariates. The adjusted odds ratio, together with its confidence interval, will be estimated from the associated regression parameters. Supplementary analyses as described in Liang and Zeger will be applied using a generalized linear mixed model approach.","study_id":160,"study_keywords_array":["Isoniazid","Serum Aspartate Aminotransferase (AST)","Alanine Aminotransferase (ALT)","Quinolone","Minocycline","Trimethoprim-Sulfamethoxazole","Nitrofurantoin","Valproic Acid","Amoxicillin","Clavulanic Acid","Phenytoin","Idiosyncratic Liver Injury Associated with Drugs (ILIAD)","Liver Disease","Drug-Induced Liver Injury (DILI)"],"study_genomic_types_array":null,"clinical_trials_url":"{https://clinicaltrials.gov/ct2/show/NCT00360646}","network_id":33,"study_website":"https://dilin.org/for-practitioners/retrospective-study/about-the-retrospective-study/","created_at":"2014-02-04T03:48:41.055Z","selection_criteria":"To be included in the ILIAD registry, the following criteria must be satisfied: \u003cul\u003e\u003cli\u003e The treating gastroenterologist / hepatologist or health care professional must believe that the subject suffered drug-induced liver injury; \u003c/li\u003e\u003cli\u003e The subject must be alive and the date of onset of the qualifying DILI episode must have occurred on or after January 1, 1994;\u003c/li\u003e\u003cli\u003eThe implicated medication is one of the following: isoniazid, phenytoin, combination clavulanic acid / amoxicillin,valproic acid, nitrofurantoin, trimethoprim-sulfamethoxazole, minocycline, and quinolone antibiotics. \u003c/li\u003e\u003cli\u003eThe subject is taking only one of these medications in the period leading up to the onset of the qualifying DILI episode.\u003c/li\u003e\u003c/ul\u003e\u003cbr/\u003e For INH, phenytoin, clavulanic acid / amoxicillin, trimethoprim-sulfamethoxazole, and quinolone antibiotics, severe liver injury is defined as a documented serum total bilirubin \u003e 2.5 mg/dl. \u003cbr/\u003e For valproic acid, it is defined as compatible symptomatic clinical presentation that is severe enough to prompt hospitalization, or that is associated with significant biochemical liver dysfunction, defined as any of the following: \u003cul\u003e\u003cli\u003eINR \u003e 1.5; \u003c/li\u003e\u003cli\u003e serum AST or ALT \u003e 3 × ULN or \u003e 3 times the baseline level, if the baseline level is elevated; \u003c/li\u003e\u003cli\u003ebilirubin \u003e 1 × ULN or \u003e 1 times the baseline level, if the baseline level is elevated; unexplained elevated arterial or venous NH3 levels; or, \u003c/li\u003e\u003cli\u003e liver biopsy showing steatosis.\u003c/li\u003e\u003c/ul\u003e For nitrofurantoin and minocycline, severe liver injury is defined as documented serum total bilirubin \u003e 2.5mg/dl or documented fibrosis / cirrhosis on liver biopsy. \u003cbr/\u003e Subjects will be excluded if they are not willing to have medical information and blood samples taken, or if they are unable to adequately give informed consent to participate in the study. Individuals less than 2 years old at the time of study enrollment are excluded due to blood volume requirements.","doi":"https://doi.org/10.58020/2v81-5f48","study_network":"Drug-Induced Liver Injury Network (DILIN)","study_condition":"Drug-Induced Liver Injury; Cirrhosis of Liver","study_keywords":"Isoniazid; Serum Aspartate Aminotransferase (AST); Alanine Aminotransferase (ALT); Quinolone; Minocycline; Trimethoprim-Sulfamethoxazole; Nitrofurantoin; Valproic Acid; Amoxicillin; Clavulanic Acid; Phenytoin; Idiosyncratic Liver Injury Associated with Drugs (ILIAD); Liver Disease; Drug-Induced Liver Injury (DILI)","study_citation":"Barnhart, Huiman (2017). DILIN: Retrospective(V3) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/2v81-5f48","study_end_date":"2028-07","study_procedure":null,"study_research_area_array":["Liver Disease"],"@version":"1","slug":"dilin-retro","outcome":null,"study_start_date":"2004-09","acronym":"DILIN Retro","resource_use_acknowledgment":"The DILIN: Retrospective (DILIN Retro) was conducted by the DILIN Retro Investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data and biospecimens from the DILIN Retro (https://doi.org/10.58020/2v81-5f48) reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the DILIN Retro study and does not necessarily reflect the opinions or views of the DILIN Retro study, NIDDK-CR, or NIDDK.","study_research_area":"Liver Disease","study_target_population":"Children; Adults","name":"DILIN: Retrospective","study_specimen_types_array":null,"study_sites_number":"6","specimen_availability":"Specimens Available for Request","division":"DDN"},"sort":["DILIN Retro"]},{"_index":"study_v001","_id":"sP21bpMBC2xkvCSB5Bnq","_score":null,"_source":{"dbgap_link":"{https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000681.v2.p1}","main_outcome_measures":"The primary outcome measure was development of diabetes, diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association: a value for plasma glucose of 126 mg per deciliter (7.0 mmol per liter) or higher in the fasting state, or 200 mg per deciliter (11.1 mmol per liter) or higher two hours after a 75-g oral glucose load.\r\nSecondary outcomes included cardiovascular risk profile and disease; and changes in glycemia, β-cell function, insulin sensitivity, renal function, body composition, physical activity, and nutrient intake, and health-related quality of life.","study_population_size":null,"study_image_types":null,"has_data":"Data Available for Request","modified_at":"2024-07-16T21:19:52.234Z","study_type":"Interventional","study_cohort_size_range":null,"data_availability_statement":"Data from the Diabetes Prevention Program[(V9) https://doi.org/10.58020/3hw5-cf91] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.","@timestamp":"2024-11-27T17:40:30.187Z","study_specimen_types":null,"study_genomic_types":null,"study_target_population_array":["Adults"],"study_condition_array":["Cardiovascular Disorder","Type 2 Diabetes Mellitus","Prediabetes Syndrome"],"study_image_types_array":null,"study_medication":null,"objective":"The primary goal of the DPP study was to compare the efficacy and safety of three interventions—an intensive lifestyle intervention, metformin, or placebo—in preventing or delaying the development of diabetes in high risk individuals. In addition, the study sought to assess differences between the three treatment groups in the development of cardiovascular disease and its risk factors; changes in glycemia, β-cell function, insulin sensitivity, obesity, physical activity, nutrient intake, and health-related quality of life; and occurrence of adverse events.","study_id":38,"study_keywords_array":["Weight Loss","Sex Hormones","Oral Glucose-Tolerance Test (OGTT)","Glucophage","Metformin","Diabetes Mellitus, Type 2 (T2D)","Prediabetic State","Lifestyle Intervention","Nutrient Intake","Obesity"],"study_genomic_types_array":null,"clinical_trials_url":"{http://www.clinicaltrials.gov/show/NCT00004992}","network_id":null,"study_website":"https://dppos.bsc.gwu.edu/web/dppos/dppos","created_at":"2005-05-26T19:00:36.000Z","selection_criteria":"Eligibility criteria included:\r\n\r\n- An age of at least 25 years\r\n- A body-mass index of 24 or higher (22 or higher in Asians)\r\n- A plasma glucose concentration of 95 to 125 mg/deciliter (5.3 to 6.9 mmol/liter) in the fasting state (≤125 mg/deciliter in the American Indian clinics)\r\n- A plasma glucose concentration of 140 to 199 mg/deciliter (7.8 to 11.0 mmol/liter) two hours after a 75-g oral glucose load\r\n\r\nEligible persons were excluded if they were taking medicines known to alter glucose tolerance or if they had illnesses that could seriously reduce their life expectancy or their ability to participate in the trial.","doi":"https://doi.org/10.58020/3hw5-cf91","study_network":null,"study_condition":"Cardiovascular Disorder; Type 2 Diabetes Mellitus; Prediabetes Syndrome","study_keywords":"Weight Loss; Sex Hormones; Oral Glucose-Tolerance Test (OGTT); Glucophage; Metformin; Diabetes Mellitus, Type 2 (T2D); Prediabetic State; Lifestyle Intervention; Nutrient Intake; Obesity","study_citation":"Fowler, Sarah (2024). Diabetes Prevention Program(V9) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/3hw5-cf91","study_end_date":"2001-04","study_procedure":null,"study_research_area_array":["Multidisciplinary Research","Diabetes","Nutrition","Obesity"],"@version":"1","slug":"dpp","outcome":"The DPP study found that both lifestyle changes and treatment with metformin reduced the incidence of diabetes in persons at high risk; the lifestyle intervention proved more effective than metformin in preventing the onset of diabetes. These results suggest that that type 2 diabetes can be prevented or delayed in high-risk persons through weight loss, a diet low in fat and calories, and regular physical activity.\r\n\r\nThe supplemental data measurements demonstrated that sex hormones had predictive value for diabetes risk in men only. However, both obesity and glycemia were found to be stronger predictors of diabetes risk than sex hormones for both men and women.","study_start_date":"1996-07","acronym":"DPP","resource_use_acknowledgment":"The Diabetes Prevention Program (DPP) was conducted by the DPP Research Group and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the General Clinical Research Center Program (GCRC), the National Institute of Child Health and Human Development (NICHD), the National Institute on Aging (NIA), the Office of Research on Women's Health (ORWH), the Office of Research on Minority Health (ORMH), the Centers for Disease Control and Prevention (CDC), and the American Diabetes Association (ADA). The data and biospecimens from the DPP were supplied by NIDDK Central Repository (NIDDK-CR). This manuscript was not prepared under the auspices of the DPP Research Group and does not represent analyses or conclusions of the DPP Research Group, the CDC, NIDDK-CR, or NIH.","study_research_area":"Multidisciplinary Research; Diabetes; Nutrition; Obesity","study_target_population":"Adults","name":"Diabetes Prevention Program","study_specimen_types_array":null,"study_sites_number":"27","specimen_availability":"Specimens Available for Request","division":"DEM"},"sort":["DPP"]}]},"aggregations":{"filters#study_network":{"meta":{},"buckets":[{"doc_count":187,"sterms#study_network":{"doc_count_error_upper_bound":0,"sum_other_doc_count":0,"buckets":[{"key":"Acute Kidney Injury Network (AKI)","doc_count":1},{"key":"Acute Liver Failure Study Group (ALFSG)","doc_count":2},{"key":"Adult Living Donor Liver Transplantation Studies (A2ALL Network)","doc_count":1},{"key":"African American Study of Kidney Disease Study Group (AASK)","doc_count":2},{"key":"ChiLDReN Network (ChiLDReN)","doc_count":17},{"key":"Chronic Kidney Disease Consortium (CKD)","doc_count":3},{"key":"Chronic Prostatitis Collaborative Research Network (CPCRN)","doc_count":4},{"key":"Clinical Islet Transplantation Consortium (CITC)","doc_count":8},{"key":"Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP Network)","doc_count":1},{"key":"Cure Glomerulonephropathy (CureGN Network)","doc_count":1},{"key":"Dialysis Access Consortium (DAC)","doc_count":2},{"key":"Drug-Induced Liver Injury Network (DILIN)","doc_count":2},{"key":"FSGS Study Group (FSGS)","doc_count":2},{"key":"Familial Barrett's Esophagus Consortium (FBEC)","doc_count":1},{"key":"Frequent Hemodialysis Network (FHN)","doc_count":2},{"key":"Gastroparesis Clinical Research Consortium (GpCRC)","doc_count":5},{"key":"Hepatitis B Research Network (HBRN)","doc_count":8},{"key":"Interstitial Cystitis Clinical Research Network (ICCRN)","doc_count":3},{"key":"Liver Transplantation Database (LTD)","doc_count":1},{"key":"Lower Urinary Tract Dysfunction Research Network (LURN Network)","doc_count":2},{"key":"Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia (MIST Network)","doc_count":1},{"key":"Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP Network)","doc_count":2},{"key":"Nonalcoholic Steatohepatitis Clinical Research Network (NASH)","doc_count":14},{"key":"PALF Network (PALF Network)","doc_count":1},{"key":"Prevention of Lower Urinary Tract Symptoms Consortium (PLUS)","doc_count":1},{"key":"RIVUR Network (RIVUR Network)","doc_count":2},{"key":"Silymarin Trials for Hepatitis C and NASH (SyNCH Network)","doc_count":1},{"key":"The Environmental Determinants of Diabetes in the Young (TEDDY) Network (TEDDY Network)","doc_count":3},{"key":"The HALT Progression of Polycystic Kidney Disease (HALT PKD Network)","doc_count":1},{"key":"The RISE Consortium (RISE)","doc_count":3},{"key":"The Treatment Options for Type 2 Diabetes in Adolescents and Youth Network (TODAY Network)","doc_count":4},{"key":"Type 1 Diabetes Genetics Consortium (T1DGC Network)","doc_count":2},{"key":"Type 1 Diabetes TrialNet (TrialNet)","doc_count":19},{"key":"Urinary Incontinence Research Network (UITN)","doc_count":4},{"key":"Urinary Stone Disease Research Network (USDRN)","doc_count":2}]}}]},"filters#has_data":{"meta":{},"buckets":[{"doc_count":187,"sterms#has_data":{"doc_count_error_upper_bound":0,"sum_other_doc_count":0,"buckets":[{"key":"Data Available for Request","doc_count":157},{"key":"Data Expected","doc_count":20},{"key":"Data Not Available","doc_count":10}]}}]},"filters#study_target_population_array":{"meta":{},"buckets":[{"doc_count":187,"sterms#study_target_population_array":{"doc_count_error_upper_bound":0,"sum_other_doc_count":0,"buckets":[{"key":"Adults","doc_count":149},{"key":"Children","doc_count":87},{"key":"Dialysis Patients","doc_count":14},{"key":"Pregnant (or Nursing) Women","doc_count":4},{"key":"Transplant Patients","doc_count":21}]}}]},"filters#specimen_availability":{"meta":{},"buckets":[{"doc_count":187,"sterms#specimen_availability":{"doc_count_error_upper_bound":0,"sum_other_doc_count":0,"buckets":[{"key":"Requires Collaboration with Parent Study","doc_count":42},{"key":"Specimens Available for Request","doc_count":102},{"key":"Specimens Expected","doc_count":3},{"key":"Specimens Not Available","doc_count":40}]}}]},"filters#study_condition_array":{"meta":{},"buckets":[{"doc_count":187,"sterms#study_condition_array":{"doc_count_error_upper_bound":0,"sum_other_doc_count":0,"buckets":[{"key":"AV Fistula Thrombosis","doc_count":1},{"key":"Acute Kidney Injury","doc_count":5},{"key":"Acute Liver Failure","doc_count":5},{"key":"Alagille Syndrome","doc_count":6},{"key":"Alpha 1-Antitrypsin Deficiency","doc_count":4},{"key":"Arteriosclerosis Disorder","doc_count":1},{"key":"Asthma","doc_count":1},{"key":"Autoimmune Hepatitis","doc_count":2},{"key":"Barrett Esophagus","doc_count":1},{"key":"Benign Prostatic Hyperplasia","doc_count":4},{"key":"Bile Duct Disorder","doc_count":14},{"key":"Biliary Atresia","doc_count":11},{"key":"Biliary Dyskinesia","doc_count":1},{"key":"Budd-Chiari Syndrome","doc_count":1},{"key":"Cancer","doc_count":9},{"key":"Cardiovascular Disorder","doc_count":14},{"key":"Celiac Disease","doc_count":1},{"key":"Cholelithiasis","doc_count":1},{"key":"Cholestasis","doc_count":9},{"key":"Chronic Kidney Disease","doc_count":20},{"key":"Cirrhosis of Liver","doc_count":14},{"key":"Colitis","doc_count":2},{"key":"Congenital Bile Acid Synthesis Defect","doc_count":1},{"key":"Congestive Heart Failure","doc_count":2},{"key":"Crigler-Najjar Syndrome","doc_count":1},{"key":"Crohn Disease","doc_count":1},{"key":"Cystic Fibrosis","doc_count":3},{"key":"Cystic Kidney Disease","doc_count":4},{"key":"Deep Vein Thrombosis","doc_count":1},{"key":"Diabetic Kidney Disease","doc_count":6},{"key":"Diabetic Neuropathy","doc_count":5},{"key":"Diabetic Retinopathy","doc_count":5},{"key":"Drug-Induced Liver Injury","doc_count":2},{"key":"Dyspepsia","doc_count":1},{"key":"End Stage Renal Failure","doc_count":16},{"key":"Erectile Dysfunction","doc_count":1},{"key":"Esophageal Adenocarcinoma","doc_count":1},{"key":"Fatty Liver Disease","doc_count":14},{"key":"Fibromyalgia","doc_count":1},{"key":"Fibrotic Liver Disease","doc_count":11},{"key":"Focal Segmental Glomerulosclerosis","doc_count":4},{"key":"Fulminant Viral Hepatitis","doc_count":1},{"key":"Gastroparesis","doc_count":5},{"key":"Gestational Diabetes","doc_count":2},{"key":"Glomerular Disorder","doc_count":3},{"key":"Glomerulonephritis","doc_count":2},{"key":"Glucose Metabolism Disease","doc_count":1},{"key":"Glycogen Storage Disease","doc_count":1},{"key":"HIV Infectious Disease","doc_count":1},{"key":"Hemangioendothelioma","doc_count":1},{"key":"Hepatic Encephalopathy","doc_count":1},{"key":"Hepatitis A Virus Infection","doc_count":1},{"key":"Hepatitis B Virus Infection","doc_count":9},{"key":"Hepatitis C Virus Infection","doc_count":5},{"key":"Hepatoblastoma","doc_count":1},{"key":"Hepatocellular Carcinoma","doc_count":6},{"key":"Hypertensive Disorder","doc_count":8},{"key":"Hypogonadism","doc_count":1},{"key":"IgA Glomerulonephritis","doc_count":1},{"key":"Inborn Disorder of Bile Acid Synthesis","doc_count":1},{"key":"Indeterminate Colitis","doc_count":1},{"key":"Inflammatory Bowel Disease","doc_count":2},{"key":"Interstitial Cystitis","doc_count":9},{"key":"Irritable Bowel Syndrome","doc_count":2},{"key":"Isolated Congenital Hepatic Fibrosis","doc_count":1},{"key":"Lipoid Nephrosis","doc_count":2},{"key":"Membranous Glomerulonephritis","doc_count":2},{"key":"Metabolic Dysfunction-Associated Steatohepatitis","doc_count":11},{"key":"Metabolic Dysfunction-Associated Steatotic Liver Disease","doc_count":14},{"key":"Mitochondrial Disease","doc_count":2},{"key":"Morbid Obesity","doc_count":1},{"key":"Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome","doc_count":1},{"key":"Myocardial Infarction","doc_count":1},{"key":"Myocardial Ischemia","doc_count":1},{"key":"Neonatal Hemochromatosis","doc_count":1},{"key":"Nephritis","doc_count":1},{"key":"Nephrolithiasis","doc_count":2},{"key":"Nephrotic Syndrome","doc_count":1},{"key":"Obesity Disorder","doc_count":10},{"key":"Pancreatic Insufficiency","doc_count":1},{"key":"Pancreatitis","doc_count":1},{"key":"Parenteral Nutrition-Associated Cholestasis","doc_count":1},{"key":"Peripheral Vascular Disease","doc_count":2},{"key":"Polycystic Kidney Disease","doc_count":4},{"key":"Prediabetes Syndrome","doc_count":8},{"key":"Preeclampsia","doc_count":1},{"key":"Primary Hyperoxaluria","doc_count":1},{"key":"Primary Sclerosing Cholangitis","doc_count":2},{"key":"Progressive Familial Intrahepatic Cholestasis","doc_count":2},{"key":"Prostatitis","doc_count":7},{"key":"Pulmonary Embolism","doc_count":1},{"key":"Pulmonary Hypertension","doc_count":1},{"key":"Sleep Apnea Syndrome","doc_count":1},{"key":"Stroke","doc_count":1},{"key":"Type 1 Diabetes Mellitus","doc_count":46},{"key":"Type 2 Diabetes Mellitus","doc_count":22},{"key":"Tyrosinemia","doc_count":1},{"key":"Ulcerative Colitis","doc_count":3},{"key":"Urea Cycle Disorder","doc_count":1},{"key":"Ureterolithiasis","doc_count":1},{"key":"Urinary Bladder Disorder","doc_count":8},{"key":"Urinary Incontinence","doc_count":8},{"key":"Urinary Tract Infection","doc_count":2},{"key":"Vascular Disorder","doc_count":3},{"key":"Vesicoureteral Reflux","doc_count":2},{"key":"Wilson Disease","doc_count":1}]}}]},"filters#study_research_area_array":{"meta":{},"buckets":[{"doc_count":187,"sterms#study_research_area_array":{"doc_count_error_upper_bound":0,"sum_other_doc_count":0,"buckets":[{"key":"Diabetes","doc_count":67},{"key":"Digestive Diseases","doc_count":24},{"key":"Endocrine Diseases and Metabolic Diseases","doc_count":6},{"key":"Hematologic Diseases","doc_count":3},{"key":"Kidney Disease","doc_count":44},{"key":"Liver Disease","doc_count":47},{"key":"Multidisciplinary Research","doc_count":49},{"key":"Nutrition","doc_count":8},{"key":"Obesity","doc_count":14},{"key":"Pancreatic Disease","doc_count":3},{"key":"Urologic Diseases","doc_count":27}]}}]}}},"facetList":[{"displayLabel":"Research Area","entityPropertyName":"study_research_area_array"},{"displayLabel":"Network","entityPropertyName":"study_network"},{"displayLabel":"Study Type","entityPropertyName":"study_type"},{"displayLabel":"Target Population","entityPropertyName":"study_target_population_array"},{"displayLabel":"Data Availability","entityPropertyName":"has_data"},{"displayLabel":"Study Population Size Range","entityPropertyName":"study_cohort_size_range"},{"displayLabel":"Data Types","entityPropertyName":"study_data_types"},{"displayLabel":"Specimen Availability","entityPropertyName":"specimen_availability"},{"displayLabel":"Available Specimen Types","entityPropertyName":"study_specimen_types"},{"displayLabel":"Condition","entityPropertyName":"study_condition_array"},{"displayLabel":"Image Data","entityPropertyName":"study_image_types"},{"displayLabel":"Omics Data","entityPropertyName":"study_genomic_types"},{"displayLabel":"Procedure","entityPropertyName":"study_procedure"},{"displayLabel":"Medication or Intervention Agent","entityPropertyName":"study_medication"},{"displayLabel":"NIDDK Division","entityPropertyName":"division"}],"properties":{"Title":[{"displayLabel":"Study Name","entityPropertyName":"name","sortable":true}],"Representative":[{"displayLabel":"Study Acronym","entityPropertyName":"acronym","sortable":true},{"displayLabel":"Research Area","entityPropertyName":"study_research_area","sortable":true},{"displayLabel":"Data Availability","entityPropertyName":"has_data","sortable":true},{"displayLabel":"Specimen Availability","entityPropertyName":"specimen_availability","sortable":true},{"displayLabel":"Network","entityPropertyName":"study_network","sortable":true}],"Detail":[{"displayLabel":"Omics Data","entityPropertyName":"study_genomic_types","sortable":false},{"displayLabel":"Outcome Measure","entityPropertyName":"main_outcome_measures","sortable":false},{"displayLabel":"Eligibility Criteria","entityPropertyName":"selection_criteria","sortable":false},{"displayLabel":"Outcome","entityPropertyName":"outcome","sortable":false},{"displayLabel":"Medication or Intervention Agent","entityPropertyName":"study_medication","sortable":false},{"displayLabel":"Study Population Size Range","entityPropertyName":"study_cohort_size_range","sortable":false},{"displayLabel":"General Description","entityPropertyName":"general_description","sortable":false},{"displayLabel":"DOI","entityPropertyName":"doi","sortable":false},{"displayLabel":"Study Start Date","entityPropertyName":"study_start_date","sortable":false},{"displayLabel":"Study End Date","entityPropertyName":"study_end_date","sortable":false},{"displayLabel":"Data Types","entityPropertyName":"study_data_types","sortable":false},{"displayLabel":"Study Type","entityPropertyName":"study_type","sortable":false},{"displayLabel":"Condition","entityPropertyName":"study_condition","sortable":false},{"displayLabel":"Image Data","entityPropertyName":"study_image_types","sortable":false},{"displayLabel":"Available Specimen Types","entityPropertyName":"study_specimen_types","sortable":false},{"displayLabel":"Keywords","entityPropertyName":"study_keywords","sortable":false},{"displayLabel":"Procedure","entityPropertyName":"study_procedure","sortable":false},{"displayLabel":"Objectives","entityPropertyName":"objective","sortable":false},{"displayLabel":"Target Population","entityPropertyName":"study_target_population","sortable":false},{"displayLabel":"NIDDK Division","entityPropertyName":"division","sortable":false}]},"initialQuery":{"search":"","facets":[],"sorting":{"sort":"asc","field":"acronym"},"pagination":{"page":"1","size":"50","total":{"value":187,"relation":"eq"},"totalPages":4,"firstNum":1,"secondNum":50},"view":"table","advancedQuery":null},"CSV_URL":"https://repository.niddk.nih.gov/api/search/v1/studies/csv?\u0026size=50\u0026page=1","siteUrl":"https://repository.niddk.nih.gov"},"__N_SSP":true},"page":"/search/study","query":{"size":"50","page":"1"},"buildId":"4IwPCL7p9Vb_-_lB6rNWm","isFallback":false,"isExperimentalCompile":false,"gssp":true,"scriptLoader":[]}</script></body></html>